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ABSTRACT 
 Classification of breast cancer relies on the presence or absence of estrogen 
receptor alpha (ERα) and progesterone receptor (PR) as well as the overexpression or 
amplification of the Her2/neu receptor. Targeted therapies against these proteins has 
increased the overall 5-year survival rate of breast cancer patients. However, a subset of 
breast cancer patients can acquire resistance or are initially unresponsive to these 
therapies. Understanding the molecular pathways that can cause resistance within the 
various types of breast cancer is of high priority. The cell cycle regulatory factor Speedy 
(Spy1) has been found to be upregulated in a variety of human cancers, including 
invasive mammary carcinomas, as well as being downstream of two important pathways 
in breast cancer initiation and progression; MAPK and c-Myc. My study sought to 
investigate the role of Spy1 downstream of ERα and to determine its role in regulating 
treatment response in the presence or absence of ERα. My work defines a novel positive 
feedback loop whereby Spy1 activates ERK1/2 in a MEK-independent fashion. This 
activation was further demonstrated to increase the ligand-independent activation of ERα, 
correlating with a decrease in tamoxifen sensitivity. We tested our findings using an in 
vivo zebrafish model, demonstrating elevated levels of Spy1 alter tamoxifen sensitivity. 
We further demonstrate significantly high levels of Spy1 within the triple negative group 
of breast cancers; which correlates with decreased sensitivity to chemotherapy as well as 
CDK inhibitor treatment. These data could define an efficient mechanism driving 
proliferation and resistance in select cancers and may represent a potent drugable target.  
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Breast Cancer Heterogeneity 
 Breast cancer is a complex disease with no single cause, affecting 1 in 9 Canadian 
women (CBCF, 2014). It is a heterogenous disease that can be classified under 
histological or genetic/molecular classifications. Mammalian female breasts, or 
mammary glands, undergo growth and development postnatally and can continue to 
undergo cycles of regeneration and development throughout the life of the organism. 
Development and regeneration of the female breast is tightly regulated by cascades of 
hormones and growth factors. While 1% of breast cancer cases occur in males, 99% of 
the disease occurs in females supporting that these cycles of regulation are an important 
component in the initiation and progression of a large subset of the disease (Medina, 
1996; Silberstein et al., 1994; Visvader and Stingl, 2014).  The mature female mammary 
gland is comprised of rings of epithelial cells called alveoli that are capable of producing 
milk during pregnancy (Malhotra et al., 2010; Visvader and Stingl, 2014). Several alveoli 
are grouped together into lobules and share one lactiferous duct, that transports milk from 
the lobules to the nipples (Malhotra et al., 2010; Visvader, 2009). The alveoli and ductal 
structures are organized as a 2 cell layer system, an inner luminal epithelial layer and an 
outer myoepithelial layer. In the alveoli the luminal cells are capable of differentiating 
into milk producing alveolar cells. Myoepithelial cells are contractile cells which serve 
the purpose of forcing the milk proteins through the ductal network (Visvader, 2009). 
containing adipocytes, fibroblasts and inflammatory cells. The majority of breast cancers 
arise in the epithelial cells of the lobules or ducts (Malhotra et al., 2010). Breast cancer 
metastasis requires transit from this organized network into other tissues, such as the 
This entire network is encased in connective tissue, extracellular matrix and stroma 
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bones, lymphatic system, liver, lung, or the brain (Malhotra et al., 2010; Pestalozzi, 2009; 
Petrut et al., 2008; Selzner et al., 2000; Shayan et al., 2006). Understanding the cues 
regulating breast epithelial cells is critical in the successful treatment of this disease.  
Classification of Breast Cancer 
Histological Classification 
 Histological classification of breast cancer can be broadly separated into two 
groups; in situ carcinoma and invasive or infiltrative carcinoma. Breast cancer is then 
sub-categorized depending on where in the tissue it originated; ductal or lobular. Ductal 
carcinoma in situ (DCIS) is more common than lobular carcinoma in situ (LCIS) and is 
further sub-typed dependent upon the characteristics of the tumour (Malhotra et al., 
2010). Invasive/infiltrative carcinomas can also be found in the duct or lobules, but there 
are more subdivisions of invasive tumour types including papillary, medullary, tubular 
and mucinous carcinomas. Infiltrating ductal carcinoma (IDC) is the most common and 
affects approximately 80% of invasive lesions (Malhotra et al., 2010; Weigelt et al., 
2010). IDC can be further subtyped based on the differentiation status of the tumour; 
grade I-well-differentiated, grade II-moderately differentiated, and grade III-poorly 
differentiated (Malhotra et al., 2010). 
 The more differentiated the tumour cell, the less the cell resembles a stem cell and 
the greater the ability to specifically target and treat the cancer cells. The existence of 
cancer stem cells (CSCs) within a tumour has been established in multiple cancers, 
discovered first in leukemia studies. Clarkson and Fried (1971) found CSCs in leukemia 
lead to relapse and failure to treat the cancer with chemotherapy (Clarkson and Fried, 
1971). CSCs have been correlated with prognosis in medulloblastoma, lung cancer, and 
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prostate cancer; however, whether CSCs have a role in treatment resistance is still being 
speculated in the breast (Al-Ejeh et al., 2011). CSCs have three characteristic functions, 
they can initiate tumourigenesis, are capable of self-renewal, and can differentiate into 
tumour cells that do not self-renew (Al-Ejeh et al., 2011; McDermott and Wicha, 2010). 
Breast cancer stem cells are characterized as tumour initiating cells. The CSC theory 
states that a tumour is composed of cells with tumour initiating and progression potential, 
while the remaining tumour cells have a low tumourigenic potential (Malhotra et al., 
2010). Where CSCs arise and which cell is the cell of origin for the CSCs is still a subject 
of debate; there is data to support that CSCs can arise from naturally occurring stem cells 
that are protected in a quiescent state thereby evading apoptosis, enabling a mutated stem 
cell to pass dangerous mutations to its daughter cells through self-renewal (McDermott 
and Wicha, 2010; Wicha et al., 2006). There is also data to support the hypothesis that 
CSCs arise from progenitor cells that gain the capacity to self-renew and give rise to 
different sub-types (Malhotra et al., 2010; McDermott and Wicha, 2010). 
Molecular Classification 
 The growth pattern and differentiation of a tumour results in a specific histology, 
classically used to diagnose the disease and guide treatment decisions (Malhotra et al., 
2010; Weigelt et al., 2010). The World Health Organization (WHO) has classified at least 
17 histological breast cancer subtypes, encompassing different types and grades of 
tumour (Weigelt et al., 2010). After basic histology, clinicians look at receptor and 
growth factor status of the cancer with a focus on estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor (Her)2/neu protein levels 
(Malhotra et al., 2010). The presence or absence of these pathways provides important 
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prognostic information and determines the course of treatment. While not currently used 
as standard practise in the clinic, it is now well established that patients can also be 
subclassified according to their gene expression signature. The basic molecular signatures 
can be divided into five main subtypes of breast cancer; luminal A, luminal B, Her2-
enriched, basal-like, and claudin-low (Perou et al., 2000). 
I) Luminal A 
  Luminal breast cancers (subtypes A and B) arise from the luminal cells, which 
line the alveoli and ducts. Luminal A breast cancer is one of the most prevalent subtypes 
of breast cancers, making up approximately 40% of breast cancer cases (Ethier et al., 
1993; Malhotra et al., 2010; Ogba et al., 2014; Zubor et al., 2015). Patients grouped in 
this subtype are found to be ER positive, PR positive, and Her2 low or negative. 
Furthermore, this subtype has low expression of the proliferation marker, Ki67, and less 
than half of the tumours in this group have a mutated p53 gene; a tumour suppressor gene 
involved in DNA damage response signalling (Malhotra et al., 2010; Perou et al., 2000). 
Luminal A patients have the best prognosis with low recurrence rates (Metzger-Filho et 
al., 2013; Paik et al., 2004). 
II) Luminal B 
 Luminal B breast cancers have a worse prognosis among the luminal cancers. 
Luminal B tumours comprise approximately 20% of all breast cancer cases. They are 
characterized as having lower ER expression than luminal A, and are PR and Her2 
positive (Ethier et al., 1993; Malhotra et al., 2010; Ogba et al., 2014; Zubor et al., 2015). 
Furthermore, they have high Ki67 expression and 30% of all luminal B breast cancer 
cases have a mutated p53 gene (Malhotra et al., 2010). Survival rates for patients in this 
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subtype are still high; however, not as high as luminal A breast cancer survival rates 
(Anders et al., 2011; Metzger-Filho et al., 2013). 
III) Her2-enriched 
 Her2 is a transmembrane tyrosine kinase protein and is a part of the Her family of 
human growth factor receptors. Her2 can form homo- or heterodimers with other family 
members including Her1/epidermal growth factor receptor (EGFR), Her3, and Her4 
(Lund et al., 2010; Malhotra et al., 2010; Weigelt et al., 2010). Following dimerization, 
phosphorylation occurs on the tyrosine residues of the cytoplasmic domain, which 
activates the downstream pathways, phosphoinositide 3-kinase (PI3K)/Akt and mitogen-
activated protein kinase (MAPK) (Lund et al., 2010). The Her2-enriched subtype 
comprise approximately 10% to 15% of all breast cancer cases. Clinically, 60% of cases 
labelled as Her2 positive will fall into this subtype. Most Her2-enriched patients have a 
lower expression of ER and PR; however, 30% to 40% present with ER positive tumours 
(Perou, 2010; Perou et al., 2000). Furthermore, the Her2-enriched subtype does not 
necessarily contain Her2 positive or Her2 amplified tumours, some patients are Her2 
negative, but are a part of the Her2-enriched subtype due to the similarity of the gene 
expression profile of the tumour in comparison to those with Her2 positive or Her2 
amplification. The Her2-enriched subtype is also characterized by a high expression of 
Ki67 and approximately 75% of these tumours have a mutated p53 gene. Patients with 
this subtype of breast cancer have a poorer prognosis than luminal subtypes and are prone 
to early recurrence rates and increased metastasis (Lund et al., 2010; Perou, 2010; Perou 
et al., 2000). Her2-positive patients can be treated with the targeted therapy trastuzumab, 
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which binds to and inhibits the dimerization of Her2 transmembrane protein (Dean-
Colomb and Esteva, 2008; Yaal-Hahoshen and Safra, 2006; Zhang et al., 2015). 
IV) Basal-like 
 The term basal-like breast cancer is used because this subtype has similar features 
and cytokeratin expression, expressing cytokeratins 5, 6, or 17, as the basal epithelial 
cells of the skin and airways as well as the basal or outer layer of the mammary ducts 
(Perou, 2010; Perou et al., 2000; Prat and Perou, 2011). They are characterized as having 
no expression of ER, PR, or Her2/neu expression or amplification. They have, however, 
been found to have positive expression of EGFR. Basal-like breast cancer represents 
approximately 10% to 25% of all breast cancers. The majority of basal-like breast cancers 
are p53 mutated and are found to be highly proliferative (Perou et al., 2000). These 
tumours lack Retinoblastoma protein (pRB) function, which is critical in cell cycle 
regulation. The loss of pRB and p53 enhances cell growth and proliferation (Perou, 
2010). Moreover, there is a high association of basal-like breast cancers with a mutation 
in breast cancer 1 type, early onset, susceptibility protein (BRCA1). BRCA1 is a tumour 
suppressor gene responsible for DNA repair and when mutated, the DNA repair 
mechanism cannot fix damaged DNA (Hill et al., 2014). Basal-like breast cancer is 
labelled as the breast cancer with the poorest prognosis. Targeted therapies do not exist 
for this subtype and treatment relies solely on chemotherapy. Recurrence and metastasis 
rates are high in these patients, especially within the first 3 years of treatment, and overall 
survival of the patients is low (Perou et al., 2000).  
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V) Claudin-low 
 Claudin-low breast cancer is a newly categorized subtype. Previously, patients 
under this subtype were classified as basal-like; however, after DNA microarray studies 
were performed, it was found that a subset of tumours presented with low levels of the 
claudin genes. Claudins are needed for epithelial cell tight-tight junctions (Prat et al., 
2010). Tumours in this subtype, which make up 5% to 10% of all breast cancers, show 
low expression for claudins 3, 4, and 7, as well as E-cadherin, a protein required for cell-
cell junction (Perou, 2010; Perou et al., 2000; Prat and Perou, 2011). Furthermore, they 
are normally ER/PR/Her2 negative (Sabatier et al., 2014). Claudin-low tumours have 
shown an increase in immune cell infiltration, stem cell features, and features 
representing epithelial-mesenchymal transition (EMT). Some researchers believe claudin-
low breast cancers derive from the lobules, mainly because they are associated with high 
grade tumours, have little differentiation and are able to infiltrate the immune cells (Prat 
et al., 2010; Sabatier et al., 2014). Similar to basal-like breast cancers, claudin-low breast 
cancers also have a poor prognosis and cannot benefit from targeted therapy, and, 
therefore, only chemotherapy is used as a form of treatment (Perou et al., 2000). 
Characteristics of Triple Negative Breast Cancer 
 The Her2-enriched, basal-like, and claudin-low breast cancers share one common 
feature; all have the potential to encompass a special group of breast cancer, triple 
negative breast cancer (TNBC). TNBC are generally characterized as being negative for 
ER, PR, and Her2 (Perou, 2010; Perou et al., 2000). Basal-like breast cancer accounts for 
over 50% of all TNBC cases and all claudin-low breast cancers are triple negative. 
TNBCs are also found to be less differentiated, have increased proliferative capacity, 
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have a poor prognosis, and the rate of relapse is significantly increased within the first 3 
years of chemotherapy treatment (Malhotra et al., 2010; Perou, 2010; Perou et al., 2000; 
Sabatier et al., 2014). Molecular and immunohistochemical profiles have been produced 
to investigate a possible molecular signature for TNBC. TNBC profiles show specific 
expression of myoepithelial and basal markers as well as p53 gene mutations and gene 
amplification and overexpression of the transcription factor, c-Myc (Kreike et al., 2007). 
ER Signalling; A Central Driver of Luminal Breast Cancers 
ER Structure and Signalling 
 The ER is a part of the nuclear receptor protein superfamily that can act as a 
transcription factor by binding to estrogen response elements (EREs) on DNA either as a 
monomer or homodimer. There are two isoforms of ER, ER alpha (ERα) and ER beta 
(ERβ). The two isoforms have opposing roles in the proliferation and differentiation of 
breast cancer (Kampa et al., 2013). Biological functions mediated by mitogenic effects 
are governed by ERα (Brisken and Ataca, 2015; Kampa et al., 2013; Morani et al., 2008; 
Musgrove et al., 1993), whereas ERβ has more of a tumour suppressive role (Kampa et 
al., 2013; Rizza et al., 2014). ERβ can inhibit specific ERα gene expression targets, and 
has been considered a partial dominant negative receptor. When ERβ is co-expressed 
with ERα, patient prognosis is much more favourable and has a less aggressive 
phenotype (Rizza et al., 2014).  
ERα can be bound by steroid hormones, thyroid hormones, retinoids, and vitamin 
D3. Most commonly, it is bound to and activated by 17β-estradiol (E2) (Musgrove et al., 
1993). ERα is characterized by 3 principle domains; the N-terminal domain (NTD), a 
highly conserved DNA binding domain (DBD) and a ligand binding domain (LBD). ERα 
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also contains two activation function domains (AF1 and AF2), which reside in the NTD 
and LBD, respectively. ERα contains two other regions; the D-region or hinge region, 
found between the DBD and LBD, which contains the nuclear localization signal, and the 
F-region, which follows the LBD and is found to be important in receptor dimerization 
(Figure 1) (Kallen et al., 2007; Kumar et al., 2011). The AF1 and AF2 are responsible for 
the transcriptional activity of ERα. AF2 is ligand-dependent and promotes classical 
signalling of ERα through direct binding of EREs and activation or repression of specific 
genes (Figure 2A). When E2 binds to the hormone binding pocket of the LBD, helix 12 
realigns and exposes a hydrophobic motif (LXXLL), which allows for the binding of 
cofactors. 'Non-classical' genomic signalling also exists where the E2-ER complex 
interacts with co-activators Fos and Jun, to transcriptionally regulate genes like Cyclin 
D1 that do not contain EREs (Figure 2A) (Castro-Rivera et al., 2001; Gottlicher et al., 
1998; Musgrove et al., 1993; Planas-Silva and Weinberg, 1997). The AF1 region within 
the NTD does not require the binding of E2 for activation (Kumar et al., 2011; Shiau et 
al., 1998; Tanenbaum et al., 1998). This mode of ligand independent activation is 
triggered when amino acid residues within the AF1 region are modified through 
phosphorylation (Benecke et al., 2000; Kumar et al., 2011; Tanenbaum et al., 1998). This 
post-translational modification results in ERα dimers that can complex directly with G-
proteins, receptor tyrosine kinases, and non-receptor tyrosine kinases triggering 
downstream pathways, such as the Ras/MAPK and the PI3K/Akt pathways  (Figure 2B) 
(Levin, 2005; Likhite et al., 2006). When fully phosphorylated, ERα dimers can activate 
both classical and non-classical transcriptional signalling. 
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Figure 1. Schematic representation of estrogen receptor domains. The estrogen receptor
structure contains domains A-F. A/B make up the N-terminal domain (NTD). Within
domain B there is the activating function (AF)1, which regulates ligand-independent
signalling. Phosphorylation sites within the NTD are dependent upon ERK1/2, GSK3,
and Akt signalling. The C region contains the DNA binding domain (DBD). The D
region or hinge region, contains the nuclear localization signal. The E region contains
the ligand binding domain and AF-2 region. This domain promotes classical and non-
classical genomic signalling. Finally, the F region promotes receptor dimerization.
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Figure 2. Schematic diagram of estrogen receptor signalling. (A) Classical activation of
ER targets require E2 binding (E2-ER), E2-ER dimerization, and binding of estrogen
response elements (ERE). Genes without EREs are activated by non-classical genomic
signalling, where after dimerization, transcription factors such as Fos and Jun tether the
E2-ER dimers to specific promoters to initiate transcription. (B) Non-genomic
signalling. After ER alpha is stimulated by growth factors, cytoplasmic signalling
cascades, such as the Ras-Raf-MEK-ERK pathway and the PI3K/Akt pathway, are
activated. The ER can be activated through phosphorylation by tyrosine kinase receptor
(TKR) or through the signalling cascades, promoting ligand-independent signalling.
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Post-Translational Modification of ERα 
ERα is modified on many different sites, all influencing ERα function. ERα 
modification can lead to stability as well as non-genomic signalling; acetylation can 
activate or inhibit transcription, depending on which site is modified, sumoylation can 
activate transcription and assist DNA binding, and palmitoylation promotes nuclear 
localization (Le Romancer et al., 2011). A primary and well-documented form of 
modification is phosphorylation (Bunone et al., 1996). Phosphorylation can facilitate 
ligand binding and classical activation of the ER, it can also alter the efficiency by which 
select ligands can bind, and it can promote ligand-independent signalling (Kumar et al., 
2011). 
One of the primary pathways to modify ERα is the MAPK pathway.  Extracellular 
signal-related kinase (ERK)1/2 is the final kinase within the MAPK pathway; following 
Ras-Raf-MEK1/2 signalling. The MAPK pathway is an important mitogen-driven 
pathway found to be hyper-activated in 30% of human cancers (Giltnane and Balko, 
2014; Huynh et al., 2003). In breast cancer, elevated levels of ERK1/2 are positively 
correlated with more aggressive tumour formation (Cui et al., 2006; Giltnane and Balko, 
2014); partially through its activation of the proto-oncogene c-Myc, which high levels 
have been linked to lower ERα levels and a basal-like genomic subtype (Dimitrakakis et 
al., 2006; Musgrove et al., 2008a; Riggins et al., 2007). ERK1/2 can modify ERα through 
phosphorylation on multiple residues, with primary sties being serine (S)102/4/6, S118, 
S167, and S305 (Chen et al., 2013; Thomas et al., 2008). These sites can also be modified 
by glycogen synthase kinase (GSK)3 (S102/4/6, S118), Cyclin A-cyclin dependent kinase 
(CDK)2 complex (S104/S206), CDK7 (S118), mTOR (S118), IKKα (S118), and 
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PI3K/AKT (S167) (Chen et al., 2000; Chen et al., 2002; Cheng et al., 2007; Thomas et 
al., 2008). The resulting function of the ERα can differ when modified by a differential 
pathway, likely indicating that other changes/binding partners cooperate in the final 
response to treatment (Bunone et al., 1996).    
Cancer Initiation and Progression Depends on Abnormal Cell Cycle Regulation 
 All cells are under the regulation of the cell cycle and at a pivotal level the cell 
cycle regulates growth, differentiation and decisions to undergo senescence and 
apoptosis. In many cancers, including breast cancer, there is a disruption of the core 
machinery driving the cell cycle (Collins et al., 1997). How the cell cycle is altered in 
specific cancers impacts the growth characteristics of that cancer and also determines 
how the cancer will respond to therapies that depend on a cell cycle arrest and apoptosis.  
The cell cycle is made up of interphase; comprising Gap phase 1 (G1), DNA 
replication phase (S), and Gap phase 2 (G2), and mitosis (M). When conditions are not 
favourable for growth, the cell will enter a state of quiescence (G0). Quiescent cells do 
not enter S phase and stay metabolically active, awaiting cell cycle re-entry (Salomoni 
and Calegari, 2010). Each phase of the cell cycle is regulated by the oscillating 
accumulation of proteins referred to as cyclins, which are selectively expressed and 
degraded at different phases. Their catalytic partners, the CDKs, are expressed at a 
constant level although, enzymatically, they are inactive until bound by their cyclin 
binding partner (Solomon, 1993).  
Activation of CDKs 
The active site of the CDK, where ATP binds, is found deep within a cleft. CDK 
substrates interact with this active site; however, in an inactive CDK, a T-loop blocks this 
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site to suppress its activity (Gu et al., 1992; Jeffrey et al., 1995). Cyclin binding induces a 
conformational change, which exposes the catalytic cleft and presents the CDK with a 
domain essential for substrate selection and binding (Bourne et al., 1996; Brown et al., 
1999; Holmes and Solomon, 2001; Schulman et al., 1998). Binding of cyclins does not 
fully activate the CDK. Full activation of the CDK requires posttranslational 
modifications. CDK activating kinase (CAK), which is composed of CDK7, Cyclin H, 
and Mat1, phosphorylates a threonine residue found on the T-loop of the CDK. 
Phosphorylation of this specific residue flattens the T-loop, moving it near the cyclin. 
This creates a binding site for substrates that contain a consensus sequence 
((S/T)PX(K/R)) (Bourne et al., 1996; Gould et al., 1991; Holmes and Solomon, 2001; 
Jeffrey et al., 1995; Solomon and Kaldis, 1998). Cyclins also have a hydrophobic patch, 
which is characterized by an MRAIL motif. This patch has the ability to bind to a CDK 
substrate with moderate affinity if the substrate has the complementary RXL sequence. 
This extra interaction increases the affinity of the kinase for its substrate (Brown et al., 
1999; Horton and Templeton, 1997; Loog and Morgan, 2005; Parker et al., 1992; 
Schulman et al., 1998; Solomon and Kaldis, 1998; Watanabe et al., 1995; Welburn et al., 
2007). Furthermore, inhibitory phosphorylation of threonine (T)-14 and tyrosine (Y)-15 
by Wee1 and Myt1 kinases must be removed by the Cdc25 phosphatases (Parker et al., 
1992; Solomon and Kaldis, 1998; Watanabe et al., 1995; Welburn et al., 2007). Three 
isoforms of Cdc25 exist, each regulating specific cyclin-CDK complexes (Donzelli and 
Draetta, 2003; Karlsson-Rosenthal and Millar, 2006). Cdc25A dephosphorylates Cyclin 
E-CDK2, Cyclin A-CDK2 and Cyclin B-CDK1, promoting entry into S phase and 
progression into G2/M transition. Cdc25B and Cdc25C only dephosphorylate Cyclin B-
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CDK1 and, therefore, promote entry into M phase (Donzelli and Draetta, 2003; Karlsson-
Rosenthal and Millar, 2006). Specific formation of cyclin-CDK complexes and their 
subsequent activation govern each phase of the cell cycle. 
G1 Phase Regulation 
 G1 phase prepares the cell for replication. This phase is controlled by D-type 
cyclins bound to CDK4/6 and E-type cyclins bound to CDK2. From early to mid-G1 
phase, Cyclin D-CDK4/6 forms a complex and controls the cell cycle. Three D-type 
cyclins, D1, D2, and D3, are expressed differently depending on cell lineage. Initially, 
growth factors stimulate the expression of Cyclin D1 (Lim and Kaldis, 2013; Salomoni 
and Calegari, 2010). The binding and activation of Cyclin D1-CDK4/6 triggers the 
phosphorylation of pRB (Smith and Nevins, 1995; White et al., 2005). The RB protein 
plays an important role as a checkpoint regulator in G1, known as the restriction point, to 
block entry into S-phase. pRB is normally bound to E2F, a family of transcription factors. 
When pRB is hyperphosphorylated, it releases E2F, which then promotes the 
transcription of a number of genes, including the two isoforms of E-type Cyclins, E1 and 
E2 (Nevins et al., 1991; Smith and Nevins, 1995; White et al., 2005). Cyclin E activation 
of CDK2 occurs in late G1 phase and promotes entry into S-phase. Cyclin E-CDK2 
complex continues to phosphorylate pRB, inhibiting its function as a transcriptional 
repressor (Horton and Templeton, 1997; Hwang and Clurman, 2005; White et al., 2005).  
S- and G2 Phase Regulation 
 S-phase allows for DNA replication. As stated previously, the complex 
controlling S-phase is Cyclin A-CDK2. Cyclin A is required for the progression through 
S-phase and also controls entry into G2 (Brown et al., 1995). Cyclin A is a unique cyclin, 
17 
 
such that it can bind to and activate CDK2 and CDK1 (in G2 phase). No other classical 
cyclin has the ability to activate two CDKs (Arellano and Moreno, 1997). 
 G2 phase prepares the cell for mitosis. This phase requires Cyclin A to bind to 
and activate CDK1, but it also requires Cyclin B to bind to and activate CDK1 (Lindqvist 
et al., 2009; Solomon et al., 1990). These complexes phosphorylate specific transcription 
factors, such as FoxM1; a member of the forkhead box (Fox) superfamily (Laoukili et al., 
2008). Activation of transcription factors upregulates target genes/regulators required for 
mitosis and the spindle assembly checkpoint (Rattani et al., 2014). Prior to entry into 
mitosis, cells undergo another checkpoint to check for DNA damage. If damage is 
detected, CDK1 is inhibited and blocks entry into mitosis (Arellano and Moreno, 1997). 
CDK Inhibitors (CKIs) 
G1/S phase of the cell cycle can be transiently inhibited by a family of CKIs, the 
Cip/Kip family. This family includes p21
Cip1
, p27
Kip1
, and p57
Kip1
. These CKIs can inhibit 
not only Cyclin E-CDK2, but also the S-phase complex, Cyclin A-CDK2. This family of 
CKIs inhibit the cyclin-CDK complexes by binding to both the hydrophobic MRAIL 
patch on the cyclin and a large domain on the CDK. This interaction alters the 
conformation of the complex, limiting access to the catalytic cleft (Brown et al., 1995; 
Nakayama, 1998). Cyclin D-CDK4/6 sequesters p27
Kip1
, to hinder its inhibitory actions 
on the other cyclin-CDK complexes. The sequestered p27
Kip1
 is released once mitogen 
signalling has ended. This, in turn, enables p27
Kip1
 to bind to and inhibit Cyclin E-CDK2 
activation and S-phase entry (Cheng et al., 1999; Nakayama, 1998; Promwikorn et al., 
2000). Cyclin E-CDK2 also has the ability to phosphorylate p27
Kip1
 on threonine (T)-187, 
which is a specific residue for ubiquitin mediated degradation of p27
Kip1
 by SCF
Skp2 
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(Alessandrini et al., 1997). Another family of CKIs, specific only for CDK4/6 is the Ink4 
family, consisting of p16
Ink4a
 or its alternate reading frame (ARF) p14
ARF
, p15
Ink4b
, 
p18
Ink4c
, p19
Ink4d 
and p19
ARF 
(Bandoh et al., 2005; Nakayama, 1998; Sangfelt et al., 1997). 
This family of inhibitors specifically binds to monomeric CDK4 or 6, inducing a 
conformational change, effectively inhibiting the ability of Cyclin D to bind and activate 
the complex (Nakayama, 1998). Regulation of G1 to S phase by these cyclin-CDK 
complexes have an important role in the initiation and progression of breast cancer. 
D-type Cyclins in Breast Cancer 
 In breast cancer, Cyclin D1 and D3 have been found to be upregulated in ERα 
positive breast cancers (Kenny et al., 1999; Peurala et al., 2013). E2 activation of ERα 
targets Cyclin D1 to promote its mitogenic effects. There have been positive correlations 
between Cyclin D1 levels and a positive ERα status (Barone et al., 2006; Castro-Rivera et 
al., 2001). Furthermore, upregulated Cyclin D1 is mainly present in low grade tumours 
that are well-differentiated and slow-growing. No specific correlation has been made with 
regard to PR or Her2/neu status. Cyclin D1 is amplified in 20% of all breast cancers, 
while over 50% of breast cancers have Cyclin D1 overexpressed (Kenny et al., 1999; 
Perez-Roger et al., 1999; Weroha et al., 2006). The other two isoforms of Cyclin D have 
not been as highly documented as Cyclin D1; however, it was discovered that breast 
cancer progression correlates with a loss of Cyclin D2 expression (Evron et al., 2001). 
Furthermore, in Her2-induced breast cancers, it was found that Cyclin D1 expression is 
downregulated, while Cyclin D3 levels were significantly elevated (Zhang et al., 2011).  
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E-type Cyclins in Breast Cancer 
 Both E-type cyclins have been associated with breast cancer in different ways; 
however, both are regulated by estrogen signalling. Both Cyclin E isoforms have been 
found to be overexpressed and amplified, but there are also cases of Cyclin E truncations 
which form constitutively active Cyclin E complexes (Dhillon and Mudryj, 2002; Hwang 
and Clurman, 2005; Keyomarsi et al., 2002). Using a database with 863 breast cancer 
patient transcripts, Caldon et al. (2012) showed both Cyclin E1 and Cyclin E2 genes, 
CCNE1 and CCNE2, respectively, increased with progression from benign breast cancer 
to DCIS to IDC, as well as correlating with an increase in tumour grade (Caldon et al., 
2012). However, both genes were found to be differentially expressed in different 
subtypes. CCNE1 was found to be upregulated in basal-like breast cancers, and CCNE2 
was higher in both basal-like breast cancers and Her2 amplified (Caldon et al., 2012; 
Scaltriti et al., 2011). Cyclin E2 has been correlated with poor disease outcome in ERα 
positive breast cancers (Keyomarsi et al., 2002).  
The Potent Mammary Oncogene c-Myc 
 The transcription factor c-Myc can regulate approximately 10% to 15% of the 
human genome, having potent effects on cell proliferation, differentiation, apoptosis, and 
senescence (Amati and Land, 1994; Amati et al., 1993; Evan et al., 1994; Evan et al., 
1992), which has made c-Myc a desirable target for many different cancers. c-Myc 
activates transcription by forming a complex with its binding partner MYC-associated 
factor X (Max) (Amati et al., 1992; Littlewood et al., 1992). This complex binds to E-box 
elements containing the consensus sequence CACGTG (Amati, 2004). c-Myc not only 
transcriptionally activates other genes, it can also repress genes by binding to MYC-
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interacting zinc finger protein-1 (Miz-1) (Adhikary and Eilers, 2005). c-Myc expression 
activates the cell cycle by activating Cyclin E bound to CDK2 as well as repressing the 
CDK inhibitor (CKI), p21
Cip1 
(Amati et al., 1998). Repression of p21
Cip1 
increases G1 to S 
phase entry into the cell cycle, as well as cell differentiation (Wu et al., 2003). c-Myc has 
also been shown to inhibit the transcription of another CKI, p27
Kip1
, while activating 
Cyclin D1, CDK4, Cdc25A, and the E2F family of transcription factors (Xu et al., 2010). 
Comparatively, c-Myc can also trigger cell cycle arrest and apoptosis. c-Myc activates 
the tumour suppressor p19
ARF
, which then antagonizes the regulation of Mdm2 on p53. 
This stabilizes p53 and induces the activation of pro-apoptotic genes (Tao and Levine, 
1999; Weber et al., 2000; Wu et al., 2003; Xu et al., 2010). Furthermore, c-Myc can 
suppress Ras-induced senescence with aid from CDK2. CDK2 has been shown to 
phosphorylate c-Myc on Serine 62 (S62), which is a stabilization site (Hydbring et al., 
2010; Hydbring and Larsson, 2010a; Hydbring and Larsson, 2010b; Sears et al., 1999). 
When CDK2 binds c-Myc and phosphorylates S62, it is correlated with low expression of 
genes which activate senescence, p21
Cip1
 and p16
INK4A
, and higher expression of hTERT 
and BMI1, which are genes that suppress senescence (Campaner et al., 2010; Hydbring et 
al., 2010; Hydbring and Larsson, 2010a). However, in CDK2 null cell lines, c-Myc was 
found to induce senescence when p53/p21 and p16-pRB pathways were intact, which are 
the same pathways that are normally upregulated by Ras (Campaner et al., 2010). The 
high complexity of c-Myc regulatory function creates a sensitive balance between 
regulation required for normal growth and development and the development of 
carcinogenesis. When the balance is shifted towards carcinogenesis, the high degree of c-
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Myc regulatory control over the genome creates aggressive phenotypes, which are found 
to be difficult to treat.  
Breast Cancer Therapies 
Treatment Strategies for Luminal Breast Cancers 
 Luminal breast cancer therapies have a higher success rate over the other forms of 
breast cancer because of the presence of hormone receptors. Early stages of luminal 
breast cancers are treated with surgery followed by radiotherapy. To combat recurrence, 
adjuvant treatments are administered (Al-Ejeh et al., 2011; Prat et al., 2012). ERα 
positive cancers are usually targeted through the use of selective estrogen receptor 
modulators (SERMs) and aromatase inhibitors (AIs) (Dowsett and Haynes, 2003; 
Lumachi et al., 2013); both of which aim to inhibit estrogen signalling.  
 SERMs, such as tamoxifen, are nonsteroidal compounds that antagonize ERα by 
acting as a competitive inhibitor for E2 binding (Connor et al., 2001; de Leeuw et al., 
2011). The structure of tamoxifen is similar to E2, but it lacks a second hydroxyl group 
and has a dimethylaminoethyl sidechain that extends from the C-ring of tamoxifen (Shiau 
et al., 1998). These differences cause conformational changes to ERα, such that co-
activators no longer bind. For instance, the side-chain on tamoxifen will extend between 
helices 3 and 11 of ERα creating new hydrophobic interactions (Shiau et al., 1998). One 
of the most significant changes to ERα when tamoxifen binds is the positioning of helix 
12. Helix 12 gets repositioned such that it covers the hydrophobic motif. Co-activators 
will no longer bind, ERα will remain inactivated, and the downstream genes will not be 
transcribed (de Leeuw et al., 2011; Ring and Dowsett, 2004; Shiau et al., 1998; Vendrell 
et al., 2005). Tamoxifen has been used alone or in combination with AIs.  
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 AIs block the enzyme aromatase, which reduces the amount of estrogen 
circulating in the body. Aromatase, also known as cytochrome P450 aromatase, is an 
enzyme that metabolizes testosterone to E2. There are two types of AIs; type I are 
steroidal, which is a permanent inhibition of aromatase, type II are nonsteroidal, they 
competitively inhibit aromatase and are reversible. The intention of AIs is to inhibit the 
production of E2 to decrease the activity of ERα and its downstream targets (Dowsett and 
Haynes, 2003; Lumachi et al., 2013). 
Treatment of ERα-Negative Breast Cancer 
 Breast cancer subtypes that cannot be treated with targeted therapies are treated 
through surgery, radiation, chemotherapy, or a combination of these treatments (Al-Ejeh 
et al., 2011; Raguz and Yague, 2008). Chemotherapy treatment has significantly 
increased overall survival of breast cancer patients. There are many forms of 
chemotherapy drugs with over 100 currently in use; most are designed to take advantage 
of a functioning and rapid cell division cycle and all intend to inhibit the cell cycle to 
promote cell death, or apoptosis. A disadvantage of this treatment is chemotherapy 
cannot distinguish between a cancer cell and a normal cell (Raguz and Yague, 2008). 
Understanding each phase of the cell cycle and its regulators is essential in ensuring 
proper administration of chemotherapy drugs to optimize their effects on cancer cells.  
Function of Classes of Chemotherapy Agents 
Alkylating Agents 
 Alkylating agents directly damage DNA by adding an alkyl group to the guanine 
base of DNA, forming a cross-link. Cross-linking holds the DNA in a coiled position 
unable to separate, thereby preventing DNA synthesis (Kennedy et al., 1995). A common 
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class of alkylating agents are the nitrogen mustards; one example of this is 
cyclophosphamide. Cyclophosphamide is rapidly absorbed and then metabolised by 
cytochrome P450 enzymes in the liver to its active metabolites. The main metabolites are 
4-hydroxycyclophosphamide and aldophosphamide (Emadi et al., 2009; Hall and Tilby, 
1992). Most aldophosphamide can be oxidised by aldehyde dehydrogenase (ALDH) to 
produce carboxycyclophosphamide; however, some aldophosphamide gets broken down 
into two compounds, phosphoramide mustard and acrolein. Most of the effects seen with 
cyclophosphamide administration are due to phosphoramide mustard. This metabolite is 
present only when cells have low levels of ALDH and is highly toxic to cancerous and 
normal cells. Alkylating agents have a grave disadvantage to their use (Hall and Tilby, 
1992; Kohn and Sladek, 1985); causing long-term damage to the bone marrow of a 
patient, which often leads to acute leukemia (Kohn and Sladek, 1985; Lohrmann, 1984).  
 Platinum based drugs fall in with the alkylating agents because they have a 
similar mechanism for damaging the DNA (Rosenberg et al., 1969; Wang and Lippard, 
2005). Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, differ from other 
alkylating agents in that they do not contain an alkyl group. After administration, one of 
the chloride ligands in a platinum drug is displaced by water, allowing a platinum atom to 
bind to the bases of DNA, preferably guanine. This crosslink promotes the displacement 
of the second chloride ligand, followed by the binding of the second platinum atom, 
preferably with another guanine (Siddik, 2003). The formation of cross-links interferes 
with cell division, triggering the DNA repair machinery, which will, in turn, activate the 
apoptotic pathway if damage cannot be fixed. Platinum-DNA adducts do not get 
metabolized into harmful by-products and, hence, this class of drugs is less toxic to 
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normal cells and are less likely to lead to leukemia in the future (Pruefer et al., 2008; 
Rosenberg et al., 1969; Siddik, 2003; Wang and Lippard, 2005).  
Anti-tumour Antibiotics 
 Anthracyclines, such as the drug doxorubicin, are classified as an anti-tumour 
antibiotic. They can work in all phases of the cell cycle; however, they have preference 
for interfering with the enzymes involved in DNA replication; therefore, most effects are 
seen in S-phase (Minotti et al., 2004; Pommier et al., 2010; Weiss, 1992). Anthracyclines 
have four mechanisms of action. They can inhibit DNA and RNA synthesis through 
intercalation with the DNA or RNA (Weiss, 1992), they can inhibit topoisomerase II, the 
enzyme responsible for the separation of the DNA strands so they can be transcribed 
(Pommier et al., 2010), they can generate free oxygen radicals, which then damage DNA, 
proteins and cell membranes (Weiss, 1992), and, lastly, they can provoke histone eviction 
from chromatin, which leads to activation of the DNA damage repair pathways or 
activation of apoptosis (Pang et al., 2013). Long-term use at high dosages of 
anthracyclines can permanently damage the heart and can increase the risk of a second 
cancer, such as acute myelogenous leukemia (Minotti et al., 2004; Weiss, 1992). 
Mitotic Inhibitors 
 Most mitotic inhibitors are derived from plant alkaloids and other natural products 
(Jordan and Wilson, 1998; Jordan and Wilson, 2004). They inhibit M-phase of the cell 
cycle, but damage of cells in other phases has also been discovered (Bharadwaj and Yu, 
2004). One common mitotic inhibitor is paclitaxel. When paclitaxel is administered, it is 
metabolized by isoenzymes, CYP2C8 and CYP3A4 (Marsh et al., 2007), to primarily 
produce the active metabolite 6-α-hydroxypaclitaxel. 6-α-hydroxypaclitaxel stabilizes 
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microtubules and shields the polymer from disassembly (Ganguly et al., 2010; Jordan and 
Wilson, 2004). This function leads to defects in spindle assembly, segregation of 
chromosomes, and, ultimately, cell division. This blocks mitosis and delays the spindle 
assembly checkpoint (SAC), which then activates apoptosis. A downfall of this class of 
inhibitors is that it has the potential to cause peripheral nerve damage (Bharadwaj and 
Yu, 2004; Brito et al., 2008; Lohrmann, 1984). 
Breast Cancer Treatment Resistance 
Resistance to Hormone Therapy 
 Breast cancer mortality rates have decreased 43% since 1986; this success can be 
attributed in part to the availability of targeted reagents (CBCF, 2014). However, despite 
high rates of initial response to treatment approximately 30% of hormone receptor 
positive patients fail to respond to tamoxifen treatment and have poor prognosis to 
endocrine treatment (Schiff et al., 2003). Tamoxifen resistance can occur either de novo, 
at the beginning of a patient's treatment, or the patient can acquire resistance after 
prolonged tamoxifen treatment (Osborne and Schiff, 2011; Schiff et al., 2003). 
 Lack of ERα expression and/or function is one main mechanism towards 
tamoxifen resistance. De novo resistance is driven by the lack of ERα expression when a 
histological sample is being characterized, and these negative tumours will receive 
alternate form(s) of therapy. Most patients who are ERα-positive prior to treatment 
remain so upon relapse (Ring and Dowsett, 2004; Schiff et al., 2003); however, Dowsett 
et al. (2003) found 17% of patients who were ERα-positive before tamoxifen treatment 
became ERα-negative upon relapse. This showed that ERα expression can be lost during 
tamoxifen treatment; likely due to a downregulation of ERα (Dowsett and Haynes, 2003).  
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Multiple splice variants of ERα have also been discovered. One ERα isoform, 
ERα46, lacks exon 1 and the AF1 domain (Flouriot et al., 2000). Another, ERα36, has an 
alternate transcription initiation site in intron 1. ERα36 lacks AF1, part of AF2, and has a 
unique amino acid sequence on the C-terminal end, within exon 9 (Kampa et al., 2013; 
Wang et al., 2005; Wang et al., 2006). ERα36 has been found in ERα positive and 
negative breast cancers (Lee et al., 2008). This isoform responds to E2 as well as anti-
estrogens, inducing membrane-initiated signalling cascades. Furthermore, ERα36 can 
stimulate proliferation and can contribute to a more aggressive breast cancer phenotype 
(Lee et al., 2008; Wang et al., 2005; Wang et al., 2006). Other variants have been found 
in cancer cells, all of which lack the 5'UTR of the receptor. All of the isoforms can 
heterodimerize with the wild-type, full-length ERα and repress AF1 activity (Kampa et 
al., 2013). These characteristics are pertinent in the classification of breast cancer, 
especially when molecular signatures are analysed and may be important in assessing 
response to therapy. 
Mutations within the ERα gene, ESR1, can lead to the development of a 
functionally inactive ERα, although expression of ERα will still be present. This could 
cause a false-positive during histological classification (Ring and Dowsett, 2004). 
Mutations occurring in ESR1 can alter the binding of anti-estrogens, making ERα less 
sensitive to their inhibition and more sensitive to E2 signalling (Fuqua et al., 2000; 
Herynk et al., 2010). One such mutation could be an alteration in phospho-sites within 
the AF1 domain; this could result in a conformational change or by enhancing the 
binding of co-activators even in the presence of low E2 levels (Cheng et al., 2007; 
Connor et al., 2001; Fuqua et al., 2000; Thomas et al., 2008; Yamashita et al., 2008).  
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 Alterations in post-translational modification of ERα is a common mechanism of 
endocrine resistance. Phosphorylation on (S)102/4/6 by ERK1/2 stabilizes ERα and 
controls transcriptional activity upon ligand binding (Thomas et al., 2008). S118 
phosphorylation by ERK1/2 in the absence of a ligand can render ERα hypersensitive to 
E2 and insensitive to SERMs; however, phosphorylation of this same site by CDK7 
occurs in the presence of a ligand and indicates that ERα is active, properly functioning 
and responsive to treatment (Bunone et al., 1996). S167 phosphorylation by PI3K/Akt 
and ERK1/2 is associated with conflicting clinical data; at times phosphorylation at this 
site has indicated an increased sensitivity to SERM treatment, while other patient data has 
been correlated with lack of response or future relapse (de Leeuw et al., 2011; Guo et al., 
2010; Huderson et al., 2012; Weitsman et al., 2009; Yamnik and Holz, 2010). Lastly, 
S305, which is present in the hinge region of ERα, is phosphorylated by protein kinase A 
and is correlated with resistance to SERM treatment. This site is important for the control 
of ubiquitination and proteasomal degradation of ERα (Bostner et al., 2010; Kumar et al., 
2011). There are many more phosphorylation sites in ERα, research unravelling the 
biology of the structure and function of ERα will continue to inform about the 
mechanisms by which SERM resistance can occur.  
Resistance to Chemotherapy 
 Innate chemotherapy resistance refers to the total lack of patient response to a 
given therapy, whereas acquired resistance implies that a patient develops resistance after 
an initial response. Breast cancer patients treated with anthracycline and/or paclitaxel can 
develop acquired resistance to one or both of the drugs (Raguz and Yague, 2008). There 
are also examples where after prolonged exposure to one form of therapeutic, 
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development of acquired resistance to multiple drugs occurs, this is termed cross-
resistance. Innate and acquired chemotherapy resistance occurs via multiple mechanisms, 
including drug metabolism, changes in drug target expression or function, DNA damage 
repair modifications, or altered apoptotic signalling pathways (Raguz and Yague, 2008; 
Rivera and Gomez, 2010).  
 The cytochrome P450 enzymes are a family of enzymes found in the liver that 
induce metabolism of chemotherapeutic drugs. In cancer, they are often overexpressed 
and this overexpression contributes to drug resistance through alteration of metabolic 
pathways (Marsh et al., 2007; Raguz and Yague, 2008). Chemotherapy drugs require 
appropriate activation of metabolic pathways to ensure adequate delivery and access to 
the tumour tissue. Mutations in topoisomerase II or altered activity prevents 
anthracyclines from binding and, thus, leads to the repair and transcription of the 
damaged DNA strands. DNA damage response pathways are regulated by the tumour 
suppressor gene, p53; however, p53 is one of the most common molecular mutations in 
breast cancer. Alterations in the DNA damage response pathways can lead to the evasion 
of apoptosis or senescence (Pommier et al., 2010; Raguz and Yague, 2008; Rivera and 
Gomez, 2010).  
 Paclitaxel resistance occurs widely in breast cancer patients with altered or 
overexpressed tubulin, mutations in tubulin that affect the stabilization of the 
microtubules, or post-translational modifications on tubulin (Jordan and Wilson, 1998; 
Jordan and Wilson, 2004). An important goal in the breast cancer field is to develop 
therapies that can work alone or in combination with standard of care chemotherapy to 
override known causes of resistance. Chemotherapy agents require an active cell cycle; 
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therefore, understanding the role of the cell cycle in cancer progression can increase the 
likelihood of developing novel treatment options.  
Cell Cycle Alterations in Breast Cancer Resistance 
Gene signatures for cancer progression in tamoxifen-resistant cancers or 
metastatic cancers have shown Cyclin E2 to be elevated, whereas Cyclin E1 is absent 
(Caldon et al., 2012; Muller-Tidow et al., 2001). Furthermore, higher levels of the Cyclin 
E2 gene, CCNE2, were shown to have a shorter distant metastasis-free survival after 
endocrine therapy (Muller-Tidow et al., 2001). Inhibitors of G1/S phase of the cell cycle 
are also altered. Increased phosphorylation and degradation of p27
Kip1
 has been seen in 
tumourigenesis (Abukhdeir and Park, 2008; Sheaff et al., 1997) and low levels of both 
p27
Kip1
 and p21
Cip1 
correlates with various resistant phenotypes (Abukhdeir and Park, 
2008). Abukhdeir et al. (2008) discovered that loss in p21
Cip1
 expression in ERα positive 
breast cancers increased tamoxifen resistance (Abukhdeir et al., 2008). Furthermore, a 
loss of p21
Cip1 
expression promoted tamoxifen-mediated proliferation. p21
Cip1
 null cells 
significantly increased phosphorylation of ERα on S118, a site correlated with tamoxifen-
resistance; however, when p21
Cip1
 wild-type cells were treated with tamoxifen, this 
phosphorylation of ERα was not seen (Abukhdeir et al., 2008). Similarly, loss of p21Cip1 
and p27
Kip1
 in ERα positive cells reduced cell cycle arrest when the cells were treated 
with anti-estrogens (Cariou et al., 2000). p27
Kip1
 was demonstrated to have an important 
role in response of Her2-enriched breast cancers to trastuzumab treatment. The presence 
of p27
Kip1
 indicates sensitivity to this therapy (Casalini et al., 2007; Okutur et al., 2015; 
Yang et al., 2006). This is in part because trastuzumab arrests cells in the G1 phase of the 
cell cycle and there is a subsequent decrease in proliferation due to the increase in p27
Kip1
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levels, which form complexes with CDK2 (Sheaff et al., 1997). Nahta et al. (2004) 
discovered cell lines that are resistant to trastuzumab had decreased levels of p27
Kip1
 and 
significantly increased CDK2 activity. Furthermore, using this resistant Her2 expressing 
cell line, when p27
Kip1
 was ectopically expressed in these cells they became highly 
sensitive to trastuzumab treatment (Nahta et al., 2004). p27
Kip1
 has a similar structure to 
p21
Cip1 
(Toyoshima and Hunter, 1994); however, their roles in the cell cycle are slightly 
different. Both inhibit the same CDKs, but it was found that p21
Cip1
 inhibition of the cell 
cycle was preferentially in the G1 phase. Furthermore, p21
Cip1
 can be upregulated by p53 
to induce cell cycle arrest and apoptosis. p27
Kip1
 is not upregulated by p53 and can lead to 
cell cycle arrest at any stage of interphase (Abukhdeir and Park, 2008). These small 
differences may indicate a unique role for each in resistance.  
Synthetic CKIs as an Approach for Breast Cancer Resistance  
When functional, CKIs trigger cellular response to many existing therapeutics by 
halting the cell cycle and directing cells toward apoptosis. However, many CKIs become 
deregulated during cancer progression and their cyclin targets subsequently become 
elevated, both contributing to resistance to chemotherapy and many forms of targeted 
therapy, including endocrine therapy (Abukhdeir et al., 2008; Bandoh et al., 2005; 
Caldon et al., 2012; Dhillon and Mudryj, 2002). Synthetic CKIs have been designed to 
mimic p21
Cip1
 and p27
Kip1
 by competitively binding to the ATP-binding pocket of CDKs 
to inhibit kinase activity (Nair et al., 2011). Recently, some pan-CKIs, such as 
flavopiridol and roscovitine, have entered clinical trials (Byrd et al., 2007; Meijer and 
Raymond, 2003). As single agents, these CKIs have had little success presented with 
significant toxic effects on normal cells (Byrd et al., 2007; Harrison et al., 2009). Some 
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clinical trials are introducing combinations of synthetic pan-CKIs with various 
chemotherapeutic agents (Deep and Agarwal, 2008; Johnson and Shapiro, 2010). The 
outcome thus far has not shown promising benefits for breast cancer patients, but has 
shown promising results in populations of prostate cancer cells (Deep and Agarwal, 
2008; Flaig et al., 2007) and in phase II clinical trials in relapsed and refractory multiple 
myeloma (Kumar et al., 2015).   
The downfalls of using synthetic CKIs as a therapeutic can somewhat be 
attributed to the extreme conservation of the CDK active site between different forms, 
leading to a great deal of nonspecific effects (Asghar et al., 2015). Second generation 
inhibitors have begun to selectively target specific CDKs. Among these studies very few 
have made any efforts to stratify patient populations. Only a current CDK4/6 CKI clinical 
trial specifically looking within ERα-positive breast cancer, has stratified its patient 
population based on the molecular signature of the patient (Turner et al., 2015); 
specifically looking for an amplification of Cyclin D1, loss of p16, or both of these 
characteristics (Finn et al., 2009; Turner et al., 2015). This is the first documented clinical 
trial to stratify patients, resulting in improved responses thus far (Turner et al., 2015).  
Furthermore, synthetic CKIs target proteins essential for proliferation, such as CDK1, 
and survival, such as CDK9. This form of therapy cannot differentiate between a normal 
proliferating cell and a cancerous cell; which causes greater toxicities to patients (Asghar 
et al., 2015). A better understanding of the role of select cyclin-bound complexes may 
lead to increased specificity of and response to CKIs. This may be particularly relevant 
for CDK1, which has shown synthetic lethality in aggressive TNBC patients with 
amplified c-Myc (Horiuchi et al., 2012; Kang et al., 2014). An additional point that has 
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not yet been considered in the clinic is the existence of cyclin-like proteins that can bind 
and activate CDKs in the presence of CKIs (Nebreda, 2006), the importance of these 
proteins in breast cancer has been the topic of this thesis.   
Speedy/RINGO Family of Cell Cycle Regulators 
 The first member of the Speedy/RINGO (Rapid Inducer of G2/M progression in 
Oocytes) family of proteins, coined X-Spy1, was initially isolated from a Xenopus laevis 
ovarian cDNA library in a genetic screen to find genes that confer resistance to gamma 
irradiation in a rad1 deficient strain of S. pombe (Lenormand et al., 1999). 
Microinjections of X-Spy1 mRNA into stage VI oocytes activated MAPK and CDK1 and 
induced rapid oocyte maturation in the absence of progesterone (Lenormand et al., 1999). 
X-Spy1 binds and activates CDK2, which is important for Spy1-mediated maturation, but 
structurally has no sequence homology to the classically defined cyclins (Lenormand et 
al., 1999). 
 The human homologue of X-Spy1, originally termed Spy1, has since been 
isolated from a human testis cDNA library and was found to share 40% homology with 
X-Spy1 (Porter et al., 2002). Full length Spy1, Spy1A2, appears to only be found in 
testis, but a smaller splice variant, Spy1A1, hereafter referred to as Spy1, is found in low 
levels across most adult human tissues. The family of Speedy/RINGO proteins is now 
known to consist of at least 6 proteins, all harbouring a highly conserved core of 
approximately 100 residues, called the Speedy/RINGO (S/R) box, predicted to have an α-
helical structure and found to be crucial for its interaction with CDKs (Figure 3A) (Cheng 
et al., 2005a; Dinarina et al., 2005). Diversity among the family members occurs at both 
33 
 
the C- and N-termini; possibly representing the ability of the Spy1 family members to 
bind to different CDKs or their affinity for specific substrates (Figure 3B).  
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Figure 3. Schematic of Speedy/RINGO domain organization and Speedy/RINGO
isoforms. (A) A schematic of Speedy/RINGO protein domains. (B) Table demonstrating
Speedy/RINGO family members.
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Spy1 Expression and Regulation 
 The SPDYA gene is ubiquitously expressed in many mammalian adult tissues. 
Specifically, high levels have been found in hormonally sensitive tissues, such as the 
testis and ovary (Cheng et al., 2005a; Porter et al., 2002). X-Spy1 and mammalian Spy1 
protein bind to CDK1 and CDK2, initiating kinase activity (Al Sorkhy et al., 2012; 
Karaiskou et al., 2001). Consistent with its CDK binding ability, SPDYA expression and 
Spy1 protein levels are regulated in a cell cycle dependent fashion, with expression 
coming on in late M and accumulating through G1/S  (Gutierrez et al., 2006; Porter et al., 
2002). There appears to be at least 2 different mechanisms of protein degradation, one 
that functions at late G2 phase of the cell cycle and is driven by the E3 ligase, NEDD4 
(Al Sorkhy et al., 2009), and another occurring at late G1 phase and is dependent on the 
E3 ubiquitin ligase, Skp2 (Gutierrez et al., 2006). Overexpression of Spy1 increases cell 
proliferation and shortens G1 phase of the cell cycle in a CDK2 dependent manner 
(Golipour et al., 2008; Porter et al., 2002). In contrast, a reduction of Spy1 levels 
decreases the rate of cell division and the population of cells in G1/S phase (Porter et al., 
2002). While Spy1 binds to similar residues on the CDK as canonical cyclins, Spy1 
activates the CDK in quite a unique fashion (Dinarina et al., 2005). Spy1-mediated 
activation of CDKs occurs independent of CAK-mediated phosphorylation of the 
residues T161 and T160 on CDK1 and CDK2, respectively, within the T-loop of the 
CDK (Cheng et al., 2005a; Dinarina et al., 2005). Furthermore, when Spy1 is bound to 
CDKs the complex is less sensitive to the inhibitory phosphorylation on T14 and Y15 
mediated by Wee1 and Myt1 kinases and are less susceptible to the inhibitory action of 
p21
Cip1 
(Karaiskou et al., 2001). Spy1 also indirectly activates CDKs via a direct 
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interaction with the CKI, p27
Kip1 
(McAndrew et al., 2007; Porter et al., 2003). A 
characteristic of G1/S phase transition is the degradation of p27
Kip1
 by SCF
Skp2
, through 
its phosphorylation on T187 by Cyclin E-CDK2 (Pagano et al., 1995; Sheaff et al., 1997). 
Spy1-bound p27
Kip1
 promotes the phosphorylation of p27
Kip1
 and subsequent degradation, 
thereby, effectively overriding this important CKI (McAndrew et al., 2007). Spy1-bound 
CDKs also have an altered substrate specificity. A cyclin-CDK complex has a well-
established ((S/T)PX(K/R)) consensus sequence and a strong affinity for a substrate with 
a lysine residue at the +3 position (Bourne et al., 1996; Cheng et al., 2005a; Jeffrey et al., 
1995). Spy1 bound to CDK2 is able to phosphorylate canonical CDK substrates, such as 
histone H1; however, the CDK demonstrates a broader substrate specificity with 
preference for non-canonical CDK substrates lacking lysine residues at the +3 position 
(Cheng et al., 2005a). One example of a non-canonical substrate phosphorylated by 
Spy1-CDK2 is the Cdc25 proteins, which are classically inactivated during a checkpoint 
response, potentially indicating another mechanism by which Spy1 can override these 
protective cellular barriers.  
Spy1 and DNA Damage Response (DDR) 
 The unique ability of Spy1 to activate CDKs in an environment indicative of a 
checkpoint response, and to override the effects of CKIs, such as p21
Cip1
 or p27
Kip1
, 
speaks to the mechanism by which Spy1 may override cell cycle arrest seen in the 
original yeast screen. Indeed it was later demonstrated that Spy1 can also override the 
DDR in response to a host of DNA damaging agents including cisplatin and UV damage 
(Barnes et al., 2003; Karaiskou et al., 2001). The cell cycle is protected by several 
checkpoints with the most common being the restriction point (G1/S), the G2/M 
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checkpoint, and the spindle assembly checkpoint in M-phase. The G1/S and G2/M 
checkpoints are governed by the cell inhibiting the action of the relevant CDKs (Arellano 
and Moreno, 1997). In the presence of elevated levels of Spy1, the phosphorylation effect 
on Cdc25 by Spy1-CDK2, as well as decrease in sensitivity to p21
Cip1
, allows for the 
bypass of the G1/S and G2/M checkpoints, increasing the proliferation of damaged cells 
(Gastwirt et al., 2006). Spy1 was demonstrated to have a regulatory role within the 
intrinsic DDR pathway (Barnes et al., 2003; Gastwirt et al., 2007) and confer resistance 
to p53- and p21
Cip1
-mediated apoptosis (Gastwirt et al., 2006). Elevated levels of Spy1-
CDK2 leads to a resistant phenotype to genotoxic agents, radiation, and 
chemotherapeutic agents (Barnes et al., 2003). Spy1 overexpression has been shown to 
decrease sensitivity to agents used as cancer therapeutics (Barnes et al., 2003); hence, 
elevated levels of Spy1 may represent a targetable mechanism driving aspects of drug 
resistance. 
Functional Roles for Spy1 in Normal Development and Carcinogenesis 
 The role of Spy1 in normal development in various tissues is still emerging. 
Under normal growth and developmental conditions, Spy1 levels are tightly regulated at 
select stages of development (Golipour et al., 2008; Lubanska and Porter, 2014b; Porter 
et al., 2002). In the mammary gland, Spy1 is expressed during the proliferative stages of 
the gland, such as puberty and pregnancy and reduced during terminal differentiation 
(Golipour et al., 2008). In the brain, Spy1 levels are elevated in embryonic tissues and 
decline with aging (Lubanska and Porter, 2014b). Spy1 levels are also upregulated during 
regeneration in the mammary gland (Golipour et al., 2008), peripheral nervous system 
(Huang et al., 2009) and stem cell populations in the adult brain (Lubanska et al., 2014; 
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Lubanska and Porter, 2014b). These data suggest that Spy1 has developmental roles and 
may play a role in regenerative processes. In the brain, Spy1 plays a role in regulating 
symmetric division of adult stem cell populations (Lubanska et al., 2014; Lubanska and 
Porter, 2014b). How Spy1 functions in development may provide important answers for 
its role in disease states, such as carcinogenesis.   
 Indeed, Spy1 levels are highly elevated in a number of human cancers including 
Non-Hodgkin's Lymphoma (NHL) (Hang et al., 2012), hepatocellular carcinoma (Ke et 
al., 2009), breast cancers (Al Sorkhy et al., 2012) and brain cancers (Lubanska et al., 
2014; Lubanska and Porter, 2014b). In NHL and brain cancers, Spy1 levels correlated 
with an overall poor outcome for patients (Hang et al., 2012; Lubanska et al., 2014), 
indicating Spy1 as a potentially valuable prognostic marker. In NHL samples with 
elevated Spy1, a significant increase in phosphorylated p27
Kip1
 on T187, as well as 
increased proliferation, was observed (Hang et al., 2012). In breast, Spy1 levels are 
regulated downstream of both c-Myc and MAPK and forced Spy1 expression in 
orthotopic breast models drives tumour formation (Golipour et al., 2008). Knocking 
down Spy1 in leukemic, liver, brain and breast cancer cells significantly decreased cell 
proliferation (Al Sorkhy et al., 2012; Hang et al., 2012; Ke et al., 2009; Lubanska et al., 
2014). Importantly,  Spy1 levels appear to drive a more stem like population in breast 
(unpublished data) and brain (Lubanska et al., 2014; Lubanska and Porter, 2014b) and 
targeting of Spy1 may reduce the aggressiveness and stemness of the initiating cell 
population (Lubanska and Porter, 2014a; Lubanska and Porter, 2014b). Hence, further 
resolving the potential roles for Spy1 in different cancers and determining the 
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mechanisms that would result in the most effective targeting is an important next step for 
this work.  
HYPOTHESIS AND OBJECTIVES 
 This work aims to determine the potential role of the atypical cell cycle regulator 
Spy1 as a prognostic marker and a novel, viable drug target in subsets of breast cancer. 
 This study will test the hypothesis that: Spy1 plays a pivotal role in fuelling 
proliferation downstream of ERα and promotes resistance to anti-estrogen therapy. We 
further hypothesize that Spy1 is of pivotal importance to those aggressive tumours driven 
by c-Myc and targeting Spy1 will represent a novel and important approach for this 
subset of patients. We will address this hypothesis with the following objectives: 
 To determine the molecular mechanism by which Spy1 functions in the 
ERα signalling pathway. 
 To determine the potential relevance of Spy1 as a target in Myc-driven 
tumours. 
 To determine whether Spy1 levels influence the sensitivity of breast 
cancer cells to synthetic CKIs and/or chemotherapy.  
 To determine whether CKIs can sensitize a host of chemotherapy 
treatments for TNBC.   
 The data obtained in this study will contribute to the advancement of 
understanding the role of the cell cycle regulators in breast cancer treatment. 
Furthermore, this study may reveal novel diagnostic and therapeutic strategies for 
patients with aggressive breast cancers.  
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CHAPTER 2 
THE CYCLN-LIKE PROTEIN, SPY1, REGULATES THE ERα AND ERK1/2 
PATHWAYS PROMOTING TAMOXIFEN RESISTANCE 
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INTRODUCTION 
Overall 5 year survival rates for breast cancer have increased by almost 20% since 
1975, largely because of improved screening and drugs developed against estrogen 
signalling (ie. tamoxifen) and the Her2/neu receptor (ie. trastuzumab) (Siegel et al., 
2012). Despite these advances, a subset of patients either progress to, or initially present 
with, cancers that are unresponsive to current targeted therapies (Hackshaw et al., 2011; 
Viani et al., 2007). As such, breast cancer remains the second leading cause of death from 
cancer among women (CBCF, 2014). Determining the mechanisms regulating the 
initiation and/or progression to a drug resistant status represents a current challenge in the 
breast cancer field. 
 Estrogen receptor alpha (ER) is a steroidal receptor that changes into an active 
conformation upon binding to the ligand estradiol (E2) (Klinge et al., 2001). Classical 
ERα activation promotes receptor homodimerization, nuclear translocation and 
subsequent DNA binding to estrogen response elements (EREs) to regulate the 
expression of various genes (Barone et al., 2010). 'Non-classical' genomic signalling also 
exists where the E2-ER complex bind transcription factors to regulate genes like Cyclin 
D1, which lack EREs (Castro-Rivera et al., 2001; Gottlicher et al., 1998; Musgrove et al., 
1993; Planas-Silva and Weinberg, 1997). ERα dimers, activated by E2 or other growth 
factors, can also interact and form complexes directly with G-proteins, receptor tyrosine 
kinases, and non-receptor tyrosine kinases (Levin, 2005). ERα dimers are, therefore, able 
to activate signal transduction pathways, such as Ras/mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase (PI3K/Akt) (Likhite et al., 2006). Collectively, 
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ERα works via these diverse mechanisms to promote breast cell growth and survival 
(Fujita et al., 2003; Klinge et al., 2001).  
 Tamoxifen functions by competitively binding to the ligand binding domain 
(LBD) of ERα, altering its conformation such that it can no longer bind to E2, hence, 
preventing E2 proliferative signalling (Connor et al., 2001). The binding efficiency of 
tamoxifen can be altered by the phosphorylation status of residues within ERα capable of 
inducing ligand independent signalling (Chen et al., 2002; Kato et al., 1995). 
Phosphorylation on serine (S)-118 by extracellular signal-regulated kinases (ERK)1/2 is 
one prominent example of such a modification. S118 phosphorylation promotes 
hypersensitivity to E2 and decreases ERα affinity for tamoxifen (Bunone et al., 1996; 
Chen et al., 2002; Chen et al., 2013; Cheng et al., 2007; Yamashita et al., 2008). ERK1/2 
is the final kinase at the end of the Ras/MAPK signalling cascade, succeeding Ras, Raf 
and MEK activation. Hence, ERK1/2 carries out non-classical signalling downstream of 
ERα, as well as providing a positive feedback to augment ERα signalling.  
The Ras-Raf-MEK-ERK cascade is hyperactivated in approximately 30% of 
human cancers, a large percentage characterised by a mutation in either the Ras or Raf 
genes (Giltnane and Balko, 2014; Huynh et al., 2003). Constitutively activated MEK1/2 
is frequently seen in cancer cell lines, contributing to increased cell survival, migration 
and transformation (Huynh et al., 2003). Overexpression and hyperphosphorylation of 
ERK1/2 has been seen in various cancers, including hepatocellular carcinoma and breast 
cancer (Giltnane and Balko, 2014; Huynh et al., 2003). Pharmacological intervention 
upstream of ERK1/2 has received considerable focus; however, to date clinical results are 
largely underwhelming, with pre-clinical and clinical documentation showing a 
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development of acquired resistance shortly after receiving treatment (Emery et al., 2009). 
Resistance is largely associated with re-activation of ERK1/2 signalling (Morris et al., 
2013). As such, specific inhibitors of ERK1/2 have become a focus over the last 5 years 
and promising pre-clinical data are beginning to emerge (Morris et al., 2013). To this end, 
it has been shown in melanoma, breast, and colon cancer cell lines, that the use of an 
ERK1/2 inhibitor can overcome acquired resistance to both BRAF and MEK1/2 
inhibitors (Hatzivassiliou et al., 2012; Morris et al., 2013). This exciting data has led to 
the introduction of the ERK1/2 inhibitor into phase I clinical trials for solid tumours 
(Morris et al., 2013). Understanding the activation of all components of this pathway 
influences the successful intervention of a large number of cancers, including breast 
cancer.  
This work focused on the observation that a cell cycle protein coined Spy1 
(Speedy, RINGO) (gene SPDYA) is capable of promoting the activation of the MAPK 
pathway when injected into unfertilized Xenopus oocytes (Lenormand et al., 1999). Spy1 
is one member of a family of „cyclin-like‟ proteins in that they are expressed and 
degraded in a cell cycle dependent manner and are able to directly bind and activate the 
cyclin dependent kinases (CDKs) (Dinarina et al., 2009; Ferby et al., 1999; Lenormand et 
al., 1999; Porter et al., 2002). Spy1 functions in an atypical manner to classical cyclins in 
that it binds to both the G1/S and G2/M CDKs and directs phosphorylation of non-
canonical CDK substrates (Al Sorkhy et al., 2012; Cheng et al., 2005a; Karaiskou et al., 
2001). Activation of the CDKs by Spy1 also occurs independent of phosphorylation by 
CAK within the T-loop and dephosphorylation on the defined inhibitory residues (Cheng 
et al., 2005a). Further, Spy1 directly binds and promotes the degradation of the CDK 
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inhibitor, p27
Kip1 
(McAndrew et al., 2007; Porter et al., 2003). Indeed, Spy1 supports 
rapid progression through the cell cycle even in the face of senescence and apoptotic-
inducing stimuli (Barnes et al., 2003; Gastwirt et al., 2006). This suggests a mechanism 
by which Spy1 overrides cell-cycle induced apoptosis caused by therapeutic agents, 
which could support drug resistance. Spy1 levels are elevated in a number of human 
cancers, including liver, brain, breast and blood (Hang et al., 2012; Ke et al., 2009; 
Lubanska and Porter, 2014a; Lubanska and Porter, 2014b; Zucchi et al., 2004). In the 
breast, Spy1 levels are elevated by MAPK/ERK and c-Myc signalling to promote 
proliferation and override differentiation stimuli (Golipour et al., 2008; Lenormand et al., 
1999). In this work, we questioned whether Spy1 could activate aspects of the MAPK 
pathway in human somatic cells and if this played a role in the development of resistance 
to tamoxifen. 
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MATERIALS AND METHODS 
Cell Culture.  Human embryonic kidney (HEK)-293 and MCF7 cells were purchased 
from ATCC and were subcultured in DMEM media supplemented with 10% FBS and 
30,000 units penicillin/30,000 µg streptomycin solution. LCC9 cells (Lombardi 
Comprehensive Cancer Center, Georgetown University) were routinely subcultured in 
DMEM phenol red free media supplemented with 1 mM L-glutamine, 30,000 units 
penicillin/30,000 µg streptomycin, and 10% charcoal treated FBS. All cells were 
maintained under normoxic conditions (5% CO2) at 37°C. 
Plasmids. Creation of the Myc-Spy1-pCS3 was described previously (Porter et al., 
2002). Plasmids for Rc-CMV-Cyclin E (#8963), pEGFP-C1-ERα (#28230), HA-CDK1-
DN (#1889) and pLKO-scrambled control (#8453) were purchased from Addgene. 
pLKO-shSpy1 and pLKO-shCyclin E were cloned to express a short hairpin previously 
described to knockdown Spy1 and Cyclin E, respectively, control pLKO contains a 
scrambled sequence previously described (Lubanska and Porter, 2014b). The CDK 
mutants D90 (Cheng et al., 2005c) and R170 vectors (Al Sorkhy et al., 2015, in review) 
have been previously described. pEIZ vector was generously donated from Dr. B. Welm. 
The creation of pEIZ-Spy1 was completed by inserting Spy1 oligo into the EcoRI and 
XbaI sites of pEIZ.  
Immunoblotting (IB). Total protein was isolated from cell cultures by harvesting cells 
and lysing them in NP-40 lysis buffer (1% NP-40, 50 mM Tris-HCl pH 7.5, 1 mM 
EDTA, 150 mM NaCl) containing protease inhibitors (100 µg/ml PMSF, 5 µg/ml 
aprotinin, and 2 µg/ml leupeptin) for 1 hour on ice. Bradford reagent was used to 
determine the concentration of protein following the manufacturer‟s instructions (Sigma). 
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80-100 µg of protein were subjected to electrophoresis on denaturing 10% SDS 
polyacrylamide gels and transferred to PVDF-Plus 0.45 micron transfer membrane 
(Osmonics Inc.) for 2 hours at 30 volts using a wet transfer method. Blots were blocked 
for 1 hour in 1% BSA solution at room temperature. Primary antibodies were 
reconstituted in blocker and incubated overnight at 4°C, secondary antibodies were used 
at 1:10000 dilution in blocker for 1 hour at room temperature. Blots were washed three 
times in TBST for three minutes following incubation with primary and secondary 
antibodies. Chemiluminescent Peroxidase Substrate was used for visualization following 
manufacturer‟s instruction (Pierce). Chemiluminescence was quantified on an 
AlphaInnotech HD2 (Fisher) using AlphaEase FC software. Antibodies were used at the 
following concentrations: Actin MAB150 1R (Chemicon-Millipore; 1:1000), Spy1 
(ThermoScientific; 1:1000), c-Myc (Sigma; 1:1000), anti-phospho-ERα-S118 (Abcam; 
1:1000), anti-ERα (Santa Cruz Biotechnology; 1:1000), Cyclin E1 (Abcam; 1:1000), anti-
RIPK2 (Santa Cruz Biotechnology; 1:1000), anti-phospho-Raf1 (Abcam; 1:500), anti-
Raf1 (Santa Cruz Biotechnolgy; 1:1500), anti-p-ERK 1/2 [Thr 202/Tyr 204] (Cell 
Signaling; 1:1000), anti-ERK1/2 (Santa Cruz Biotechnology; 1:1000), anti-MKP1 (Santa 
Cruz Biotechnology; 1:1000), anti-MKP2 (Santa Cruz Biotechnolgy; 1:1000), anti-MKP3 
(Santa Cruz Biotechnology; (1:1500), and anti-PP2A (Santa Cruz Biotechnology; 
(1:1000). 
Lentivirus Production. VSV-G pseudotyped lentivirus was produced by transient 
transfection of HEK-293 LentiX cells with transfer vector and the multi-deleted 
packaging plasmids (pMDG, pMDL2, pRSV) using polyethylenimine (PEI) (Sigma) 
reagent with 1:3 DNA to PEI ratio and incubation for 5 hours at 37°C, 5% CO2. The virus 
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was collected the next day and concentrated for 3 hours at 4°C using an ultracentrifuge. 
The titer for pEIZ was determined by transducing 293T cells and analysis of eGFP 
protein expression by flowcytometry at 72 hours post transduction. The titer for pLKO 
lentivirus was assessed by puromycin selection followed by crystal violet staining and 
quantification of resistant colonies. The titered virus was filter sterilized and stored at      
-80°C. 
Transfection/Infection. Transfection: Cells were transfected using PEI branched reagent 
(Sigma). In brief, 10 µg of DNA was mixed with 3 µl of 10 mg/ml PEI for 10 minutes 
then added to a 10 cm tissue culture plate. Transfection media was changed after 24 
hours. Lentiviral Infection: 8000 cells were seeded in fully supplemented growth media 
in 96-well plates for 2 hours. Cells were starved by removing serum and 
penicillin/streptomycin from the media, followed by the use of 1 mg/ml polybrene (Santa 
Cruz Biotechnology) and MOI 3 of the specific vector used. Infected media was changed 
to fully supplemented media 24 hours after infection. For knockdown, cells were 
incubated with 1mg/ml puromycin (Sigma) 48 hours after infection for 72 hours to allow 
for puromycin selection. Media is thereafter changed every 48 hours with puromycin 
included.   
Inhibition Treatments. HEK-293 cells were seeded equally in 10 cm dishes at a density 
of 5 x 10
5 
cells. Upon 80% confluency, HEK-293 cells were incubated with either 10 µM 
SB202474 (control) or 10 µM U0126 (MEK 1/2) inhibitors (Calbiochem) for 1 hour. For 
Raf inhibition, 5 µM GW5074 (Sigma) was added to the cells for 24 hours. For Ras 
inhibition, 20 µM Farnesyl Thiosalicyclic Acid (Santa Cruz Biotechnology) was added to 
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the cells for 24 hours. For ERK1/2 inhibition, 10 µM SCH772984 (ApexBio) was added 
to the cells for 24 hours.  
Estradiol/Tamoxifen Treatments. MCF7 or HEK-293 cells were seeded equally in 10 
cm dishes at a density of 5 x 10
5 
cells. Upon 70% confluency, the cells were treated with 
phenol red-free RPMI media, supplemented with 10% charcoal treated FBS and 30,000 
units penicillin/streptomycin. After 48 hours, cells were incubated with either dimethyl 
sulfoxide (DMSO), 50 ng/ml E2 (Sigma), or 100 nM 4-Hydroxytamoxifen (Sigma) for 
specified time points, followed by cell harvesting for protein extraction and IB. 
Animal Care and Handling. Wildtype Zebrafish (Daniorerio) were handled in 
compliance with local animal care regulations and standard protocols of Canada and 
following the University of Windsor animal care protocol AUPP#12-14. Adult fish were 
kept at 28.5°C and bred according to available protocols (Westerfield, 2000). 
Implantation and Treatment. Eggs were collected after fertilization and kept in E3 
embryo media (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33mM MgSO4, 10
-5
% 
Methylene Blue) at 32°C in an incubator until ready to inject. Before injection 200,000 
cells were reconstituted in 200 µL of serum-free media containing 1 µL of DiO (green) 
(Vybrant, Invitrogen) at 37°C for 20 minutes. Cells were washed with 200 µL of serum 
free media twice and resuspended in 20 µL of serum free media, kept at 37°C for 20 
minutes, and placed on ice until injection. 48 hours post-fertilization (hpf) the embryos 
were dechorionated with fine tip forceps and anesthetised with 0.168 mg/ml of Tricaine 
(Sigma). 50-100 labelled cells/ 9 nL were loaded into glass capillary needles and injected 
into the yolk sac of each embryo using a Nanoject II (Fisher Scientific). After injection, 
embryos were placed in E3 embryo media and 2 hours post-implantation (hpi) were 
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examined using a Leica fluorescence stereoscope to exclude any embryo with cells 
outside of the implantation area. 24 hpi (0 hours post-treatment (hpt)) the embryos were 
anesthetised, imaged and placed in a 96-well plate; one embryo per well.  At 48 hpi the 
embryos were treated with either DMSO or 10 µM tamoxifen. The embryos were imaged 
again at 72 hpi (24 hpt) and the fold change in tumour burden calculated.   
Image Analysis. All image analysis was completed using ImageJ software. The image 
for each embryo was imported into ImageJ, the image was converted to a 32-bit 
greyscale, and the threshold was adjusted to eliminate background pixels. Total area of 
fluorescence was measured as the area of tumour burden. All measured results were 
copied into Excel files and fold change in tumour burden calculated from 24 to 72 hpi.   
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RESULTS 
Spy1 overexpression enhances ERK1/2 phosphorylation. 
 Overexpression of Spy1 in HEK-293 cells results in a significant increase in 
phosphorylated threonine (T)202- and tyrosine (Y)204-ERK (pERK) compared to total 
ERK protein levels (Figure 1A). To determine whether the activation of pERK was 
unique to Spy1 overexpression, or if there were redundancies among the cyclin proteins, 
Spy1 and Cyclin E were overexpressed in HEK-293 cells. Spy1 overexpression 
significantly increased overall phosphorylation of ERK protein, but Cyclin E 
overexpression did not result in any significant change (Figure 1B). To determine if Spy1 
is a necessary mediator of ERK activation, cells were infected with shRNA lentivirus 
targeting two separate regions of the Spy1 mRNA (shSpy1.1, shSpy1.2). shRNA against 
Cyclin E1 was also used to address the essentiality of classical cyclin-CDK activation 
(shCyclinE) and a pLKO-shScrambled control (pLKO) was used. Both of the shSpy1 
constructs significantly decreased endogenous activated ERK levels (Figure 1C); 
however, this effect was not noted with shCyclinE treatment despite successful 
knockdown (Figure 1C; left panel representative blot). To ensure that Spy1 knockdown 
effects are specific, we have also overexpressed two different rescue constructs unable to 
be recognized by the shSpy1 (resSpy1; Figure 1D). The rescue constructs reversed Spy1 
knockdown effects on ERK phosphorylation. Collectively, these results support the 
hypothesis that Spy1 activates ERK1/2 in a manner unique from classical cyclin-CDK 
activation (i.e. Cyclin E-CDK2). 
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Figure 1. Spy1 overexpression enhances ERK1/2 phosphorylation. (A) Cells were
transfected with pCS3 or Spy1 vectors, followed by SDS-PAGE and IB. n=3 (B) Cells
were transfected with pCS3, Spy1, pCMV, and Cyclin E vectors, followed by
SDS-PAGE and IB. n=9. (C) Cells were infected with shScrambled (denoted pLKO), 2
constructs of shSpy1 (shSpy1.1, shSpy1.2), and shCyclin E (shCyclin E), followed by
SDS-PAGE and IB. (D) Cells were infected with shScrambled (pLKO), 2 constructs of
shSpy1 (shSpy1.1, shSpy1.2), and shCyclin E (shCyclin E), or rescue vectors, followed
by SDS-PAGE and IB. (A-D) A representative blot is shown (left panel) and the
densitometry ratio of protein to loading control actin is shown (right panel). Error bars
reflect SE between experiments. Student’s t-test was performed;*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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Spy1-mediated ERK phosphorylation is CDK dependent.  
 Using a previously characterized Spy1-CDK non-binding mutant (Spy1-D90A) 
(Cheng et al., 2005c), we sought to determine whether the direct binding between Spy1 
and the CDK is essential for activation of ERK1/2. Transient transfection with wild-type 
Spy1 shows a significant increase in the activation of ERK1/2, while Spy1-D90A does 
not significantly affect phosphorylated ERK1/2 levels (Figure 2A). Furthermore, a 
significant increase in proliferation was seen in Spy1 overexpressing cells as compared to 
control and D90 transfected cells (Figure 2B). These data support the hypothesis that the 
activation of ERK1/2 is dependent on Spy1-mediated CDK activity. Spy1 can bind to 
both CDK1 and CDK2 (Al Sorkhy et al., 2012; Cheng et al., 2005a; Ke et al., 2009). To 
determine which CDK is most influential on Spy1-activated ERK, cells were transfected 
with Myc-tagged Spy1 and low levels of either an HA-tagged CDK1 or CDK2 dominant 
negative (DN) vector (CDK1 DN or CDK2 DN), or relevant controls. The concentration 
of DN vector used did not significantly impair growth alone; however, both CDK1 and 
CDK2 DN vectors significantly impaired the ability of Spy1 to activate ERK1/2 (Figure 
2C). These data support that the mechanism by which Spy1 initiates the phosphorylation 
of ERK requires at least one of the CDKs to be present and bound.  
Spy1-mediated ERK1/2 activation is MEK-independent. 
 In the presence of U0126, a MEK1/2 inhibitor, we see a decrease in pERK1/2, as 
well as a significant decrease in overall Spy1 protein levels. Interestingly, in cells 
overexpressing Spy1, U0126 does not significantly reduce the ability of Spy1 to activate 
ERK1/2 (Figure 2D). Another level of regulation of ERK1/2 phosphorylation is through 
the steady state removal of phosphorylation by the relevant phosphatases. Four major 
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phosphatases regulate ERK1/2; PP2A, MAPK Phosphatase (MKP)1, MKP2, and MKP3 
(Raman et al., 2007).  Neither Spy1 or Cyclin E overexpression significantly decreased 
the phosphatases, Spy1 actually significantly increased MKP2 protein levels (Figure 2E); 
possibly indicating that the cell is attempting to regulate the enhanced activation of 
ERK1/2 to maintain steady state activity. 
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Figure 2. Spy1-mediated ERK phosphorylation is CDK dependent, MAPK
phosphatase independent. (A-B) Cells were transfected with pCS3, Spy1, and Myc-
tagged-Spy1-D90A (binding mutant) vectors. (A) SDS-PAGE and IB was performed.
(B) Trypan blue exclusion assay was performed to determine the number of living cells
after transfection. (C) Cells were transfected alone or in combination with pCS3, Spy1,
Cyclin E overexpression vector, CDK1 dominant negative, and CDK2 dominant
negative. (D) Cells were stably infected with pEIZ or Spy1 vectors and treated with 10
ug of control inhibitor or MEK inhibitor (U0126). This was followed by SDS-PAGE
and IB. (E) Cells were transfected with pCS3, Spy1, and Cyclin E overexpression
vectors, followed by SDS-PAGE and IB. (A;C-E) A representative blot is shown (left
panel) and the densitometry ratio of protein to loading control actin is shown (right
panel). (A-E) Error bars reflect SE between triplicate experiments. Student’s t-test was
performed; *p<0.05, **p<0.002, ***p<0.001.
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Activation of ERK1/2 by Spy1 is dependent on Ras and Raf. 
 To determine whether alternate upstream activators of ERK1/2 are important in 
Spy1-mediated effects we tested the consequences of Spy1 overexpression in the 
presence of Ras and Raf inhibitors, Farnesyl Thiosalicyclic Acid and GW5074, 
respectively. When c-Raf is inhibited we see a slight decrease in pERK protein levels as 
compared to the control; however, there is a significant decrease of pERK protein levels 
when the Ras inhibitor is used, indicating that the regulation of pERK by Spy1 requires 
both Raf and Ras activation (Figure 3A). Moeller et al. (2003) showed Ras activation 
requires the inhibition of p27. p27 controls the formation of the Grb2/SOS complex 
which activates Ras (Moeller et al., 2003). Spy1-CDK2 can bind to and inhibit p27 
(McAndrew et al., 2007; Porter et al., 2003). Spy1 inhibits p27 levels in the absence and 
presence of Raf/Ras inhibitors (Figure 3A), demonstrating that this aspect of Spy1 
activity is still intact and that ERK-mediated effects reside downstream of p27 
degradation. To investigate the importance of the direct Spy1-p27 interaction, a Spy1-p27 
binding mutant (R170) was utilized (AlSorkhy et al., 2015, unpublished data). When 
R170 lentivirus was infected into cells, there was a significant increase in p27 levels as 
compared to the empty vector (pEIZ) control and the pEIZ-Spy1 overexpression vector 
(Figure 3B). Interestingly, R170 expression in these cells causes a significant decrease in 
the activation of ERK as compared to Spy1 overexpression (Figure 3C). Finally, when 
R170 is used in conjunction with the Ras inhibitor, we see no significant change in the 
phosphorylation status of ERK, further supporting that activation of ERK resides 
downstream of Spy1-mediated effects on p27 protein levels (Figure 3C). These data show 
the Spy1-CDK complex requires the activation of Ras through the downregulation of p27 
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to significantly increase pERK protein levels. However, the question of how Spy1 could 
activate pERK through the Ras pathway independent of MEK1/2 remained.  
Spy1 overexpression may function through RIPK2.  
 Receptor-interacting serine-threonine kinase 2 (RIPK2) is activated through Ras-
activated Raf kinase. Activation of RIPK2 can directly phosphorylate ERK1/2 in vitro 
and in vivo (Navas et al., 1999). To determine whether the effects of Spy1 overexpression 
on ERK1/2 could be mediated through RIPK2, cells were transfected with Myc-tagged-
Spy1 followed by infection with lentivirus packaging either scrambled control shRNA 
(pLKO) or shRNA targeting two different regions of the RIPK2 mRNA (shRIPK2.1, 
shRIPK2.2) (Figure 3D). RIPK2 knockdown significantly abrogated the ability of Spy1 
to enhance phosphorylation of ERK1/2 (Figure 3D). Collectively, these results suggest 
Spy1 is activating ERK1/2 indirectly through the Ras-Raf-RIPK2 pathway. Spy1 plays a 
role in normal growth and development of the breast, and elevated levels promote rapid 
tumorigenesis in mouse models (Golipour et al., 2008). Spy1 is found at elevated levels 
in aggressive forms of breast cancer (Al Sorkhy et al., 2012). Given the role of ERK 
signalling in driving tamoxifen resistance (Chen et al., 2013; Riggins et al., 2007); we 
sought to determine whether Spy1-mediated activation of ERK1/2 in breast cells could be 
implicated in sensitivity to tamoxifen. 
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Figure 3. Activation of ERK1/2 by Spy1 is dependent on Ras and Raf. (A) Cells were
transfected with pCS3 and Spy1, followed by 20 ug of Raf inhibitor or Ras inhibitor.
This was followed by SDS-PAGE and IB. (B-C) Cells were infected with pEIZ control,
pEIZ-Spy1, or pEIZ-Spy1-R170 (p27 binding mutant) vectors. (B) This was followed
by SDS-PAGE and IB. (C) 20 ug of Ras inhibitor was added after infection. This was
followed by SDS-PAGE and IB. (D) Cells were transfected with pCS3 and Spy1.
Following transfection, cells were infected with pLKO-shScrambled (denoted pLKO)
and shRIPK2 constructs (shRIPK2.1 and shRIPK2.2). After puromycin selection cells
were subjected to SDS-PAGE and IB. (A-D) A representative blot is shown (left panel)
and the densitometry ratio of protein to loading control actin is shown (right panel).
Error bars reflect SE between triplicate experiments. Student’s t-test was performed;
*p<0.05,**p<0.01, ***p<0.001.
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Spy1 is upregulated upon activation of the estrogen receptor. 
  To determine whether Spy1 expression is endogenously regulated downstream of 
ERα activation, ERα positive MCF7 cells were treated with 50 nM of E2 for 0 to 6 hours. 
The phosphorylated protein level of ERα was significantly elevated as was the level of 
Spy1 (Figure 4A). To confirm this finding, ER negative HEK-293 cells were transfected 
with an ERα vector and treated with E2 over time (Figure 4B). Spy1 protein levels were 
significantly elevated in response to E2 treatment (Figure 4C). These data indicate that 
Spy1 is downstream of the estrogen signalling pathway. 
Increased levels of Spy1 regulate ERK1/2 feedback to ERα in breast cells. 
 To determine whether Spy1 can affect the phosphorylation of ERα on the ERK 
phosphorylation site (S118), we infected MCF7 cells with constructs to overexpress Spy1 
or Cyclin E. Increased levels of Spy1 significantly increased the level of phosphorylation 
of ERα on S118 (Figure 4D). These cells were then treated with tamoxifen in the 
presence or absence of the MEK inhibitor, U0126. When Spy1 levels were elevated, even 
in the presence of 100 nM tamoxifen, the levels of pERα-S118 were significantly 
increased as compared to control and Cyclin E overexpression and this occurred in a 
MEK-independent fashion (Figure 4E). We then wanted to determine if inhibiting 
ERK1/2 directly would alter the effect of Spy1 overexpression on pERα-S118, in the 
presence or absence of tamoxifen treatment. MCF7 cells overexpessing Spy1 were 
treated with 10 µM ERK1/2 inhibitor (SCH772984), either alone or in combination with 
100 nM tamoxifen. Initially, cells were counted for viability after treatment using the 
trypan blue exclusion assay. We show that the use of the ERK1/2 inhibitor alone 
significantly reduces the number of viable cells in both control and Spy1 overexpressing 
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cells (Figure 4F). Furthermore, Spy1-mediated proliferation was not inhibited by 
tamoxifen alone but ERK inhibition prevented Spy1-mediated effects on growth. The 
same experiment was also carried out looking at pERα-S118 status and comparing to 
overexpression of Cyclin E (Figure 4G). Spy1 significantly increases pERα-S118 in 
control situations, whereas Cyclin E had no notable effect. Spy1-mediated ER 
phosphorylation occurs in the presence of tamoxifen but not in the presence of the ERK 
inhibitor. These data indicate that Spy1 effects on ERα are mediated through a feedback 
to ERK1/2 .  
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Figure 4. Spy1 is upregulated upon activation of the estrogen receptor. (A) MCF7 cells
were treated with 50 nM of estradiol (E2) or vehicle control (DMSO) over the
indicated time course; followed by SDS-PAGE and IB. (B-C) Hek-293 cells were
transfected with the estrogen receptor (ER). (B) Transfection was confirmed by
SDS-PAGE and IB. (C) Hek-293 cells transfected with ER or control were treated with
50 nM of E2 over the indicated time course; followed by SDS-PAGE and IB. (D-G)
MCF7 cells were infected with control, Spy1, or Cyclin E, (D) followed by SDS-PAGE
and IB. (E) Cells were then treated with 10 uM MEK1/2 inhibitor, U0126, control
inhibitor, or 100 nM of tamoxifen. SDS-PAGE and IB followed. (F) Spy1
overexpressed cells were treated with 10 uM ERK1/2 inhibitor with or without 100 nM
tamoxifen and subjected to trypan blue exclusion assay. (G) Spy1 and Cyclin E
overexpressed cells were treated with 100 nM tamoxifen with or without 10 uM
ERK1/2 inhibitor, followed by SDS-PAGE and IB. (A-E; G) A representative blot is
shown (left panel) and the densitometry ratio is shown (right panel). Error bars reflect
SE between triplicate experiments. Student’s t-test was performed; *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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Spy1 levels regulate the response of cells to tamoxifen treatment.   
 To test the effect of Spy1 levels on tamoxifen response, ERα positive MCF7 cells 
were infected with pEIZ-Spy1 and empty vector control (pEIZ) (Figure 5A). Cells were 
treated with 100 nM tamoxifen for 24 hours and subjected to the trypan blue exclusion 
assay. As expected, Spy1 overexpression significantly increased cell number as compared 
to pEIZ control in untreated cells. When tamoxifen was added, Spy1 continued to drive 
cell proliferation, but pEIZ control populations failed to proliferate (Figure 5B). Previous 
studies have demonstrated that combination treatment of CDK inhibitors (CKIs) with 
tamoxifen on MCF7 cells significantly arrested cells in G1 and G2 phases of the cell 
cycle (Wesierska-Gadek et al., 2011). This group showed that the level of 
phosphorylation on ERα was significantly decreased as was subsequent ERα activation. 
We tested the effect of elevated levels of Spy1 on these drug combinations (Figure 5C). 
Two CKIs were used; roscovitine is a pan-inhibitor, inhibiting CDKs 1, 2, 5, 7, and 9, 
and it is currently in phase II clinical trials (Bach et al., 2005; Nair et al., 2011) and NU-
2058 is a specific CDK2 inhibitor that has shown potential as a therapeutic in prostate 
cancer (Harrison et al., 2009; Rigas et al., 2007). In control populations, the combination 
of CKIs and tamoxifen decreases total cell numbers significantly; however, Spy1 
overexpression significantly abrogates this effect (Figure 5C). LCC9 cells are a MCF7-
derived cell line that have been treated over time with tamoxifen and other anti-estrogens 
making them tamoxifen resistant even in the presence of ERα (Brunner et al., 1997). 
Endogenous expression of Spy1 is higher in LCC9 cells as compared to their parental 
MCF7 cell line (Figure 5D). To determine if Spy1 levels dictate any of the resistant 
characteristics of these cells, Spy1 was knocked down using shRNA against Spy1 
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(pLKO-shSpy1), a scrambled construct was used as a control (pLKO) (Figure 5E; left 
panel). Cells were then treated with tamoxifen and counted using trypan blue exclusion 
assay. While tamoxifen had no effect on the resistant LCC9 cells over time, Spy1 
knockdown had a surprising impact on cell number in response to tamoxifen, with cells 
depleted almost 10 fold by 48 hours (Figure 5E; right panel).  
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Figure 5. Spy1 levels regulate the response of cells to tamoxifen treatment.
(A-B) MCF7 cells were infected with pEIZ or Spy1; followed by treatment with 100
nM of tamoxifen or vehicle control (DMSO). (A) Confirmation of overexpression was
determined through SDS-PAGE and IB. (B) Proliferation after treatment was assayed
using the trypan blue exlcusion assay. (C) Infected cells were treated with 100 nM
tamoxifen, 20 uM roscovitine, 25 uM NU-2058, or a combination of these treatments;
followed by trypan blue exclusion assay. (D) MCF7 and LCC9 cells were measured
for endogenous levels of Spy1 through SDS-PAGE and IB. A representative blot (left
panel) and densitometry ratio of Spy1 to loading control actin (right panel) is shown.
(E) LCC9 cells were infected with shScrambled (denoted pLKO) and shSpy1,
followed by treatment with 100 nM of tamoxifen or vehicle control. Confirmation of
knockdown was seen through SDS-PAGE and IB (left panel) and proliferation after
treatment was assayed using trypan blue exclusion assay. (A-E) Cell counts are over
triplicate experiments. Error bars reflect SE between triplicate experiments. Student’s
t-test was performed; *p<0.05, **p<0.01, ***p<0.001.
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Spy1 levels affect tamoxifen response in vivo.  
 We implemented a zebrafish xenograft model to elucidate whether Spy1 levels 
can increase or decrease sensitivity to tamoxifen in vivo. To validate the model MCF7 or 
LCC9 cells were injected into embryos at 48 hours post-fertilization (hpf) and treated 
with tamoxifen for 24 hours (Figure 6). Fish were imaged and quantified using automated 
software to align many fish from similar treatments into one plane. Tumour foci at 24 
hours post-treatment (hpt) demonstrate that while the MCF7 cells respond to treatment 
the LCC9 cells are resistant to tamoxifen treatment (Figure 6A). Sensitive MCF7 cells 
were then infected with pEIZ control or pEIZ-Spy1 vectors (Figures 6B-D). Embryos 
were imaged at 0 hpt (48 hours post-implantation (hpi)) and tumour foci at 0 hpt were 
normalized between control and Spy1 injected cells. Tamoxifen was then administered to 
the fish over 24 hours and change in tumour burden recorded (Figure 6D).  Spy1 
overexpression significantly decreases sensitivity to tamoxifen treatment in vivo (Figure 
6D).  
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Figure 6. Spy1 levels affect tamoxifen response in vivo. (A) At 48 hpf, zebrafish were
injected with either MCF7 or LCC9 cells. 24 hpi, 10 uM tamoxifen was added to the
fish water and tumour foci per fish were counted for 24 hpt and the fold change,
normalized to 0 dpt, was calculated. *p<0.05. (B-C) Representative images of cells
expressing either (B) empty control vector or (C) Spy1 overexpression vector before (0
hpt) and after (24 hpt) treatment with either DMSO or 10 uM tamoxifen. (D) Graph rep-
resenting the mean fold change in tumour burden from 0 hpt to 24 hpt. ns= not
significant, **p<0.01, ***p<0.001. Scale bar=200 um.
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DISCUSSION 
 The response of breast cancer cells to E2 increases the rate of proliferation 
through upregulation of genes required for the cell cycle, such as c-Myc and Cyclin D 
(Castro-Rivera et al., 2001; Maminta et al., 1991). This is achieved through the activity of 
ERα which can signal both genomically, to transcriptionally regulate targets directly, or 
non-genomically, by activating downstream pathways, such as MAPK (Bunone et al., 
1996; Chen et al., 2000; Chen et al., 2002). The MAPK pathway influences the 
transcription of a plethora of genes, one of which is the atypical cyclin, Spy1. Spy1 is 
important for mammary gland development and is a driver of mammary carcinogenesis 
(Golipour et al., 2008). Our work demonstrates that Spy1 is upregulated downstream of 
activated ERα. Whether Spy1 is an essential mediator of ERα signalling in mammary 
development and whether Spy1 upregulation by ERα is mediated entirely through MAPK 
signalling are interesting questions for further exploration.  
 ERα proliferative signalling in breast cells is dependent upon ligand binding 
and/or post-translational modification to enable signalling in the absence of a ligand. 
Ligand-independent modifications to ERα, such as the phosphorylation on S118, can 
render the receptor resistant to anti-estrogen therapies like tamoxifen (Chen et al., 2000). 
This work demonstrates that Spy1 levels correlate with an increase in phosphorylation of 
ERα on S118. Cellular cycling influences the phosphorylation status of ERα, all 
dependent upon mitogen stimulation (Barone et al., 2006; Planas-Silva and Weinberg, 
1997). Inhibiting this cycling by inhibition of CDKs using synthetic CKIs has become an 
important target in breast cancer therapy (Nair et al., 2011; Wesierska-Gadek et al., 
2011). The use of a pan-CDK inhibitor, roscovitine, in an ERα positive cell line was 
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shown to reduce the level of basal phosphorylation of S118 in the presence or absence of 
E2 and/or tamoxifen; which at times led to the downregulation of ERα (Wesierska-Gadek 
et al., 2011). Our work showed elevated levels of Spy1 can protect ERα positive cells 
from tamoxifen treatment in combination with CKIs, roscovitine and NU-2058. Hence, 
the level of Spy1 may be prognostic to response to both tamoxifen and CKI therapy.  
 Phosphorylation on S118 is known to be regulated by ERK1/2 (Chen et al., 2000; 
Chen et al., 2013; Cheng et al., 2007), this work demonstrates for the first time that Spy1 
is capable of activating this pathway in human cells. Lenormand et al. (1999) showed that 
Spy1 could activate MAPK in Xenopus oocytes. Unlike the Lenormand data, however, 
Spy1 activation of ERK1/2 appears to be MEK independent in human breast cells (Figure 
7). We have further resolved some of this pathway demonstrating that Spy1-mediated 
ERK activation requires the direct binding of Spy1 to CDK and p27, and is mediated 
through the Ras pathway (Figure 7). We have further demonstrated that elevated Spy1 
levels and activated ERK1/2 leads to a significant elevation in specific phosphatase 
levels, specifically MKP2, potentially indicating an attempt to restore homeostatic 
balance. Mutations within Ras and Raf, or hyperactivation of MEK1/2 has influenced the 
production of upstream inhibitors of the MAPK pathway; however, resistance and relapse 
occurs within 6 to 7 months of treatment (Morris et al., 2013). Indeed, we have shown 
elevated levels of Spy1 alone can override MEK1/2 inhibitors and significantly increase 
the phosphorylation status of ERα on S118. A significant decrease in cell viability and 
pERα-S118 levels in the presence of elevated Spy1 was seen only when ERK1/2 was 
directly inhibited. These data show that Spy1 overexpression decreases sensitivity of cells 
to treatment commonly used in the clinic. The discovery of a new inhibitor specifically 
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inhibiting the ATP-binding site of ERK1/2 has shown promising results with respect to 
solid tumours (Hatzivassiliou et al., 2012; Morris et al., 2013), and, in the presence of 
elevated levels of Spy1 within ERα positive breast cells, we see a complete abrogation in 
phosphorylated S118 levels and a significant response to tamoxifen treatment. Our data 
shows Spy1 alters the post-translational status of the ERα and inhibits response to 
hormone therapy through ERK1/2 activation (Figure 7). Novel therapies focusing on the 
direct inhibition of ERK1/2 in patient populations harbouring elevated levels of Spy1 
may represent a novel therapeutic direction for both treating drug resistant patients and 
preventing/decreasing the incidence of resistance in ERα-positive patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic diagram of proposed pathway. Spy1 has been shown to be
downstream of the MAPK pathway (Golipour et al., 2008). Our data further
demonstrates elevated levels of Spy1 increase the activation of ERK1/2 through a
MEK-independent pathway, which includes inhibition of p27, the subsequent
activation of Ras and Raf, and the activation of the kinase RIPK2. The increase in
ERK1/2 activation also promotes the phosphorylation of the ER on S118, which is
implicated in resistance to tamoxifen treatment.
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THE STABILIZATAION OF C-MYC BY THE NOVEL CELL CYCLE 
REGULATOR, SPY1, DECREASES EFFICACY OF BREAST CANCER 
TREATMENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
INTRODUCTION 
 
 Breast cancer is a diverse set of diseases, with both intra- and inter-tumoral 
heterogeneity affecting response to treatment. Intertumoral heterogeneity can be 
classified into genomic subgroups; however, in the clinic breast cancers remain classified 
largely by the presence or absence of hormone/growth factor receptors. Triple negative 
breast cancer (TNBC) is one such group, identified by the lack of expression for the 
estrogen receptor alpha (ERα), progesterone receptor (PR), and the HER2/neu protein. 
TNBCs can fall under different genomic subgroups; Her2-enriched, claudin-low or basal 
breast cancers, one indicator of the varying mechanisms that can drive the phenotype for 
this form of breast cancer (Malhotra et al., 2010; Perou, 2010; Perou et al., 2000; Prat et 
al., 2010). Patients who lack ERα, including TNBC patients, are not candidates for 
hormone therapy and generally have a less favourable prognosis (Lumachi et al., 2013). 
Loss of ERα occurs in about 15-20% of resistant breast cancers (Riggins et al., 2007). 
While the mechanism for this downregulation remains to be fully elucidated, ERα levels 
can be manipulated epigenetically with histone modification and DNA methylation 
(Yang et al., 2001). Understanding the molecular pathways regulating the expression of 
ERα may provide novel mechanisms of sensitising ERα-negative patients, including 
those that are triple negative, to available therapies.  
 As early as 1984, gene amplification and overexpression of the transcription 
factor c-Myc was shown in an array of aggressive breast cancers of varying 
receptor/growth factor status (Escot et al., 1986; Kniazev et al., 1986; Kozbor and Croce, 
1984; Perou et al., 2000). Several studies show that c-Myc overexpression occurs 
frequently in ERα-negative breast cancers (Persons et al., 1997; Xu et al., 2010) and c-
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Myc is highly elevated and implicated as an important driver of TNBC (Kang et al., 
2014; Peddi et al., 2012; Perou, 2010). Only around 20% of c-Myc amplification in breast 
cancer is detectable at the mRNA level, implicating regulation at the RNA stability, 
translation or protein level (Bieche et al., 1999). c-Myc regulates approximately 10% to 
15% of the human genome, having potent effects on cell proliferation, differentiation, 
apoptosis, and senescence (Amati and Land, 1994; Amati et al., 1993; Evan et al., 1994; 
Evan et al., 1992). In the breast, c-Myc has multiple functions in normal development and 
is implicated in the initiation and progression of breast cancer (Blakely et al., 2005; Liao 
and Dickson, 2000; Littlewood and Evan, 1990; Schmidt, 1999). Although the exact 
mechanism of how ERα levels become downregulated is unknown, long-term 
overexpression of c-Myc has become a suggested mechanism towards the development 
of estrogen-independence (Xu et al., 2010). Increased transcriptional activity of c-Myc 
mimics ERα response to estradiol, specifically through the activation of ERα-targeted 
genes (Alles et al., 2009; Dadiani et al., 2009). This chapter studies the implications of 
persistent c-Myc signalling on ERα status.  
While c-Myc is an attractive target for several forms of cancer, mechanistically 
achieving this goal has been a challenge. The dominant negative mutant, Omomyc, has 
the potential to regress in vivo tumours, but tumours quickly re-establish when Omomyc 
is removed (Soucek et al., 2002). Targeting c-Myc effectors has demonstrated some 
effectiveness. Of particular interest, inhibiting the G2/M cyclin dependent kinase, CDK1, 
in TNBC has shown impressive synthetic lethality in cell systems (Horiuchi et al., 2012; 
Kang et al., 2014). CDK1 is critical for cell proliferation and this limits the ability to 
117 
 
achieve a safe therapeutic window; hence, exploiting ways to target specific aspects of 
CDK1 driven activity is required to make this a viable strategy.  
One aspect of CDK inhibitors that has been overlooked in the clinic is the 
presence of „cyclin-like‟ proteins capable of binding and activating CDKs in the presence 
of traditional inhibitors (Nebreda, 2006). Spy1 (gene SPDYA) is one member of this 
family. Spy1 can bind and activate both G1/S and G2/M CDKs independent of the 
activating phosphorylation on the T-loop and in the presence of inhibitory phosphates to 
enhance proliferation and promote the degradation of p27
Kip1 
(Cheng et al., 2005a; 
McAndrew et al., 2007). Spy1-bound CDKs appear to take on a different conformation 
with unique substrate preferences (Cheng et al., 2005b). Spy1 levels are low in most adult 
tissues, being selectively expressed in regenerative populations and elevated downstream 
of c-Myc in several human cancers, including invasive ductal carcinoma of the breast (Al 
Sorkhy et al., 2012; Golipour et al., 2008; Hang et al., 2012; Huang et al., 2009; Ke et al., 
2009; Lubanska and Porter, 2014b; Porter et al., 2002; Zucchi et al., 2004). Hence, Spy1-
CDKs may represent a unique mechanism to target for selective treatment of specific 
cancers.  Indeed Spy1 levels specifically override apoptosis following DNA damage and 
this mechanism may be particularly potent in drug resistant tumours (Barnes et al., 2003; 
Gastwirt et al., 2006).  
Herein, we demonstrate that persistent elevation of c-Myc correlates with an 
increased expression of Spy1 and a reduction in ERα levels. Knockdown of Spy1 reduces 
c-Myc levels and enhances sensitivity to both hormone and chemotherapy treatment. 
Hence, specifically targeting Spy1-directed CDKs may be an effective strategy in ERα-
negative breast cancers with elevated c-Myc.  
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MATERIALS AND METHODS 
Cell Culture.  Primary MMTV-Myc cells were isolated from the fourth mammary gland 
of MMTV-Myc mice and were subcultured in DMEM-F12 media supplemented with 
10% FBS, 30,000 units penicillin/streptomycin solution, 5ng/ml EGF, 0.5 µg/ml 
Hydrocortisone, and 5 µg Insulin. HEK-293, MCF7, MDA-MB-231, and MDA-MB-468  
cells were purchased from ATCC and were subcultured in DMEM media containing 10% 
FBS and 30,000 units penicillin streptomycin solution. LCC9 cells (Lombardi 
Comprehensive Cancer Center, Georgetown University) were routinely subcultured in 
DMEM phenol red free media supplemented with 1 mM L-glutamine, 30,000 units 
penicillin/streptomycin, and 10% charcoal treated FBS. All cells were maintained under 
normoxic conditions (5% CO2) at 37°C. 
Plasmids. Creation of the Myc-Spy1-pCS3 was described previously (Porter et al., 
2002). Rc-CMV-Cyclin E (#8963) and lentiviral constructs pLB (#11619) and pLKO-
scrambled control (#8453) were purchased from Addgene. shRNA oligos for Spy1, 
Cyclin E and a scrambled control were ligated into the pLB vector, as previously 
described, and were previously determined to be specific using multiple constructs of 
each and rescue constructs (Lubanska and Porter, 2014b). 
Immunoblotting (IB). Cells were harvested in NP-40 lysis buffer (1% NP-40, 50 mM 
Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl) containing protease inhibitors (100 µg/ml 
PMSF, 5 µg/ml aprotinin, and 2 µg/ml leupeptin) for 1 hour on ice. Bradford reagent was 
used for protein concentration as per manufacturer‟s instructions (Sigma). 80-100 µg of 
protein were subjected to electrophoresis on denaturing 10% SDS polyacrylamide gels 
and transferred to PVDF-Plus 0.45 micron transfer membrane (Osmonics Inc.) for 2 
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hours at 30 volts using a wet transfer method. Blots were blocked for 1 hour in 1% BSA 
solution at room temperature. Primary antibodies were reconstituted in blocker and 
incubated overnight at 4°C, secondary antibodies were used at 1:10000 dilution in 
blocker for 1 hour at room temperature. Blots were washed 3 times in TBST for 3 
minutes following incubation with primary and secondary antibodies. Chemiluminescent 
Peroxidase Substrate was used for visualization following manufacturer‟s instruction 
(Pierce). Chemiluminescence was quantified on an AlphaInnotech HD2 (Fisher) using 
AlphaEase FC software. The proper antibodies were used at the following concentrations: 
Actin MAB150 1R (Chemicon-Millipore; 1:1000), Spy1 (ThermoScientific; 1:1000), c-
Myc (Sigma; 1:1000), anti-phospho-c-Myc-S62 (Abcam; 1:1000), anti-phospho-c-Myc-
T58 (Santa Cruz Biotechnology; 1:1000), Cyclin E1 (Abcam; 1:1000), anti-p-ERK 1/2 
[Thr 202/Tyr 204] (Cell Signaling; 1:1000), and anti-ERK1/2 (Santa Cruz 
Biotechnology; 1:1000). 
Lentiviral Production. VSV-G pseudotyped lentivirus was produced by transient 
transfection of HEK293 LentiX cells with transfer vector and the multi-deleted packaging 
plasmids (pMDG, pMDL2, pRSV) using polyethylenimine (PEI) (Sigma) reagent with 
1:3 DNA to PEI ratio and incubation for 5 hours at 37°C, 5% CO2. The virus was 
collected the next day and concentrated for 3 hours at 4°C using an ultracentrifuge. The 
titer for pEIZ and pLB were determined by transducing 293T cells and analysis of eGFP 
protein expression by flow cytometry at 72 hours post transduction. The titer for pLKO 
lentivirus was assessed by puromycin selection followed by crystal violet staining and 
quantification of resistant colonies. The titered virus was filter sterilized and stored at      
-80°C. 
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Transfection/Infection. Transfection: Cells were transfected using PEI branched 
reagent. In brief, 10 µg of DNA was mixed with 3 µL of 10 mg/ml PEI for 10 minutes 
then added to a 10 cm tissue culture plate. Transfection media was changed after 24 
hours. Lentiviral Infection: 8000 cells were seeded in fully supplemented growth media 
in 96-well plates for 2 hours. Cells were starved by removing serum and 
penicillin/streptomycin from the media, followed by the use of 1 mg/ml polybrene (Santa 
Cruz Biotechnology) and MOI 3 of the specific vector used. Infected media was changed 
to fully supplemented media 24 hours after infection.  
Drug Treatments. Treatments included vehicle control dimethyl sulfoxide (DMSO), 100 
nM 4-Hydroxytamoxifen (Sigma), 25 nM doxorubicin (Sigma), 100nM paclitaxel, 6mM 
cyclophosphamide (Sigma) for specified time points. 
Proliferation Assay. Cells were seeded at 5x10
4
 cell density in 24-well plate. Following 
treatments cells were collected at specified time points, pelleted and resuspending in 1mL 
of media. 10 µl sample was collected, trypan blue was added and counted using a 
haemocytometer.   
BrdU Assay. BrdU stock (10 mM) was dissolved in 10 mL of culture medium to produce 
a 10 µM labelling solution. Infected and non-infected cells were seeded at 8x10
3
 cell 
density in 96-well plate, after 24 hours the culture medium was replaced with BrdU 
labelling solution for 30 minutes in CO2 incubator at 37°C. The labelling solution was 
removed and washed 2 times with 1x PBS for 2 minutes each. PBS was removed and 
3.7% formaldehyde in PBS was added to each well and incubated for 30 minutes at room 
temperature. Cells were washed with 1xPBS 3 times for 2 minutes each. Cells were 
immersed in 0.07N NaOH for 2 minutes, then in 1xPBS (pH 8.5) to neutralize the base. 
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20 µl anti-BrdU (Becton Dickinson) was mixed with 50 µl of 0.1% Tween 20/PBS. For 
indirect immunofluorescence staining, the diluted unconjugated anti-BrdU was added to 
the cells and incubated for 30 minutes in a humidified chamber. Cells were washed with 
1xPBS. 50 µl 0.1% Tween 20/PBS was added to cells. Alexa mouse (1:1000) was added 
for 30 minutes at room temperature. Cells were washed with 1xPBS and incubated with 
Hoechst. Cells were washed with water and air dried.  
Cyclohexamide (CHX) Treatment. After transfection cells were treated with 50 µg/mL 
cycloheximide (Sigma) to block de novo protein synthesis. After 0.25 to 2 hours, cells 
were pelleted, harvested and subjected to SDS-PAGE analysis and IB. 
Tissue Microarray (TMA) Construction. Embedded tissue samples were received from 
Windsor Regional Cancer Centre and constructed into TMAs using an Arraymold Inc., 
TMA mold with 72 1.5 mm cores (20015D). Briefly, paraplast X-tra paraffin (Sigma) 
was added to the mold, an embedding ring was placed on top and filled with paraffin. 
After an hour incubation on ice the mold was separated from the embedding ring. 3-4 
cores were taken from each embedded sample and placed into the TMA mold. Following 
10 minutes of incubation in 65°C oven, the mold was placed on ice. The cores were left 
overnight prior to sectioning. TMAs were sectioned using a Leica microtome at 10 µm 
and placed on Fisherbrand Superfrost Plus microscope slides (12-550-15) and heated for 
10 minutes.  
Immunohistochemistry (IHC). TMA sectioned slides were deparaffinized and 
rehydrated using 3 changes of xylene for 3 minutes each, followed by 3 changes of 100% 
EtOH for 2 minutes each, and 95%, 80%, and 70% EtOH for 2 minutes. Slides were 
washed in 1x PBS for 5 minutes. Sodium citrate antigen retrieval was performed. Briefly, 
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slides were placed in a rack in 600 ml of 10 mM Sodium Citrate (pH 6.0) in a 2L 
tupperware container, and microwaved for 20 minutes total, replacing evaporated water 
every 10 minutes. Slides were cooled for 20 minutes, washed 3 times in distilled water 
for 5 minutes each and in 1x PBS for 5 minutes. Slides were blocked for endogenous 
peroxidases using 90 ml methanol/10 ml 30% H2O2 for 10-15 minutes at room 
temperature, followed by 3 washes in 1x PBS for 5 minutes each. After circling sections 
with a PAP pen, blocking buffer (3%BSA/0.1% Tween in 1xPBS) was added for 1 hour 
at room temperature in a humidified chamber. Primary antibody was diluted 1:200 in 
blocking buffer and added to slides overnight at 4°C. After incubation, primary antibody 
was washed in 1x PBS 3 times for 10 minutes each. Biotinylated secondary antibody was 
diluted 1:500 in blocking buffer and added to the slides for 1 hour at room temperature in 
a humidified chamber. Secondary antibody was washed 3 times for 10 minutes in 1x 
PBS. ABC reagent (Vector Labs) was added to each slides and incubated for 30 minutes 
at room temperature. Slides were washed in 1x PBS 3 times for 5 minutes each. DAB 
(Vector Labs) was added to each slide and was removed once colour change was seen 
(approximately 1-10 minutes). Slides were washed in distilled water for 5 minutes. 
Haematoxylin was used as a counterstained for 1-2 minutes followed by a 1 minute wash 
in 1x PBS and then one wash in distilled water for 1 minute. Slides were dehydrated in 
95% EtOH 3 times for 5 minutes, followed by 3 changes of 100% EtOH for 5 minutes. 
Lastly, slides were put through 3 changes of xylene for 15 minutes each, coverslip was 
added after final xylene change.  
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Microscopy. Slides were imaged using Leica Stereoscope M205FA. Using Leica LAS 
V4.3 program, images were taken at 79.7x magnification using 1x stereoscope objective 
and 159x magnification using 2x stereoscope objective. 
TMA Quantification. Quantification of Spy1 and c-Myc immunostaining intensity was 
performed using Adobe Photoshop CC 2014 (Adobe Systems Inc. San Jose, CA) using 
nine random samplings of 10 x 10 pixels each, based on a previously reported 
densitometry method (Goenka et al., 2013; Matkowskyj et al., 2000). 
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RESULTS 
Primary MMTV-Myc cells acquire resistance to tamoxifen over time in culture. 
 Primary MMTV-Myc cells were passaged over time and their response to 
tamoxifen over 24 hours measured using BrdU incorporation analysis. In early passages 
(P10-P35) tamoxifen treatment reduced the number of cells going through DNA 
synthesis by 80-90%, but in late passages (P45-P85) tamoxifen had no significant effect 
(Figure 1A). Response was also recorded as a product of percent change in overall cell 
number compared to vehicle control. Early passage cells (P34) decrease in cell number 
by ~35% in response to treatment, while late passage cells (P80) do not respond to 
tamoxifen treatment (Figure 1B). We then used this model to determine any effects on 
ERα levels with persistent c-Myc signalling (Figure 1C). We find that the protein levels 
of ERα begin to decrease dramatically between P30-P80. As shown previously, levels of 
Spy1 are high in the presence of c-Myc signalling (Golipour et al., 2008), and we show 
that they remain at an elevated level at all passages.  
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Figure 1. Primary MMTV-Myc cells acquire resistance to tamoxifen over time in
culture. (A) Primary MMTV-Myc cells at passage (P) 34 and 80 were treated with 100
nM of tamoxifen or vehicle control (DMSO); followed by BrdU analysis. The percent
BrdU positive cells are depicted on y-axis (B) Primary MMTV-Myc cells at various
passages were treated with 100 nM of tamoxifen or vehicle control (DMSO) followed
by trypan blue exclusion assay. Percent difference between tamoxifen treated and
DMSO control depicted on y-axis. (C) Primary MMTV-Myc cells were passaged and
collected, followed by SDS-PAGE and IB. A representative blot is shown (left panel)
and densitometry of protein to loading control actin is shown (right panel). (A-C) Error
bars reflect SE between triplicate experiments. Student’s t-test was performed; *p<0.05,
**p<0.01, ***p<0.001.
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Spy1 levels affect cellular response to tamoxifen treatment. 
 To determine if Spy1 levels could affect the treatment response of late passage 
cells (P80), which showed an acquired resistance to tamoxifen, we infected P80 cells 
with either shScrambled (pLB) or Spy1 knockdown (shSpy1). Knockdown of Spy1 
significantly decreased c-Myc protein levels (Figure 2A). Cells with Spy1 knockdown 
had a significant reduction in cell proliferation over time compared to the aggressive 
control population (Figure 2B). Spy1 knockdown cells and control cells were also treated 
with 100 nM tamoxifen and viability measured. After 24 hours, Spy1 knockdown 
significantly decreased the number of viable cells by ~33% in response to tamoxifen 
(Figure 2C). This was also reflected by a significant difference in BrdU incorporation in 
P80-Spy1 knockdown vs. control knockdown (pLB) cells treated with tamoxifen (Figure 
2D).  
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Figure 2. Spy1 levels affect cellular response to tamoxifen. Cells were infected with
pLB empty vector or pLB-shSpy1 vector. (A) SDS-PAGE and IB was performed. A
representative blot is shown (left panel) and densitometry ratio of protein to loading
control actin is shown (right panel). (B) Infected cells were subjected to trypan blue
exclusion assay for the indicated time course. (C) Infected cells were treated with 100
nM of tamoxifen or vehicle control (DMSO). Proliferation after treatment was assayed
using trypan blue exclusion assay. (D) BrdU analysis of P80 cells infected with pLB or
shSpy1. The percent of BrdU positive cells is depicted on the y-axis. (A-D) Error bars
reflect SE between triplicate experiments. Student’s t-test was performed;
*p<0.05,**p<0.01,***p<0.001.
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Spy1 has a role in stabilizing c-Myc. 
 TNBC is associated with elevated levels of c-Myc (Horiuchi et al., 2012). We 
tested whether Spy1 levels correlated with that of c-Myc in TNBC cells (MDA-MB-231 
and MDA-MB-468) as compared to ERα-positive MCF7 or their hormone resistant 
counterpart LCC9 (Figure 3A) (Hydbring et al., 2010). TNBC cells have higher levels of 
both Spy1 and c-Myc as compared to ERα positive breast cancer cell lines. Interestingly, 
LCC9 resistant cells also have higher levels of both c-Myc and Spy1 than hormone 
sensitive MCF7 cells. To elucidate whether Spy1 is essential for elevated c-Myc levels, 
we infected MDA-MB-231 cells with shScrambled or shSpy1 and collected 24 to 72 
hours after infection. Spy1 knockdown significantly reduced c-Myc protein levels (Figure 
3B). To determine if Spy1 overexpression can affect the stabilization of c-Myc protein, 
HEK-293 cells were manipulated to overexpress Spy1 or an empty vector control (pCS3) 
followed by treatment with cycloheximide to block de novo protein synthesis and c-Myc 
protein half-life (t1/2) was monitored by western blot over time. Spy1 increases the half-
life of c-Myc almost 2 fold (Figure 3C). Half-life of the phosphorylated form was shorter 
than that of overall levels of c-Myc but also demonstrates a significant increase in the 
presence of Spy1 (Figure 3C, lower graph).  
 
 
 
 
 
 
IB: Spy1
IB: Actin
Actin
Spy1
MD
A-
MB
-23
1
MD
A-
MB
-46
8
MC
F7
LC
C9
IB: c-Myc
c-Myc
3.5
3
2.5
2
1.5
1
0.5
0
MD
A-
MB
-23
1
MD
A-
MB
-46
8
LC
C9
MC
F7
Spy1
c-Myc
D
en
si
to
m
et
ry
R
at
io
(p
ro
te
in
:a
ct
in
)
***
**
***
B
A
c-Myc
IB: c-Myc
IB: p-c-Myc
IB: Actin
p-c-Myc
(T58/S62)
Actin
0 0.2
5
10.5 2 0 0.2
5
10.5 2CHX (h)
pCS3 Spy1
D
en
si
to
m
et
ry
R
at
io
(p
ro
te
in
:a
ct
in
)
24 48 72 24 48 72 (hours)
3.5
3
2.5
2
1.5
1
0.5
0
pLKO shSpy1
Spy1
c-Myc
Actin
IB: Spy1
IB: Myc
IB: Actin
24 48 72 24 48 72
pLKO shSpy1
hours
Spy1
c-Myc
C
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
0.25 0.5 1 2
Time (hours)
Fo
ld
Ch
an
ge
p-
c-
M
yc
(re
lat
ive
to
0
ho
ur
s)
*
**
*
Spy1
Control
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
F
ol
d
C
ha
ng
e
To
ta
lc
-M
yc
(c
om
pa
re
d
to
0h
)
0.25 0.5 1 2
Time (hours)
Spy1
Control
**
***
***
*
t1/2=1
t1/2= 1.75
t1/2= 0.75
t1/2= 0.95
129
Figure 3. Spy1 has a role in stabilizing c-Myc. (A) A panel of breast cancer cell lines
were subjected to protein extraction and SDS-PAGE analysis followed by IB to
determine overall Spy1 and c-Myc levels. (B) MDA-MB-231 cells were infected with
shScrambled (denoted pLKO) or shSpy1 (denoted shSpy1); followed by SDS-PAGE
and IB. (C) Hek-293 cells were transfected with pCS3, myc-tagged Spy1 followed by
treatment with 50 ug/ml cyclohexamide. After 0.25, 0.5, 1, and 2 hours, cells were
collected and subjected to SDS-PAGE analysis and IB. Fold change of control and
overexpression to time 0 hours was calculated and graphed to determine the overall
effect on c-Myc stabilization by overexpression of Spy1. (A-C) A representative blot is
shown (left panel) and densitometry ratio of Spy1 to actin loading control is shown
(right panel). Error bars reflect SE between triplicate experiments. Student’s t-test was
performed; *p<0.05,**p<0.01,***p<0.001.
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Stabilization of c-Myc requires Spy1 and Cyclin E. 
 c-Myc protein levels are, in part, regulated post-translationally via 
phosphorylation on serine (S)-62 leading to subsequent protein stabilization. S62 can be 
phosphorylated by CDK2, CDK1, and ERK1/2 (Adhikary and Eilers, 2005; Amati, 2004; 
Amati et al., 1998; Sears et al., 2000). To determine the effect of Spy1 on the 
stabilization of c-Myc, Spy1 was overexpressed in HEK-293 cells and Cyclin E1 was 
used as a positive control. Our data confirms the literature that Cyclin E overexpression 
results in an increased phosphorylation of c-Myc at S62 (Figure 4A). Comparably, we 
show that overexpression of Spy1 also leads to the phosphorylation of c-Myc (Figure 
4A). We further investigated whether Spy1 was a necessary mediator of c-Myc 
stabilization by knocking down either Spy1 or Cyclin E1 in HEK-293 cells. Knockdown 
of either gene in HEK-293 significantly decreased the level of p-c-Myc as compared to 
control (Figure 4B).  
 
 
 
 
 
 
 
 
 
 
ASpy1
Cyclin E
IB: Spy1
IB: Cyclin E
IB: p-c-Myc
IB: c-Myc
IB: Actin
p-c-Myc (T58/S62)
c-Myc
Actin
wt pL
KO
sh
Sp
y1
sh
Sp
y1
.2
sh
cy
cli
nE
c-Myc
p-c-Myc (T58/S62)
Actin
Co
ntr
ol
Sp
y1
Co
ntr
ol
Cy
clin
E
IB: c-Myc
IB: p-c-Myc
IB: Actin
Spy1
IB: c-Myc
IB: Cyclin E
Cyclin E
6
5
4
3
2
1
0
De
ns
ito
m
et
ry
Ra
tio
(p
-c
-M
yc
:M
yc
)
Control Spy1 Control Cyclin E
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
wt
pL
KO
sh
Sp
y1.
1
sh
Sp
y1.
2
sh
Cy
clin
E
De
ns
ito
m
et
ry
Ra
tio
(p
-c
-M
yc
:M
yc
)
*
* * *
*
B
Figure 4. Stabilization of c-Myc requires Spy1 and Cyclin E. (A) Cells were
transfected with pCS3, myc-tagged pCS3-Spy1, pCMV, or pCMV-Cyclin E vector;
followed by SDS-PAGE and IB. (B) Cells were infected with shScrambled control
(denoted pLKO), two shSpy1 constructs (shSpy1.1 and shSpy1.2), and shCyclin E;
followed by SDS-PAGE and IB. (A-B) A representative blot is shown (left panel).
Densitometry ratio of protein to actin loading control is shown (right panel). Error bars
reflect SE between triplicate experiments. Student’s t-test was performed; *p<0.05.
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Spy1 levels are elevated in human TNBC tumour tissue. 
 Spy1 levels are elevated in invasive ductal carcinoma of the breast (Al Sorkhy et 
al., 2012). To determine the levels of Spy1 in TNBC, frozen adjacent pair-matched 
normal and tumour TNBC tumour samples were obtained from the Ontario Tumour Bank 
and subjected to protein extraction and IB analysis. Spy1 levels are significantly elevated 
in TNBC patient samples as compared to adjacent pair-matched normal tissue (Figure 
5A). To increase our sample size TNBC embedded patient samples were collected, 
subject to haematoxylin and eosin (H&E) staining to designate tumour versus stroma area 
and 1.5 mm cores used in a TMA construction. At least 3 normal patient samples were 
included on each array and IHC/DAB staining was performed for Spy1 (Figure 5B-C) 
and c-Myc protein levels (Figure 5D-E). Spy1 protein levels are significantly higher than 
in control, with increases in intensity of over 2 fold over all samples (Figure 5C). c-Myc 
protein levels were also significantly upregulated as compared normal tissue, being 
greater than 2 fold elevated (Figure 5E). The data collected from this study has also been 
individualized for each patient sample and will be used to determine whether there are 
any correlations between Spy1 and/or c-Myc protein levels and response to therapy.  
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Figure 5. Spy1 levels elevated in human TNBC tumour tissue. (A) Protein from frozen
tumour tissue was extracted and analysed by SDS-PAGE and IB. Densitometry
analysis for Spy1 levels is seen in the right panel. TMAs were constructed and stained
for Spy1 protein (B-C) or c-Myc protein (D-E). (B) Representative images of patient
samples stained for Spy1 protein. (i) negative control. (ii, iv & vi) Image taken at 79.7x
using a 1x stereoscope. (iii, v & vii) Image taken at 159x using a 2x stereoscope.
(C) Average Spy1 intensity over 75 patient samples obtained by random sampling of
10x10 pixels each and quantified in Adobe Photoshop. (D) Representative images of
samples stained for c-Myc protein. (i) negative control. (ii, iv & vi) Image taken at
79.7x using a 1x stereoscope. (iii, v & vii) Image taken at 159x using a 2x stereoscope.
(E) Average c-Myc intensity over 75 patient samples obtained by random sampling of
10x10 pixels each and quantified in Adobe Photoshop. (A,C, & E) Error bars reflect
SE between triplicate cores. Student’s t-test was performed; ***p<0.001.
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Spy1 knockdown increases TNBC cell line response to chemotherapy treatment.  
 ERα-negative breast cancers, including TNBC, undergo a chemotherapy regimen, 
one common standard of care regimen includes an anthracyclin, cyclophosphamide, and 
taxol combination, also known as AC/T (Citron et al., 2003). To determine whether 
chemotherapy regimens can work more effectively in vitro when Spy1 levels have been 
depleted or are low, MDA-MB-231 cells were infected to knockdown either Spy1 or 
Cyclin E1 (Figure 6A). Knockdown of either gene significantly reduced levels of c-Myc. 
However, Spy1 knockdown also demonstrated a significant decrease in percent cell 
viability with the use of each drug treatment alone or in combination (AC/T). This effect 
was not consistently seen with Cyclin E1 knockdown, especially with the individual use 
of paclitaxel (Figure 6B), indicating this is a trait unique to Spy1.  
 
 
 
 
 
 
 
 
 
 
 
 
Actin
Cyclin E
Spy1
pL
KO
sh
Sp
y1
sh
Cy
clin
E
IB: Actin
IB: Cyclin E
IB:Spy1
IB: c-Myc
c-Myc
120
100
80
60
40
20
0
Co
ntr
ol
AC
/T
Do
xo
rub
icin
Pa
clit
ax
el
%
Vi
ab
ilit
y
pLKO
shSpy1
shCyclin E
Cy
clo
ph
os
ph
am
ide
***
***
**
*
* *** *
***
A B
Figure 6. Spy1 knockdown increases TNBC cell line response to chemotherapy
treatment. (A-C) Cells were infected using pLKO, shSpy1, and shCyclin E.
(A) Confirmation of knockdown was seen through SDS-PAGE and IB analysis. (B)
Cel l s were t reated wi th 100 nM pacl i taxel , 25 nM doxorubicin , 6 mM
cyclophosphamide, or a combination of the three (AC/T). Following incubation times,
cells were subjected to trypan blue exclusion assay. Error bars reflect SE between
triplicate experiments. Two-way ANOVA was performed; *p<0.05, **p<0.01,
***p<0.001.
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DISCUSSION 
 Breast cancer is a heterogenous disease, divided into 5 main subtypes. Each 
subtype is defined by its molecular signature; with 3 important proteins to aid in its 
classification; ERα, PR, and Her2/neu (Dolle et al., 2009). The presence of at least one of 
these three proteins enables a patient to receive targeted therapies; which have 
significantly increased the overall 5-year survival rate of breast cancer patients to 88% 
(CBCF, 2014). However, a subset of patients cannot respond to these forms of treatments 
or become resistant to therapies through the loss of ERα, PR, or Her2/neu (Dolle et al., 
2009). Loss/absence of all three genes is classified as the highly aggressive TNBC group, 
with a majority of patients being younger than 50 years of age (Dolle et al., 2009). The 
aggressiveness of this subtype is also in part due to the upregulation of various genes, 
such as the oncogene c-Myc or mutation of the tumour suppressor gene p53 (Alles et al., 
2009; Perou, 2010). 
 Transcriptional upregulation of c-Myc over time can confer control over ERα-
targeted genes (Alles et al., 2009; Dadiani et al., 2009). This characteristic of c-Myc has 
been correlated with the basal breast cancer subtype and acquired resistance to hormone 
therapies, such as tamoxifen (Dimitrakakis et al., 2006; Musgrove et al., 2008a; 
Musgrove et al., 2008b). Our data shows that persistent c-Myc signalling using the 
MMTV-Myc model results in a decreased response to tamoxifen over time, leading to a 
resistant phenotype; which correlates with a loss of ERα protein expression. The 
mechanism behind this differential response and loss of expression is currently unknown. 
There is data to suggest, however, that a loss/downregulation of ERα may be through the 
activation of downstream c-Myc targets that feedback to the ERα (Dimitrakakis et al., 
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2006). Much research has focused on targeting c-Myc; however, this has proven 
challenging due to the vast number of c-Myc targets, directing multiple biological 
functions, including proliferation, differentiation, apoptosis, and senescence (Amati and 
Land, 1994; Amati et al., 1993). For instance, c-Myc null cells have a 2.5 fold decrease in 
protein synthesis which leads to growth defects due to a delay in both G1 and G2 phases 
of the cell cycle (Schmidt, 1999). Whether targeting specific downstream targets, such as 
the atypical cyclin Spy1, can avoid lethality of healthy cells and provide adequate 
targeting to cancer cells is a hypothesis that this work supports.  
 Spy1 has been found to follow a similar expression profile as c-Myc within the 
developing mammary gland (Golipour et al., 2008), and we showed Spy1 protein levels 
remain upregulated in c-Myc driven breast cancer cells in culture as they acquire 
resistance to hormone therapy.  Spy1 and c-Myc are upregulated in similar cancers, such 
as neuroblastoma and invasive breast carcinomas (Al Sorkhy et al., 2012; Golipour et al., 
2008; Kniazev et al., 1986; Lubanska and Porter, 2014b; Perou, 2010; Perou et al., 2000; 
Xu et al., 2010; Zucchi et al., 2004). We show, for the first time, that Spy1 and c-Myc are 
co-regulated in TNBC patient samples and cell lines and that Spy1 levels influence the 
protein stabilization of c-Myc. Importantly, in c-Myc overexpressing MMTV-Myc 
mammary carcinoma cells, knockdown of Spy1 not only significantly decreases the rate 
of proliferation, but it also sensitized late passage resistant cells to tamoxifen. ERα-
negative tumours, specifically TNBC, are known to have no response to hormone 
therapies and are dependent on a chemotherapeutic regimen (Dent et al., 2007; Peddi et 
al., 2012). Standard of care for many cancers is through the use of doxorubicin, 
cyclophosphamide, and paclitaxel, commonly referred to as AC/T (Citron et al., 2003). 
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Knockdown of Spy1 in TNBC cells significantly sensitized cells to both single agent as 
well as combination AC/T therapy. Importantly, the sensitivity seen with Spy1 
knockdown was unique; similar effects were not seen in all treatments when Cyclin E1 
was knocked down. We have shown that although Spy1 functions similar to Cyclin E1 in 
stabilizing and influencing the levels of c-Myc, manipulation of Spy1 levels uniquely 
enhances sensitivity to treatment. Spy1 has a unique set of substrates and overrides CDKs 
using a mechanism different than that of classical cyclin-CDKs (Cheng et al., 2005b; 
Gastwirt et al., 2007; Karaiskou et al., 2001); hence, targeting Spy1-driven CDKs in 
cancers with high expression levels of both c-Myc and Spy1 could promote novel, and 
potentially specific therapeutics. 
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CHAPTER 4 
 
SPY1 PROTEIN LEVELS SENSITIZE TRIPLE NEGATIVE BREAST CANCER 
CELLS TO COMBINATION CISPLATIN AND CDK INHIBITOR TREATMENT 
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INTRODUCTION 
 Triple negative breast cancer (TNBC) is clinically characterized by the lack of 
expression, or low levels of the estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (Her2/Neu) (Musgrove et al., 1993; Perou et 
al., 2000). Absence of these receptors renders TNBC typically unresponsive to existing 
targeted therapies; hence, chemotherapy remains the standard of care for these patients 
(Perou, 2010; Perou et al., 2000). TNBC represents approximately 10-20% of the breast 
cancer population, patients are statistically younger and have a worse prognosis over all 
subtypes of breast cancer (Boyle, 2012). Hence, there is an urgent need to improve 
therapy options for TNBC patients.  
 One of the current chemotherapy regimens for TNBC includes treatment with 
doxorubicin, cyclophosphamide, and paclitaxel at varying doses and time points 
dependent upon a patient's mass and severity/grade of cancer. These drugs directly bind 
to either the DNA (doxorubicin, cyclophosphamide) or microtubules (paclitaxel) to 
prevent cell cycle progression and ultimately trigger apoptosis (Hall and Tilby, 1992; 
Jordan and Wilson, 2004; Stordal et al., 2007). One clinical trial has shown that the 
administration of four cycles of AC every two weeks followed by paclitaxel 
administration every 2 weeks significantly improved the overall disease free survival of 
patients (Citron et al., 2003). Furthermore, there is evidence to support the administration 
of an anthracycline based chemotherapy regimen in TNBC patients that shows higher 
chances of disease free and overall survival (Miyoshi et al., 2010). The response rate to 
chemotherapy is impressive; however, the high recurrence rate shows there is a need for 
further investigations into less cytotoxic, more effective therapies. 
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 Data support that combining platinum drugs, such as cisplatin or carboplatin, may 
represent a valuable new combination therapy for TNBC that has the potential to increase 
efficacy without increasing toxicity (Liu et al., 2015; Pruefer et al., 2008; Rosenberg et 
al., 1969; Siddik, 2003; Wang and Lippard, 2005). Platinum drugs function through the 
formation of DNA adducts, usually in the S-phase of the cell cycle. Torrissi et al. (2008) 
showed the addition of cisplatin to the chemotherapy regimen of TNBC patients 
increased the pathologic complete response (pCR); which correlates with a better 
prognosis (Torrisi et al., 2008). Although the results from this study showed promising 
results when combining a platinum to standard of care chemotherapy, the long-term 
benefits and molecular stratification of patients were not elucidated.  
 At a molecular level, overcoming, or preventing, resistance to standard 
chemotherapy reagents may be achieved by sensitizing cells to trigger apoptosis in 
response to DNA damage. During the DNA damage response (DDR) the drivers of the 
cell cycle, the cyclin dependent kinases (CDKs) and cyclin partners, are inhibited via 
upregulation of CDK inhibitors (CKIs), such as p21
Cip1 
(Arellano and Moreno, 1997). 
Prolonged arrest of the cell cycle due to inappropriate repair of DNA leads to triggering 
of the apoptotic machinery and long-term expression of p21
Cip1
, and its family of 
inhibitors (Di Leonardo et al., 1994). Paradoxical to this goal, however, most cancers, 
including breast cancer, have upregulated drivers of the cell cycle and decreased levels of 
CKIs to permit the evolving accumulation of DNA mutations (Bandoh et al., 2005; 
Caldon et al., 2012; Zhang et al., 2011). Strategies to reinforce this important cell cycle 
checkpoint with synthetic CKIs have been established over the past decade. Pan-CKIs, 
such as roscovitine, have shown some success to date in pre-clinical trials, but 
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demonstrate low efficacy in the clinic, with a high toxicity rate (Bach et al., 2005; Byrd et 
al., 2007; Nair et al., 2011). Better results have been achieved using more selective 
inhibitors (Finn et al., 2009) and, indeed, there are panels of second and third generation 
inhibitors that remain to be tested. Selectivity of CKIs is challenging due to similarities in 
the active site of the CDKs and clinical results suggest that it is important to identify the 
patients who will benefit from select CKI treatment (Finn et al., 2009; Malinkova et al., 
2015). Yet another complication to this field is the presence of non-cyclin proteins that 
bind to and activate CDKs in a unique manner (Nebreda, 2006). One such protein, Spy1 
(gene SPDYA, also called RINGO, Spy1A1, Speedy), does not require the removal of 
inhibitory phosphorylation on threonine (T)-14 and tyrosine (Y)-15 from CDKs and it 
can lead to the activation of CDKs even in the absence of the activating phosphorylation 
in the T-loop of the active site of the CDK or presence of natural CKIs (Cheng et al., 
2005a; Karaiskou et al., 2001; Porter et al., 2003). Based on these characteristics, the 
presence of Spy1 may alter sensitivity to synthetic CKIs. Elevated levels of Spy1 are 
found in several human cancers, including invasive breast cancers (Al Sorkhy et al., 
2012; Hang et al., 2012; Ke et al., 2009; Lubanska and Porter, 2014b) and overexpression 
in cell systems is a potent mechanism of overriding apoptosis and cell cycle arrest 
triggered by the DNA damage response  (Barnes et al., 2003; Gastwirt et al., 2006). 
Herein, we investigated whether Spy1 levels are implicated in the sensitivity of TNBC to 
emerging chemotherapy treatments. We show that Spy1 levels are elevated in TNBC cell 
lines and we demonstrate that manipulating Spy1 levels can sensitize TNBC cells to 
treatment with cisplatin and available CKI treatment.  
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MATERIALS AND METHODS 
Cell Culture. MDA-MB-231 and MCF7 cells were purchased from ATCC and were 
cultured in DMEM media supplemented with 10% FBS and 30,000 units 
penicillin/30,000 µg streptomycin solution. Cells were maintained under normoxic 
conditions (5% CO2) at 37°C. 
Plasmids. pLKO-scrambled control (#8453) was purchased from Addgene. pLKO-
shSpy1 and pLKO-shCyclin E1 were cloned to express a short hairpin previously 
described to knockdown Spy1 specifically or Cyclin E1 specifically in the place of the 
scrambled sequence; previously determined to be specific using multiple constructs of 
each and rescue constructs (Lubanska and Porter, 2014b). pEIZ vector was generously 
donated from Dr. B. Welm. The creation of pEIZ-Spy1 was completed by inserting Spy1 
oligo into the EcoRI and XbaI sites of pEIZ. 
Immunoblotting (IB). Cells were lysed in NP-40 buffer (1% NP-40, 50 mMTris-HCl pH 
7.5, 1 mM EDTA, 150 mMNaCl) containing protease inhibitors (100 µg/ml PMSF, 5 
µg/ml aprotinin, and 2 µg/ml leupeptin) for 1 hour on ice. Bradford reagent was used to 
determine the concentration of protein following the manufacturer‟s instructions (Sigma). 
80-100 µg of protein were subjected to electrophoresis on denaturing 10% SDS 
polyacrylamide gels and transferred to PVDF-Plus 0.45 micron transfer membrane 
(Osmonics Inc.) for 2 hours at 30 volts using a wet transfer method. Blots were blocked 
for 1 hour in 1% BSA solution at room temperature. Primary antibodies were 
reconstituted in blocker and incubated overnight at 4°C, secondary antibodies were used 
at 1:10000 dilution in blocker for 1 hour at room temperature. Blots were washed 3 times 
in TBST for 3 minutes following incubation with primary and secondary antibodies. 
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Chemiluminescent Peroxidase Substrate was used for visualization following 
manufacturer‟s instruction (Pierce). Chemiluminescence was quantified on an 
AlphaInnotech HD2 (Fisher) using AlphaEase FC software. The proper antibodies were 
used at the following concentrations: Actin MAB150 1R (Chemicon-Millipore; 1:1000), 
human Spy1 (ThermoScientific; 1:1000), and Cyclin E1 (Abcam; 1:1000). 
Lentiviral Production and Infection: VSV-G pseudotyped lentivirus was produced by 
transient transfection of HEK293 LentiX cells with transfer vector and the multi-deleted 
packaging plasmids (pMDG, pMDL2, pRSV) using polyethylenimine (PEI) (Sigma) 
reagent with 1:3 DNA to PEI ratio and incubation for 5 hours at 37°C, 5% CO2. The virus 
was collected the next day and concentrated for 3 hours at 4°C using an ultracentrifuge. 
The titer for pEIZ was determined by transducing 293T cells and analysis of eGFP 
protein expression by flowcytometry at 72 hours post transduction. The titer for pLKO 
lentivirus was assessed by puromycin selection followed by crystal violet staining and 
quantification of resistant colonies. The titered virus was filter sterilized and stored at      
-80°C. 80,000 cells were seeded in fully supplemented growth media in 24-well plates for 
2 hours. Cells were starved by removing serum and penicillin/streptomycin from the 
media, followed by the use of 1 mg/ml polybrene (Santa Cruz Biotechnology) and MOI 3 
of the specific virus used. Infected cells were changed to fully supplemented media 24 
hours after infection. For knockdown, cells were incubated with 1mg/ml puromycin 
(Sigma) 48 hours after infection for 72 hours to allow for puromycin selection. Media is 
thereafter changed every 48 hours with puromycin included.   
Drug Dosage. Cells were treated with 25 nM doxorubicin (Sigma), 100 nM paclitaxel 
(Sigma), 6 mM cyclophosphamide (Sigma), or 43 µM cisplatin (Sigma) for 24 hours 
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when used alone. AC/T treatment (doxorubicin, cyclophosphamide treatment first for 24 
hours, recover for 24 hours,  followed by paclitaxel treatment for 24 hours). Addition of 
cisplatin treatment to AC/T regimen occurs concurrently with paclitaxel treatment.  CDK 
inhibitors included 20 µM roscovitine (Santa Cruz Biotechnology) or 25 µM NU-2058 
(Tocris) for 48 hours, unless otherwise indicated. 
Proliferation Assay. Cells were seeded at 5x10
5
 cell density in 24-well plate. Following 
incubation times with drug treatments, indicated above, cells were collected, pelleted and 
resuspended in 1 ml of media. 10 µl samples were collected, trypan blue was added and 
live cells were counted using a haemocytometer.   
MTT Assay. Cell numbers were optimized to ensure log phase of growth was used for 
each MTT thereafter. Cells were seeded at 8 x 10
3
 cell density in a 96-well plate. 
Following incubation times with drug treatments, indicated above, 5 mg/ml MTT was 
added. The plate was incubated for 3 hours in 5% CO2 at 37°C. After incubation, 100 µl 
extraction buffer (20% sodium dodecyl sulfate [SDS] in 50% N,N-dimethylformamide 
[DMF], containing 0.5% [v:v] 80% acetic acid and 0.4% [v:v] 1N HCl) was added. The 
plate was incubated for 30 minutes-1 hour in 5% CO2 at 37°C and then read on a Wallac 
Victor 1420 plate reader (PerkinElmer, software Workout 2.0). 
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RESULTS 
Spy1 enhances the efficacy of CKIs. 
 The TNBC cell line, MDA-MB-231, was treated with 20 µM roscovitine or 25 
µM NU-2058 for 24-72 hours, followed by analysis of metabolic activity by use of MTT 
and trypan blue exclusion assay (Figure 1A). The percent viability was calculated at each 
time-point in comparison to vehicle control (DMSO). There was a significant decrease in 
viability at the earliest time-point with the highly specific CDK2 inhibitor, NU-2058, 
while roscovitine began to show a significant effect at 48 hours. Both inhibitors showed 
the greatest effect at 72 hours. TNBC cell lines have higher levels of Spy1 than ERα-
positive luminal breast cancer cell lines (Al Sorkhy et al., 2012). Hence, triple negative 
MDA-MB-231 cells were infected with shScrambled, shSpy1, or shCyclin E. Following 
confirmation of knockdown (Figure 1B), cells were treated with the synthetic CKIs to 
determine if Spy1 levels could affect their efficacy. The percent viability was calculated 
through MTT analysis and trypan blue exclusion assay (Figure 1C) in comparison to 
vehicle control (DMSO). Spy1 knockdown significantly increases the efficacy of both 
CKIs, NU-2058 and roscovitine; however, knocking down Cyclin E shows no notable 
effects on the viability of the cells over that of inhibitor alone. These data suggest that 
Spy1 directed activity is not completely inhibited by CKIs and is still driving aspects of 
cell growth. 
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Figure 1. Spy1 enhances the efficacy of CKIs (A) Cells were treated with vehicle
control (DMSO), 25 uM NU-2058 or 20 uM roscovitine for the indicated time.
Following each time point the viability was assessed using MTT (left panel) and trypan
blue exclusion assay (right panel). (B-C) Cells were infected with shScrambled
(denoted pLKO), shSpy1, or shCyclin E. Following confirmation of knockdown (B),
cells were treated with vehicle control (DMSO), 25 uM NU-2058, or 20 uM
roscovitine. (C) Following 48 hour incubation, cells were subjected to MTT assay (left
panel) or trypan blue exclusion assay (right panel). (A,C) Percent viability is
determined as percent of vehicle control. Error bars reflect SE between triplicate
experiments. Student’s t-test was performed; *p<0.05, ***p<0.001.
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Synthetic CKIs have a synergistic effect when combined with cisplatin. 
 To determine if the efficacy of cisplatin treatment on TNBC cells could be 
enhanced when in combination with CKIs, MDA-MB-231 cells were treated with the 
inhibitors (roscovitine or NU-2058) or cisplatin, or a combination of cisplatin with each 
inhibitor. As seen in Figure 2A and 2C, when each CKI is used alone there is a 
significant decrease in cell viability. Furthermore, when cisplatin treatment is combined 
with CKI treatment, percent viability is further decreased. We have shown that the 
addition of a CKI can sensitize these cells to cisplatin treatment. Moreover, using 
CompuSyn software, the data shows that the use of the combination of drugs can induce a 
synergistic effect as shown by a combination index (CI) value less than 1 (Figure 2B and 
2D). CI values for the combination of cisplatin and roscovitine as well as cisplatin and 
NU-2058 are summarized in Table I and Table III, respectively. CompuSyn was also able 
to provide the CI values for the effective dose (ED) from ED50 to ED95, which are 
summarized for each combination in Table II and Table IV. In short, these data conclude 
that 50% to 100% inhibition of the population of cells, provided by the combination of 
cisplatin and a synthetic CKI, shows a synergistic effect. 
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Figure 2. Synthetic CKIs have a synergistic effect when treated with cisplatin. (A)
Cells were treated with vehicle control (DMSO), 25 uM NU-2058, 45 uM cisplatin, or a
combination for the indicated time. (B) Output graph of MTT results from CompuSyn
program showing synergistic effect (CI<1) at 48 hours when 50% to 100% of the
population is affected (F(a)). (C) Cells were treated with vehicle control (DMSO),
20 uM roscovitine, 45 uM cisplatin, or a combination for the indicated time.
(A,C) Following each incubation, cells were assessed through MTT analysis (left panel)
or trypan blue exclusion assay (right panel). (D) Output graph of MTT results from
CompuSyn program showing synergistic effect (CI<1) at 48 hours when 50% to 100%
of the population is affected. (A-D) Percent viability is determined as percent of vehicle
control. Error bars reflect SE between triplicate experiments. Student’s t-test was
performed; *p<0.05, **p<0.01, ***p<0.001.
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Fraction Affected 
(Fa) 
Combination Index Interaction 
0.45 23.012 Antagonistic 
0.5 0.71357 Synergistic 
0.55 2.23x10
-2
 Synergistic 
0.6 6.54x10
-4
 Synergistic 
0.65 1.6x10
-5
 Synergistic 
0.7 3.3x10
-7
 Synergistic 
0.75 4.46x10
-9
 Synergistic 
0.8 3.2x10
-11
 Synergistic 
0.85 8.5x10
-14
 Synergistic 
0.9 3.2x10
-17
 Synergistic 
0.95 9.4x10
-23
 Synergistic 
0.97 1.1x10
-26
 Synergistic 
 
Table I. Combined effects of cisplatin and roscovitine. 
 
Ratio 
(cisplatin:roscovitine) 
Effective Dose 
(ED) 
Combination 
Index (CI) 
Interaction 
1:1 ED50 0.71357 Synergistic 
ED75 4.46x10
-9
 Synergistic 
ED90 3.2x10
-17
 Synergistic 
ED95 9.4x10
-23
 Synergistic 
 
Table II. Effective dose effects of cisplatin and roscovitine at a molar concentration of 
1:1. 
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Fraction Affected 
(Fa) 
Combination Index Interaction 
0.45 0.96 Synergistic 
0.5 0.28645 Synergistic 
0.55 0.08588 Synergistic 
0.6 0.02513 Synergistic 
0.65 0.00698 Synergistic 
0.7 0.00177 Synergistic 
0.75 3.93x10-4 Synergistic 
0.8 6.99x10
-5
 Synergistic 
0.85 8.65x10
-6
 Synergistic 
0.9 5.39x10
-7
 Synergistic 
0.95 6.09x10
-9
 Synergistic 
0.97 2.5x10
-10
 Synergistic 
 
Table III. Combined effects of cisplatin and NU-2058. 
 
Ratio 
(Cisplatin:NU-
2058) 
Effective Dose 
(ED) 
Combination Index 
(CI) 
Interaction 
1:1 ED50 0.28645 Synergistic 
ED75 3.93x10
-4
 Synergistic 
ED90 5.39x10
-7
 Synergistic 
ED95 6.09x10
-9
 Synergistic 
 
Table IV. Effective dose effects of cisplatin and NU-2058 at a molar concentration of 
1:1. 
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Spy1 knockdown increases the effect between cisplatin and CKIs. 
 Elevated levels of Spy1 can confer resistance to genotoxic agents (Barnes et al., 
2003); therefore, to determine if the levels of Spy1 can affect the efficacy of these drugs, 
Spy1 knockdown was performed followed by the use of each drug individually or in 
combination. We first show that Spy1 knockdown sensitizes cells to cisplatin treatment, 
but knockdown of Cyclin E has no significant effect and, in fact, dramatically prevents a 
decrease in viability (Figure 3A). When NU-2058 (Figure 3A) or roscovitine (Figure 3B) 
are combined with cisplatin, viability enhances over cisplatin alone, supporting that 
combination therapy with these reagents needs to be avoided or conducted in sequential 
cycles. Interestingly, while knockdown of Cyclin E significantly enhances viability in the 
face of each combination, knockdown of Spy1 significantly sensitized cells to 
combinations of cisplatin and CKIs. To determine whether Spy1 knockdown had effects 
on cisplatin in combination with standard of care chemotherapy, cells were treated with 
the combination of doxorubicin, cyclophosphamide, and paclitaxel (AC/T)  and percent 
viability was determined through MTT analysis. While both Spy1 and Cyclin E 
knockdown significantly decrease the viability of the cells to AC/T treatment, the 
addition of cisplatin significantly decreases cell viability when Spy1 is knocked down, an 
effect not seen with Cyclin E knockdown (Figure 3C). To resolve whether an ERα cell 
line with overexpression of Spy1 or Cyclin E would respond to standard of care treatment 
with or without cisplatin, MCF7 cells were treated with each regimen. In both instances, 
overexpression of Spy1 and Cyclin E show an increase in cell viability with AC/T 
treatment; however, addition of cisplatin to Cyclin E overexpressing cells significantly 
decreases percent viability back to control levels (Figure 3D). These data suggest that 
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levels of Spy1 can change the efficacy of cisplatin as well as the standard of care 
chemotherapy regimen.  
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Figure 3. Spy1 knockdown increases the effect between cisplatin and CKIs.
(A-C) MDA-MB-231 cells were infected with shScrambled (denoted pLKO), shSpy1,
or shCyclin E. (A) Infected cells were treated with vehicle control (DMSO), 25 uM
NU-2058, 45 uM cisplatin, or a combination. Cells were assessed using MTT analysis
(left panel) or trypan blue exclusion assay (right panel). (B) Infected cells were treated
with vehicle control (DMSO), 20 uM roscovitine, 45 uM cisplatin, or a combination.
Cells were assessed using MTT analysis (left panel) or trypan blue exclusion assay
(right panel). (C) Cells were treated with AC/T or AC/T + cisplatin and viability was
assessed using MTT analysis. (D-E) MCF7 cells were infected with pEIZ, Spy1, or
Cyclin E. Following confirmation of overexpression (D), cells were treated with AC/T
or AC/T + cisplatin and assessed using MTT analysis. (A-C & E) Percent viability is
determined as percent of vehicle control. Error bars reflect SE between triplicate
experiments. Two-way ANOVA was performed; *p<0.05,**p<0.01, ***p<0.001.
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DISCUSSION 
 TNBC is a highly aggressive disease with no targeted treatment options available. 
Chemotherapy drugs that inhibit the cell cycle have had a huge impact on the overall 
survival rate; however, TNBC patients still risk a high rate of relapse within 3 years after 
therapy (Pogoda et al., 2013). Resolving the key regulators of resistance can uncover 
novel treatment options and offer new promise to this group of patients. 
 Chemotherapy is highly dependent on actively dividing cells and works by 
inhibiting the cell cycle at various stages and then triggering apoptosis (Bharadwaj and 
Yu, 2004; Emadi et al., 2009; Hall and Tilby, 1992; Jordan and Wilson, 2004; Minotti et 
al., 2004). Within the last decade, many regimens have added the use of platinum drugs, 
such as cisplatin, in combination with standard of care chemotherapy. Cisplatin is 
standard of care for stomach and ovarian cancer and has been receiving attention in the 
treatment of TNBC (Helm and States, 2009; Liu et al., 2015; Roth et al., 2007). Cisplatin 
forms DNA adducts, usually during S phase of the cell cycle, that alter DNA 
conformation triggering the initiation of the DNA damage response, followed by 
apoptosis (Rosenberg et al., 1969; Wang and Lippard, 2005). The use of platinum drugs 
as a single agent therapy or in combination with chemotherapy regimens came about by 
the presence of frequent mutations in the BRCA1 gene in TNBC patients. BRCA1 
mutations leads to a decreased ability for DNA repair and, therefore, the tumour is unable 
to fully recover from DNA-damaging agents, promoting tumour cell apoptosis (Hill et al., 
2014). Indeed, our work demonstrates that the inclusion of cisplatin in the treatment of 
TNBC cell lines significantly decreases cell viability over an AC/T regimen alone. 
Resistance has been shown to develop over time in ovarian cancer patients (Siddik, 
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2003); however, since cisplatin is not routinely used for breast cancer therapies, there are 
no clinical trials yet to determine whether TNBC patients develop cisplatin resistance. In 
this study, we explore whether targeting the cell cycle with CKIs may be a valuable 
mechanism of optimizing cisplatin combinations to avoid this problem.  
 During initiation of carcinogenesis, the increase in DNA damage and mutations is 
significant. This elicits the DNA damage response in hopes of repairing the damage. 
Chemotherapy promotes damage to induce cell cycle arrest and apoptosis. If the repair 
pathway can be superseded, then chemotherapy stops working (Johnson and Shapiro, 
2010). The unique 'cyclin-like' protein, Spy1, has been shown to override the DNA 
damage pathway and when Spy1 is overexpressed it can override the apoptotic effects of 
p53 and the DNA repair pathway (Barnes et al., 2003; Gastwirt et al., 2006). 
Furthermore, elevated levels of Spy1 have shown a resistant phenotype to chemotherapy 
and genotoxic agents (Barnes et al., 2003). Spy1 is elevated in several human cancers, 
including invasive breast cancers (Al Sorkhy et al., 2012; Hang et al., 2012; Ke et al., 
2009; Lubanska and Porter, 2014b), and, hence, may represent a potent mechanism for 
inducing chemotherapy resistance. In this study, we demonstrate that Spy1 knockdown 
sensitizes TNBC cells to existing CKI drugs, NU-2058 and roscovitine, as well as to 
cisplatin. Interestingly, our results support that this is not through classically defined 
activation of the G1/S CDK, CDK2, as Cyclin E knockdown does not mimic these 
effects.  
 Synthetic CKIs have been added into the regimen for chemotherapy in many 
clinical trials to further inhibit cell cycle progression (Deep and Agarwal, 2008). These 
inhibitors were originally modelled after the Cyclin A-CDK2 crystal structure (Brown et 
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al., 1995), and have shown some effectiveness in pre-clinical trials (Deep and Agarwal, 
2008; Nair et al., 2011). Spy1 activates CDKs even in the presence of the CKIs, p27
Kip1
 
and p21
Cip1 
(Cheng et al., 2005a; Porter et al., 2003). These results support that it is 
important to begin to understand how cyclin-like proteins differentially regulate CDK 
activity and to develop synthetic reagents to target this mechanism. Recent CKI trials in 
ERα-positive breast cancer patients have stratified patient populations with Cyclin D1 
amplification, loss of p16, or both and utilized select CDK4/6 inhibitors (Finn et al., 
2015; Finn et al., 2009) with significantly improved results. Late breaking ASCO 
abstracts reveal survival rates for these patient groups have doubled (Finn et al., 2015; 
Turner et al., 2015). It is an important next step for the TNBC field to conduct trials 
stratifying patient populations for levels of cyclins, cyclin-like proteins, CDKs and 
natural CKIs and testing the efficacy of targeted second generation CKI therapies. This 
approach may offer radical improvements for this subset of patients.  
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CHAPTER 5 
SPY1 IS A SELECTIVE TARGET FOR TREATMENT WITH SINGLE AGENT 
PACLITAXEL IN TRIPLE NEGATIVE BREAST CANCER CELLS 
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INTRODUCTION 
 Cyclin dependent kinases (CDKs) and their cyclin binding partners regulate 
progression though the cell cycle to ultimately control cell proliferation. A healthy cell 
detects potentially harmful changes in the cellular environment, including damage to the 
DNA, by halting the cell cycle through the upregulation of CDK inhibitors (CKIs) to 
allow for repair of the situation, or initiating apoptosis in the case of irreparable damage 
(Johnson and Shapiro, 2010). Bypass of these protective checkpoints is an essential step 
in the progression of tumourigenesis (Arellano and Moreno, 1997; Nakayama, 1998). 
Indeed, CKIs, such as p27
Kip1
 and p21
Cip1
, are commonly downregulated in various 
cancers (Abukhdeir and Park, 2008; Jeffrey et al., 1995). Chemotherapy drugs target 
critical aspects of cell proliferation, including damaging the DNA, and, ironically, rely 
heavily on cell cycle checkpoints to detect these errors and trigger apoptosis of the cancer 
cell (Bharadwaj and Yu, 2004; Johnson and Shapiro, 2010). Reinstalling CKI function 
represents an attractive mechanism for sensitizing cells to chemotherapy treatment.  
 Paclitaxel is a common chemotherapy drug used for many different malignancies, 
including prostate, breast, and lung cancers (Bharadwaj and Yu, 2004; Jordan and 
Wilson, 2004). Paclitaxel disrupts microtubule depolymerization by reversibly binding to 
tubulin, resulting in stable non-functioning microtubules. This interferes with mitosis and 
leads to apoptosis (Jordan and Wilson, 1998). Although paclitaxel has had success in the 
clinic for many cancer treatments, patients with triple negative breast cancer (TNBC) 
commonly present with de novo resistance or develop acquired paclitaxel resistance 
(Blanchard et al., 2015). Since TNBC patients do not express hormone or Her2/neu 
receptors, they are not eligible for hormone or targeted Her2/neu therapy treatment and 
177 
 
rely heavily on chemotherapy (Perou, 2010). The development of resistance to current 
chemotherapy regimens accounts for an average survival rate, calculated over all four 
stages, of approximately 57% for TNBC patients, compared to 73% for hormone receptor 
positive breast cancers (Polyak and Metzger Filho, 2012).  
 Synthetic CKIs have been designed to inhibit the cyclin-CDK complex by binding 
to the ATP binding site on the CDK (Asghar et al., 2015; Jeffrey et al., 1995). Synthetic 
CKIs, such as the pan-inhibitor roscovitine, have entered clinical trials but results to date 
have been largely disappointing (Johnson and Shapiro, 2010). Few trials have attempted 
to stratify patient populations according to cyclin, CDK or CKI levels and all trials have 
been conducted in conjunction with chemotherapies, most of which were not thoroughly 
tested in either pre-clinical or clinical settings. Combinations of paclitaxel and synthetic 
CKIs have shown particularly disappointing effects, likely because proper function of 
paclitaxel is dependent upon activation of cyclin-CDK complexes throughout the cell 
cycle to ensure the entry of cells into M-phase (Marsh et al., 2007). Nakayama et al. 
(2009) showed that activity of CDKs, specifically CDK1 and CDK2, can predict 
paclitaxel sensitivity and that a change in the activity of CDKs changes the efficacy of 
the treatment (Nakayama et al., 2009). Furthermore, Pushkarev et al. (2012) showed only 
at lower than physiologically relevant concentrations of paclitaxel does the combination 
of paclitaxel and CDK inhibitors have a promising outcome for colon and anaplastic 
thryroid cancer in the clinic. They documented that as paclitaxel concentrations increase 
closer to physiologically relevant levels, the addition of CKIs produced antagonistic 
outcomes in colon and anaplastic thyroid cancer cells (Pushkarev et al., 2012).  
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 In addition, a confounding issue not yet considered in a clinical setting is the 
existence of cyclin-like proteins that activate CDKs in an atypical manner insensitive to 
natural CKIs, such as p21
Cip1
 (Nebreda, 2006). One cyclin-like protein Spy1A1 (gene 
SPDYA, herein referred to as Spy1), can bind to both CDK1 and CDK2 in a novel 
manner, requiring no activating phosphorylation on the threonine (T)-160/161 residue in 
the T-loop and without the necessary dephosphorylation of threonine (T)-14 and tyrosine 
(Y)-15 residues (Cheng et al., 2005a). This unique binding may alter the normal 
conformation of the CDK and may not allow for the binding of the synthetic CKI. Our 
data supports the work of Nakayama et al. (2009) that CKIs, roscovitine and NU-2058, 
do not significantly enhance the effectiveness of paclitaxel. We show that knockdown of 
Spy1 in TNBC cells increases the efficacy of TNBC cells to paclitaxel alone, however, 
neither knockdown of Spy1 or Cyclin E improved combination therapy with CKI 
treatment and paclitaxel.  
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MATERIALS AND METHODS 
Cell Culture. MDA-MB-231 were purchased from ATCC and were subcultured in 
DMEM media supplemented with 10% FBS and 30,000 units penicillin/30,000 µg 
streptomycin solution. Cells were maintained under normoxic conditions (5% CO2) at 
37°C. 
Plasmids. pLKO-scrambled control (#8453) was purchased from Addgene. pLKO-
shSpy1 and pLKO-shCyclin E1 were cloned to express a short hairpin previously 
described to knockdown Spy1 or Cyclin E1 specifically in the place of the scrambled 
sequence; previously determined to be specific using multiple constructs of each and 
rescue constructs (Lubanska and Porter, 2014b). 
Immunoblotting (IB). Total protein was isolated from cell cultures using NP-40 lysis 
buffer (1% NP-40, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl) containing 
protease inhibitors (100 µg/ml PMSF, 5 µg/ml aprotinin, and 2 µg/ml leupeptin) for 1 
hour on ice. Bradford reagent was used to determine the concentration of protein 
following the manufacturer‟s instructions (Sigma). 80-100 µg of protein were subjected 
to electrophoresis on denaturing 10% SDS polyacrylamide gels and transferred to PVDF-
Plus 0.45 micron transfer membrane (Osmonics Inc.) for 2 hours at 30 volts using a wet 
transfer method. Blots were blocked for 1 hour in 1% BSA solution at room temperature. 
Primary antibodies were reconstituted in blocker and incubated overnight at 4°C, 
secondary antibodies were used at 1:10000 dilution in blocker for 1 hour at room 
temperature. Blots were washed three times in TBST for three minutes following 
incubation with primary and secondary antibodies. Chemiluminescent Peroxidase 
Substrate was used for visualization following manufacturer‟s instruction (Pierce). 
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Chemiluminescence was quantified on an AlphaInnotech HD2 (Fisher) using AlphaEase 
FC software. The proper antibodies were used at the following concentrations: Actin 
MAB150 1R (Chemicon-Millipore; 1:1000), human Spy1 (ThermoScientific; 1:1000), 
and Cyclin E1 (Abcam; 1:1000). 
Lentiviral Production and Infection. VSV-G pseudotyped lentivirus was produced by 
transient transfection of HEK293 LentiX cells with transfer vector and the multi-deleted 
packaging plasmids (pMDG, pMDL2, pRSV) using polyethylenimine (PEI) (408719, 
Sigma) reagent with 1:3 DNA to PEI ratio and incubation for 5 hours at 37°C, 5% CO2. 
The virus was collected the next day and concentrated for 3 hours at 4°C using an 
ultracentrifuge. The titer for pLKO lentivirus was assessed by puromycin selection 
followed by crystal violet staining and quantification of resistant colonies. The titered 
virus was filter sterilized and stored at -80°C. 80,000 cells were seeded in fully 
supplemented growth media in 24-well plates for 2 hours. Cells were starved by 
removing serum and penicillin/streptomycin from the media, followed by addition of 1 
mg/ml polybrene (Santa Cruz Biotechnology) and MOI 3 of the specific vector used. 
Infected media was changed to fully supplemented media 24 hours after infection. Cells 
were incubated with 1mg/ml puromycin (Sigma) 48 hours after infection for 72 hours to 
allow for puromycin selection. Media is thereafter changed every 48 hours with 
puromycin included.   
Drug Dosage. Cells were treated with 100 nM paclitaxel (Sigma), with or without CDK 
inhibitors; 20 µM roscovitine (Santa Cruz Biotechnology) or 25 µM NU-2058 (Tocris). 
Paclitaxel treatment occurred for 24 hours and CDK inhibitors treatment occurred for 48 
hours. 
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Proliferation Assay. Cells were seeded at 5x10
5
 cell density in 24-well plate. Following 
incubation times with drug treatments, indicated as above, cells were collected, pelleted 
and resuspended in 1 ml of media. 10 µl samples were collected and trypan blue added 
and counted using a haemocytometer.   
MTT Assay. Cells were seeded at 8 x 10
3
 cell density in a 96-well plate. Following 
incubation times with drug treatments, indicated as above, 5 mg/ml MTT was added. The 
plate was incubated for 3 hours in 5% CO2 at 37°C. After incubation, 100 µl extraction 
buffer (20% sodium dodecyl sulfate [SDS] in 50% N,N-dimethylformamide [DMF], 
containing 0.5% [v:v] 80% acetic acid and 0.4% [v:v] 1N HCl) was added. The plate was 
incubated for 30 minutes-1 hour in 5% CO2 at 37°C. 
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RESULTS 
CKIs decrease the efficacy of paclitaxel.  
 To determine whether paclitaxel can continue to be an optimal treatment for 
TNBC when CDK activity is inhibited by synthetic CKIs, we treated MDA-MB-231 cells 
with each CDK inhibitor alone (roscovitine or NU-2058), paclitaxel alone, or with the 
combination of roscovitine and paclitaxel or NU-2058 and paclitaxel. Here we show that 
TNBC cells treated with paclitaxel and CDK inhibitors alone respond through a decrease 
seen in the percent viability of the cells (Figure 1A). However, in combination with the 
pan-CDK inhibitor roscovitine, we show that at an effect on 50% to 95% of the 
population there is an antagonistic effect on the viability of this TNBC cell lines, through 
the use of the CompuSyn software (Figure 1B and Table I). Furthermore, the effective 
dose (ED50 to 95) were also shown to be antagonistic (Table II). In contrast, there is a 
small decrease in cell viability when the specific CDK2 inhibitor, NU-2058, is used in 
combination with paclitaxel (Figure 1A). Using CompuSyn software, CI values were 
found to be larger than 1, indicating the relationship is antagonistic and have non-
synergistic interaction (Table III).  
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Figure 1. CKIs decrease the efficacy of paclitaxel. (A-B) Cells were treated with
vehicle control (DMSO), 20 uM roscovitine, 25 uM NU-2058, 100 nM paclitaxel, or a
combination of paclitaxel with CDK inhibitors. (A) Following appropriate incubation
time, cells were assessed using MTT analysis (left panel) and trypan blue exclusion
assay (right panel). Cell viability was determined in comparison to vehicle control.
Error bars reflect SE between triplicate experiments. Student’s t-test was performed;
***p<0.001. (B) CompuSyn software was used to determine the effect between
paclitaxel and roscovitine. CI>1 above 40% fraction affected, showing an antagonistic
effect between the two drugs.
Trypan Blue ExclusionMTT Analysis
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Fraction Affected 
(Fa) 
Combination Index Interaction 
0.05 9.5x10-10 Synergistic 
0.1 5.04x10-7 Synergistic 
0.15 2.45x10-5 Synergistic 
0.2 4.55x10-4 Synergistic 
0.25 0.00510 Synergistic 
0.3 0.04202 Synergistic 
0.35 0.28547 Synergistic 
0.4 1.1 Additive 
0.45 9.56628 Antagonistic 
0.6 51.5586 Antagonistic 
0.65 277.882 Antagonistic 
0.7 1550.44 Antagonistic 
0.75 63271.9 Antagonistic 
0.9 5.467x10
9
 Antagonistic 
0.95 5.93x10
12
 Antagonistic 
 
Table I. Combined effects of paclitaxel and roscovitine. 
 
Ratio 
(Paclitaxel:Roscovitine) 
Effective Dose 
(ED) 
Combination 
Index (CI) 
Interaction 
1:1 ED50 51.5586 Antagonistic 
ED75 521749 Antagonistic 
ED90 5.467x10
9
 Antagonistic 
ED95 5.93x10
12
 Antagonistic 
 
Table II. Effective dose effects of paclitaxel and roscovitine at a molar concentration of 
1:1. 
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Fraction Affected 
(Fa) 
Combination Index Interaction 
0.45 8961.62 Antagonistic 
0.5 16155.7 Antagonistic 
0.55 31862.4 Antagonistic 
0.6 63847.9 Antagonistic 
0.65 131818 Antagonistic 
0.7 286054 Antagonistic 
0.95 3.53x10
8
 Antagonistic 
 
Table III. Combined effects of paclitaxel and NU-2058. 
 
Ratio 
(Paclitaxel:NU-
2058) 
Effective Dose 
(ED) 
Combination Index 
(CI) 
Interaction 
1:1 ED50 16155.7 Antagonistic 
ED75 671288 Antagonistic 
ED90 2.79x10
7
 Antagonistic 
ED95 3.53x10
8
 Antagonistic 
 
Table IV. Effective dose effects of paclitaxel and NU-2058 at a molar concentration of 
1:1. 
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Spy1 levels affect the efficacy of single agent paclitaxel and CKI treatment.  
 Previously published data has shown Spy1 protein levels to be high in TNBC cell 
lines (Al Sorkhy et al., 2012). To determine the effect of Spy1 on combination therapy 
for TNBC cells, MDA-MB-231 cells were infected to knockdown either Spy1 or Cyclin 
E. When Spy1 levels were knocked down, TNBC cells responded greater to CDK 
inhibitor treatment alone as well as paclitaxel treatment alone (Figure 2A and 2B). 
Although there is a decrease in cell viability when the combination of paclitaxel and 
CKIs were used during Spy1 knockdown, in comparison to paclitaxel alone, the 
percentage of living cells increases (Figure 2A and 2B). During control or knockdown of 
either Spy1 or Cyclin E, a combination of the two drugs leads to antagonism. Cyclin E 
knockdown, however, has no significant decrease in cell viability when CDK inhibitors 
are used. This data suggests targeting Spy1 alone or in combination with paclitaxel and/or 
CDK inhibitors could be beneficial in treating TNBC patients. 
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Figure 2. Spy1 levels affect the efficacy of single agent paclitaxel and CKI treatment.
(A-C) Cells were infected with shScrambled (denoted pLKO), shSpy1, or shCyclin E.
(A) Confirmation of knockdown assessed by SDS-PAGE and IB. (B) Infected cells were
treated with vehicle control (DMSO), 25 uM NU-2058, 100 nM paclitaxel, or a
combination. (B) Infected cells were treated with vehicle control (DMSO), 20 uM
Roscovitine, 100 nM paclitaxel, or a combination. (A-B) Following the appropriate
incubation, cells were assessed using MTT analysis (left panel) and trypan blue
exclusion assay (right panel) and percent viability was measured in comparison to
DMSO. Error bars reflect SE between triplicate experiments. Two-way ANOVA was
performed; *p<0.05,**p<0.01, ***p<0.001.
90
100
80
60
40
20
0
%
V
ia
b
ili
ty
70
10
30
50 NU-2058
Paclitaxel
Paclitaxel +
NU-2058
pLKO shSpy1 shCyclin E
*
MTTAnalysis Trypan Blue Exclusion
120
100
80
60
40
20
0
%
V
ia
b
ili
ty
Roscovitine
Paclitaxel
Paclitaxel +
Roscovitine
pLKO shSpy1 shCyclinE
Trypan Blue ExclusionMTT Analysis
***
***
***
**
*******
**
Actin
Cyclin E
Spy1
pL
KO
sh
Sp
y1
sh
Cy
clin
E
IB: Actin
IB: Cyclin E
IB:Spy1
A
187
188 
 
DISCUSSION 
 The G1/S cyclin is frequently upregulated in many solid cancers, including TNBC 
(Caldon et al., 2012; Dhillon and Mudryj, 2002) and CKIs, such as p27
Kip1
 and p21
Cip1
, 
are significantly downregulated (Abukhdeir and Park, 2008; Bandoh et al., 2005). 
Synthetic CKIs have been modelled against the binding of p21
Cip1
 to the Cyclin A-CDK2 
complex to compensate for the loss of the natural CKIs (Jeffrey et al., 1995). Many of the 
synthetic CKIs tested have shown promising efficiency in pre-clinical trials; however, in 
the clinic they showed little to no efficacy and have had severe adverse effects in patients 
due to dosing problems, administrative schedules and target specificity (Asghar et al., 
2015; Byrd et al., 2007; Deep and Agarwal, 2008). Current clinical trials have added 
CKIs in combination with standard of care chemotherapy regimens without thorough in 
vitro testing of each drug individually (Byrd et al., 2007; Harrison et al., 2009; Johnson 
and Shapiro, 2010). A more thorough assessment of how to combine these drugs into 
existing regimens is required.  
 Clinical trials with the pan-CDK inhibitor flavopiridol have shown the change in 
efficacy of chemotherapeutic agents is dependent on time of dosage (Motwani et al., 
1999). Administration of flavopiridol prior to paclitaxel decreases the efficacy of 
paclitaxel due to the prevention of cells into M-phase. However, when gastric and breast 
cells are treated with flavopiridol after paclitaxel treatment there was an increase in 
apoptosis (Motwani et al., 1999). Our data shows addition of the pan-inhibitor, 
roscovitine, after paclitaxel decreases the efficacy of paclitaxel in TNBC cells. When a 
selective CDK2 inhibitor, NU-2058, was added after paclitaxel, there was also a 
significant decrease in cell viability. In refractory malignancies such as lung, prostate, 
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and esophageal cancers, phase I clinical trials with flavopiridol and paclitaxel have 
shown promising results (Schwartz et al., 2002); however, breast cancer shows only 
partial responses to this treatment (Motwani et al., 1999; Nair et al., 2011). Roscovitine is 
presently in phase II clinical trials for breast cancer and has also only shown partial 
response to treatment due to its toxic effect on normal cells (Nair et al., 2011). While 
most clinical trials focus on the use of pan-inhibitors, it may be valuable to focus on 
selective inhibitors that may selectively reinforce essential checkpoints while allowing 
cells to proceed through the phase of the cell cycle required for chemotherapy to 
function. Our current data support the literature that combination therapy with CKIs 
following paclitaxel treatment is not an effective regimen.  
 Synthetic CKIs continue to evolve by changing one or two chemical groups on 
the previous model. CDK4 inhibitors have begun to show great success in estrogen 
receptor alpha (ERα) positive breast cancers  (Finn et al., 2009) and have also shown to 
protect mammary gland cells from Ras or Her2 induced tumorigenesis, but not c-Myc-
induced tumourigenesis (De Falco and De Luca, 2010). Hence, the driving molecular 
signature plays a role in the sensitivity of the cell cycle to select inhibitors, likely due to 
the composition of cyclin-CDKs, and cyclin-like proteins expressed in individual cancers. 
TNBC cell lines have high levels of the atypical cyclin-like protein, Spy1 (Al Sorkhy et 
al., 2012). Spy1 can bind to and activate CDKs in the presence of the CKIs, p21
Cip1
 and 
p27
Kip1 
(Cheng et al., 2005a) and, hence, elevated levels of Spy1 could contribute to the 
efficacy of synthetic CKIs. We show here that the knockdown of Spy1 in TNBC cells 
decreases cell viability alone and enhances the efficacy of paclitaxel and CKIs 
individually, particularly enhancing the effects of the select CDK2 inhibitor, NU-2058. 
190 
 
These results were not noted with the G1/S classical cyclin, Cyclin E and, hence, 
suggests that this is due to the unique ability of Spy1 to override these select checkpoints.  
 Chemotherapeutic regimens have had an immense impact on overall survival for 
aggressive cancers, such as TNBC. However, recurrence and relapse can occur quickly 
after chemotherapy treatment. One study showed 33.9% of TNBC patients showed 
distant recurrence in 2.6 years after chemotherapy treatment in comparison to "other" 
breast cancers, which showed a 20.4% distant recurrence rate in 5 years (Dent et al., 
2007). Furthermore, the adverse effects of chemotherapy have led clinicians to minimize 
these inconsistencies by combining the chemotherapy with other cell cycle regulator 
inhibitors (Deep and Agarwal, 2008). Currently, targeting the cell cycle in combination 
with chemotherapy is plagued with inconsistent data in patients due in large part to the 
lack of solid information regarding the timing and dosing of each reagent and how to 
stratify patients appropriately. Our data supports that high levels of the cyclin-like protein 
Spy1 may be prognostic for response to paclitaxel and CKI treatment and selective 
targeting of this mechanism may sensitize patients to these reagents alone. Further work 
is required, however, to determine whether CKIs can be used safely in combination with 
paclitaxel.  
 
 
 
 
 
 
 
191 
 
REFERENCES 
Abukhdeir, A. M., and Park, B. H. (2008). P21 and p27: roles in carcinogenesis and drug 
resistance. Expert Rev Mol Med 10, e19. 
Al Sorkhy, M., Ferraiuolo, R. M., Jalili, E., Malysa, A., Fratiloiu, A. R., Sloane, B. F., 
and Porter, L. A. (2012). The cyclin-like protein Spy1/RINGO promotes mammary 
transformation and is elevated in human breast cancer. BMC Cancer 12, 45. 
Arellano, M., and Moreno, S. (1997). Regulation of CDK/cyclin complexes during the 
cell cycle. Int J Biochem Cell Biol 29, 559-573. 
Asghar, U., Witkiewicz, A. K., Turner, N. C., and Knudsen, E. S. (2015). The history and 
future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14, 
130-146. 
Bandoh, N., Hayashi, T., Takahara, M., Kishibe, K., Ogino, T., Katayama, A., Imada, M., 
Nonaka, S., and Harabuchi, Y. (2005). Loss of p21 expression is associated with p53 
mutations and increased cell proliferation and p27 expression is associated with apoptosis 
in maxillary sinus squamous cell carcinoma. Acta Otolaryngol 125, 779-785. 
Bharadwaj, R., and Yu, H. (2004). The spindle checkpoint, aneuploidy, and cancer. 
Oncogene 23, 2016-2027. 
Blanchard, Z., Paul, B. T., Craft, B., and ElShamy, W. M. (2015). BRCA1-IRIS 
inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast 
Cancer Res 17, 5. 
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., 
Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007). Flavopiridol 
administered using a pharmacologically derived schedule is associated with marked 
clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 
109, 399-404. 
192 
 
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., 
Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012). Cyclin E2 
overexpression is associated with endocrine resistance but not insensitivity to CDK2 
inhibition in human breast cancer cells. Mol Cancer Ther 11, 1488-1499. 
Cheng, A., Gerry, S., Kaldis, P., and Solomon, M. J. (2005). Biochemical 
characterization of Cdk2-Speedy/Ringo A2  BMC Biochem 6, 19. 
De Falco, M., and De Luca, A. (2010). Cell cycle as a target of antineoplastic drugs. Curr 
Pharm Des 16, 1417-1426. 
Deep, G., and Agarwal, R. (2008). New combination therapies with cell-cycle agents. 
Curr Opin Investig Drugs 9, 591-604. 
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., 
Lickley, L. A., Rawlinson, E., Sun, P., and Narod, S. A. (2007). Triple-negative breast 
cancer: clinical features and patterns of recurrence. Clin Cancer Res 13, 4429-4434. 
Dhillon, N. K., and Mudryj, M. (2002). Ectopic expression of cyclin E in estrogen 
responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21, 4626-4634. 
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., 
Atefi, M., Chen, I., Fowst, C., et al. (2009). PD 0332991, a selective cyclin D kinase 4/6 
inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human 
breast cancer cell lines in vitro. Breast Cancer Res 11, R77. 
Harrison, L. R., Ottley, C. J., Pearson, D. G., Roche, C., Wedge, S. R., Dolan, M. E., 
Newell, D. R., and Tilby, M. J. (2009). The kinase inhibitor O6-
cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by 
mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol 77, 1586-
1592. 
Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and 
Pavletich, N. P. (1995). Mechanism of CDK activation revealed by the structure of a 
cyclinA-CDK2 complex. Nature 376, 313-320. 
193 
 
Johnson, N., and Shapiro, G. I. (2010). Cyclin-dependent kinases (cdks) and the DNA 
damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer 
strategy for solid tumors. Expert Opin Ther Targets 14, 1199-1212. 
Jordan, M. A., and Wilson, L. (1998). Microtubules and actin filaments: dynamic targets 
for cancer chemotherapy. Curr Opin Cell Biol 10, 123-130. 
Jordan, M. A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat 
Rev Cancer 4, 253-265. 
Lubanska, D., and Porter, L. A. (2014). The atypical cell cycle regulator Spy1 suppresses 
differentiation of the neuroblastoma stem cell population. Oncoscience 1, 336-348. 
Marsh, S., Somlo, G., Li, X., Frankel, P., King, C. R., Shannon, W. D., McLeod, H. L., 
and Synold, T. W. (2007). Pharmacogenetic analysis of paclitaxel transport and 
metabolism genes in breast cancer. Pharmacogenomics J 7, 362-365. 
Motwani, M., Delohery, T. M., and Schwartz, G. K. (1999). Sequential dependent 
enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated 
human gastric and breast cancer cells. Clin Cancer Res 5, 1876-1883. 
Nair, B. C., Vallabhaneni, S., Tekmal, R. R., and Vadlamudi, R. K. (2011). Roscovitine 
confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer 
Res 13, R80. 
Nakayama, K. (1998). Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell 
cycle engine during development. Bioessays 20, 1020-1029. 
Nakayama, S., Torikoshi, Y., Takahashi, T., Yoshida, T., Sudo, T., Matsushima, T., 
Kawasaki, Y., Katayama, A., Gohda, K., Hortobagyi, G. N., et al. (2009). Prediction of 
paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast 
Cancer Res 11, R12. 
Nebreda, A. R. (2006). CDK activation by non-cyclin proteins. Curr Opin Cell Biol 18, 
192-198. 
194 
 
Perou, C. M. (2010). Molecular stratification of triple-negative breast cancers. Oncologist 
15 Suppl 5, 39-48. 
Polyak, K., and Metzger Filho, O. (2012). SnapShot: breast cancer. Cancer Cell 22, 562-
562 e561. 
Pushkarev, V. V., Kovzun, O. I., Pushkarev, V. M., and Tronko, M. D. (2012). The effect 
of the combined action of roscovitine and Paclitaxel on the apoptotic and cell cycle 
regulatory mechanisms in colon and anaplastic thyroid cancer cells. ISRN Biochem 2012, 
826305. 
Schwartz, G. K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., Maslak, P., 
Stoltz, M., Eden, L., Perkins, P., et al. (2002). Phase I study of the cyclin-dependent 
kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced 
solid tumors. J Clin Oncol 20, 2157-2170. 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
DISCUSSION & FUTURE DIRECTIONS 
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 This work demonstrates the role of the 'cyclin-like' protein, Spy1 (Speedy, 
RINGO, Spy1A1; gene SPDYA) in regulating signalling of the estrogen receptor alpha 
(ERα), including both c-Myc and mitogen activated protein kinase (MAPK) pathways 
(Bunone et al., 1996; Liao and Dickson, 2000; Musgrove et al., 2008a). Both c-Myc and 
MAPK signalling are highly elevated in breast carcinogenesis and are linked to treatment 
resistance (Adeyinka et al., 2002; Liao and Dickson, 2000). Previous work demonstrated 
that Spy1 is a downstream target of both c-Myc and MAPK during normal mammary 
growth and development (Golipour et al., 2008; Lenormand et al., 1999). Hence, we 
sought to determine whether Spy1 is directly affected by estrogen signalling or has an 
independent role, and to dissect the involvement of the c-Myc and MAPK pathways. We 
have found that estradiol (E2) binding to ERα upregulates Spy1 protein levels and that 
persistent Spy1 signalling correlates with a downregulation and/or altered post-
translational modification of ERα. Mechanistically, altered post-translational 
modification of ERα occurs in a MEK1/2-independent fashion and is mediated via an 
activation of ERK1/2, a result unique to Spy1 and not demonstrated by elevated levels of 
a classical cyclin, Cyclin E. This increase in ERK1/2 activity was very interesting and 
exciting data that indicated a possible feedback loop to the MAPK pathway. Previous 
work showed MAPK activation downstream of Spy1 microinjections in Xenopous 
oocytes (Lenormand et al., 1999); however, this is the first demonstration that Spy1-
CDKs can influence MAPK signalling in a human cell system.  
Spy1-CDK complexes activate substrates with non-canonical sequence motifs; 
specifically non-basic residues at the +3 position in the ((S/T)PX(K/R)) (Cheng and 
Solomon, 2008). The site of phosphorylation known in literature as the main activation 
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site of ERK1/2 is threonine (T)-202/tyrosine (Y)-204 (TXY) (Raman et al., 2007). 
Although the TXY motif is not a canonical consensus sequence for CDKs, this 
combination of sites has not been tested as a potential substrate for Spy1 bound to CDK. 
Furthermore, a computer generated program showing non-canonical phosphorylation 
sites predicted a site, SPSQ, close to the TXY sequence which has potential to be 
phosphorylated by CDK complexes (data not shown). Future work needs to be performed 
through mutations of the canonical and non-canonical sites in the presence of 
overexpressed Spy1 to determine if there is an increase in phosphorylated ERK1/2 and at 
which site this may take place. Crystallographic studies demonstrating how Spy1 binds to 
CDKs are also of the utmost importance to elucidate whether conformational changes of 
the CDK are responsible for this unique activation of ERK1/2.   
 Ras and Raf signalling promote ERK1/2 activation and activating mutations in 
either one of these genes significantly increases ERK1/2 phosphorylation, driving 
proliferative cell programs. Cancer treatments aim to inhibit this pathway by specifically 
inhibiting one of these two genes (Roberts and Der, 2007). In the presence of Spy1 
overexpression, Ras and Raf inhibitors decrease the activation of pERK1/2, supporting 
that Spy1 requires these pathways. In 2003, Moeller et al. showed that Ras activation was 
dependent upon the inhibition of p27 (Moeller et al., 2003). p27 is a CKI that also 
functions in cell adhesion, apoptosis, and senescence, and some data support that these 
properties could be independent of CDK (Lim and Kaldis, 2013). In the Moeller study, 
p27 was isolated as a Grb2 (growth factor receptor bound protein 2) interacting protein 
and shown to compete for SOS (son of sevenless) (Moeller et al., 2003). Grb-SOS 
complex formation activates Ras, and, hence, this competition inhibits Ras activation. 
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Spy1 promotes the binding and degradation of p27 (McAndrew et al., 2007; Porter et al., 
2003) and, hence, we questioned whether this could be an important link to the feedback 
to ERK1/2. We have shown that Spy1 mutants unable to interact with p27 have a 
significant reduction in ERK1/2 activation. These data support the conclusion that Spy1-
mediated degradation of p27 enables the activation of Ras/Raf and downstream activation 
of ERK1/2. How this can occur in a MEK1/2 independent fashion was still a mystery, 
however. Receptor-interacting serine/threonine protein kinase (RIPK)2 is a kinase 
activated by Raf and has been shown to directly phosphorylate ERK1/2 on the TXY 
sequence, independent of MEK1/2 (Navas et al., 1999). We have further shown that 
overexpression of Spy1 works independently through RIPK2 to phosphorylate ERK1/2. 
Hence, our data supports that in at least subsets of breast cancer cells, Spy1 is activated 
downstream of ERα and persistent signalling activates ERK1/2 via a unique MEK-
independent mechanism dependent on Spy1 binding to p27 and activation of the kinase 
RIPK2.  
Increased pERK1/2 protein levels have been correlated in various human cancers, 
including hepatocellular carcinoma and breast cancer (Adeyinka et al., 2002; Huynh et 
al., 2003). Similarly, Spy1 has been found to be upregulated in both of these cancers and 
has been shown to be one of the fifty most upregulated genes in invasive carcinomas of 
the breast (Al Sorkhy et al., 2012; Ke et al., 2009; Zucchi et al., 2004). ERK1/2 activation 
is associated with the development of an tamoxifen-resistant phenotype, primarily 
mediated through the phosphorylation of ERα on serine 118 (S118) (Kato et al., 1995). 
Hence, we questioned whether elevated levels of Spy1 would play a role in driving this 
functional outcome. We find that Spy1 overexpression leads to a significant increase in 
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pERα-S118 and increased proliferation and this leads to tamoxifen resistance both in vivo 
and in vitro. Our data further support that manipulation of Spy1 levels may re-sensitize 
select resistant breast cancer cells to treatment. The future implications of this, both for 
prognosis and treatment, is an exciting and important direction.  
 Downregulation of ERα and patients presenting without hormone receptors (triple 
negative breast cancer, TNBC), cannot be treated with tamoxifen or targeted therapies 
and, therefore, chemotherapy is the only option (Prat and Perou, 2011). Understanding 
how a patient may acquire this status is important in preventing this progression in patient 
populations. Understanding the pathways driving growth in an ERα-negative cell system 
also provides novel opportunity for therapeutic intervention. The protein levels of the 
proto-oncogene, c-Myc, have been correlated with breast cancers that initially begin with 
a positive hormone receptor status, but, following extended c-Myc transcriptional activity 
and/or amplification, resemble the basal-like breast cancer subtype (Dimitrakakis et al., 
2006; Liao and Dickson, 2000; Musgrove et al., 2008b). Mechanistic insight into this 
phenomenon has been lacking. It has been speculated that c-Myc controls the activation 
of genes that can increase the phosphorylation of ERα, which leads to its degradation (de 
Leeuw et al., 2013; Dimitrakakis et al., 2006). Our study designed a cell model system 
where prolonged c-Myc signalling demonstrated a marked downregulation of the ERα 
and subsequent resistance to hormone therapy. We demonstrated using this system and in 
human cell systems that elevated levels of Spy1 downstream of c-Myc play an important 
role in stabilizing c-Myc protein via phosphorylation on serine 62 (S62). CDK2 and 
ERK1/2 have a stabilizing effect on c-Myc and it is through the S62 phosphorylation site 
that c-Myc can mediate strong effects on driving proliferative programs (Amati, 2004; 
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Campaner et al., 2010). Our data explored the biological relevance of the ability of Spy1 
to regulate c-Myc stability. We have demonstrated that Spy1 knockdown re-establishes 
response to tamoxifen in resistant cells expressing high levels of c-Myc, showing a 
possible correlation between Spy1, c-Myc, and ERα protein levels and response to 
hormone therapies.  
 While chemotherapy has increased survival of TNBC patients, they still show a 
significantly high rate of relapse within the first 3 years after treatment and have a high 
metastasis rate (Perou, 2010). A newly emerging form of cancer therapeutic is the 
reintroduction of lost/downregulated CKIs through the use of synthetic CKIs (Asghar et 
al., 2015). Synthetic CKIs are purine-based drugs designed to mimic the mechanism of 
p21
Cip1
 in the ATP-binding site of the CDK, blocking full CDK activation (Bach et al., 
2005; Deep and Agarwal, 2008; Harrison et al., 2009). Synthetic CKIs, if effective, can 
be an invaluable tool in promoting a homeostatic state to inhibit the cell cycle of a 
cancerous cell and trigger apoptosis in response to damaged DNA; however, problems 
and inconsistencies with treatment have resulted in suboptimal data in patient 
populations. CKIs have had a high success rate in pre-clinical trials, but to date have had 
high cytotoxic effects in clinical trials (Byrd et al., 2007; Harrison et al., 2009; Nair et al., 
2011; Rigas et al., 2007). This downfall is partly due to the lack of understanding 
regarding the exact mechanism of how CKIs work and which CDKs they inhibit. The 
specificity of CKI activity is lacking. Initial clinical trials have all focused on pan-CKIs 
capable of inhibiting a very wide variety of CDKs. Second and third generation CKIs are 
now attempting to increase specificity (Asghar et al., 2015; Deep and Agarwal, 2008; 
Malinkova et al., 2015). Given the essentiality of CDKs in cell growth it is important to 
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determine how to properly direct specificity to reduce cytotoxic effects and enhance long-
term benefits (Asghar et al., 2015). Importantly, the majority of clinical trials assessing 
the efficacy of synthetic CKIs have failed to stratify patient populations in any significant 
manner (Asghar et al., 2015; Deep and Agarwal, 2008). The first clinical trial to stratify 
ERα positive breast cancers for amplified Cyclin D, loss of p16, or both has just released 
a late breaking ASCO abstract showing that the addition of a select CDK4/6 inhibitor 
nearly doubles 5-year disease free survival rates (Turner et al., 2015); solidifying that 
stratification and directing specified CKIs is a critical step to optimize the use of this 
class of drugs. 
Most clinical trials testing CKIs in breast cancer to date have focused on ERα 
positive populations with or without Her2/neu expression (Turner et al., 2015, Finn et al., 
2015); the implications of these drugs in resistant populations and in TNBC populations 
remain to be thoroughly tested. In vitro studies on TNBC indicate that those populations 
with an amplification of c-Myc may respond specifically to CKIs blocking CDK1 (Kang 
et al., 2014). This presents a complication as CDK1 is an essential gene and this strategy 
may risk high toxicities. We explored the possibility of targeting Spy1-directed CDKs, 
which utilize an alternate mechanism and may enable a more specific approach with 
reduced toxicities. Importantly, Spy1-directed CDKs can override p53- and p21- 
dependent apoptosis and can bypass cell cycle checkpoints, hence, this approach may 
sensitize drug resistant cells to existing therapies. We show here, for the first time, that 
Spy1 levels are high in TNBC patient samples and that Spy1 knockdown significantly 
increased the sensitivity of cells to CKIs alone and in combination with known 
chemotherapeutic agents, including cisplatin and paclitaxel. Spy1 knockdown showed a 
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synergistic effect when used in combination with chemotherapies and CKIs; this was a 
unique observation as Cyclin E knockdown did not show this effect. In fact, under 
specific conditions Cyclin E knockdown increased the viability of TNBC cells with 
treatment, stressing the potential importance of fine-tuning the targeting of the CKIs.  
It is an important next step to test these interactions within in vivo models prior to 
movement into patient populations. These experiments classically weigh heavily on 
assessment in mouse model systems. We have established the efficacy of using zebrafish 
models to assess human cancer cell response to drug treatments (Chapter 2, Figure 6). 
One true benefit of this system is that the model has an intact adaptive immune system 
and microenvironment similar to that of a patient (Novoa and Figueras, 2012) and, hence, 
can provide us with a better understanding of the response, sensitivity, and metabolism of 
the treatment within a patient. Our work to date has focused on available cell systems, or 
an established primary mouse cancer cell system; future work will also focus on using 
primary cells derived from patient samples of ERα positive and TNBC patients. It is 
important to test the effects of Spy1 manipulation on human patient samples in the 
presence and absence of synthetic CKIs and chemotherapy. It is also extremely important 
to determine if Spy1 levels can predict a patient‟s response to therapy, this could then 
represent an important prognostic marker for guiding therapeutic decisions.  
Further elucidating the biology underlying Spy1-mediated effects on treatment 
sensitivity in conjunction with in vivo studies remains a crucial step in determining the 
role of Spy1 in mammary tumourigenesis and in effectively targeting Spy1-directed 
effects in the correct patient population. Further dissecting the biochemistry of the Spy1 
structure when bound to specific CKIs, and how and why Spy1 levels are elevated in 
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aggressive breast cancer phenotypes are important questions that require further research. 
These basic research questions are critical in moving studies forward into the clinic to 
benefit patients.  
 In summary, the data from this study supports the hypothesis that Spy1 levels 
accumulate downstream of ERα-signalling and that Spy1 is capable of feeding back to 
activate the ERK1/2 pathway to modify ERα and subsequent response to hormone 
therapy.  Furthermore, we demonstrate that Spy1 levels correlate with that of c-Myc in 
TNBC patients, and that Spy1 plays an active role in maintaining accumulated levels of 
c-Myc in this aggressive form of breast cancer. We show that manipulating the levels of 
Spy1 can sensitize TNBC cells to current chemotherapy treatment as well as to both a 
pan-CKI and a second generation CDK1/2 inhibitor. Our data supports that CKIs can 
sensitize drug resistant and TNBC cells to hormone and chemotherapy regimens, but that 
the stratification and specification of the CKI is an important step in optimizing the 
addition of this treatment. Much work remains to be done; however, this body of data 
moves forward our understanding of how to better direct research efforts to continue to 
improve the care available for breast cancer patients.  
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